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ABSTRACT 
Background/aims  
The macula is a specialised part of the retina responsible for detailed central and colour 
vision. The carotenoids, lutein, zeaxanthin and meso-zeaxanthin are uniquely concentrated 
in the inner and central layers of the primate macula, where they are known as macular 
pigment (MP). It has been shown that MP is entirely of dietary origin and that lutein and 
zeaxanthin levels in serum, diet and retina correlate. Age-Related Macular Degeneration 
(AMD) is a disease of the macula and results in loss of central vision. MP, because of its 
optical filtration and antioxidant properties, may have an important role in the prevention or 
delay of AMD, and also in the enhancement and preservation of visual performance in 
healthy individuals.  
 
Objectives:  
To assess whether macular pigment optical density (MPOD) is associated with visual 
performance by attenuating short wavelength light. To modify the McCance and 
Widdowsons nutritional database to include nutritional data for lutein and zeaxanthin and 
using this database, assess the accuracy of two self-administered food frequency 
questionnaires (FFQ‘s), to estimate dietary lutein and zeaxantin intake in an Irish 
population. To compare two heterochromatic flicker photometry (HFP) methods for 
measuring MPOD and evaluate the suitability of one of such devices, the MPS 9000, for 
use in clinical practice.  
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Methods  
The spatial profile of macular pigment was measured by customised HFP and values 
correlated with visual performance psychophysical tests, such as best corrected visual 
acuity (BCVA), mesopic, photopic contrast sensitivity and glare sensitivity, on 51 healthy 
subjects. In a separate study, dietary intake of lutein and zeaxanthin was assessed by two 
different FFQ‘s and this data was then analysed using two different lutein and zeaxanthin 
databases, on 22 healthy subjects. The validity of the questionnaires and nutrient databases 
are determined using biomarkers; serum lutein and zeaxanthin and MPOD. Finally, two 
flicker photometers, the MPS 9000 and the Densitometer
TM
 were compared by measuring 
MP on 89 healthy subjects. Instrument repeatability was also assessed by taking three 
MPOD measurements on each instrument for 50 subjects. 
 
Results  
We report a positive and statistically significant relationship between BCVA and MPOD  at 
0.25
o
 and 0.5
o
 retinal eccentricity (r = 0.345, p = 0.013, r = 0.317, p = 0.024, respectively). 
When dietary intake of lutein and zeaxanthin was assessed using the Scottish Colloborative 
Group (SCG) FFQ and modified Italian FFQ, differences of up to 4.88mg/day indicated a 
poor level of agreement. A strong positive correlation was found between the MPS 9000 
and the Densitometer (r=0.68, p<0.001), however Bland Altman analysis indicated poor 
agreement between instruments.  
 
Conclusion  
Although measures of central visual function, such as visual acuity, are positively 
associated with MPOD, a longitudinal, placebo-controlled and randomised supplementation 
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trial would be required to ascertain whether augmentation of MP can influence visual 
performance. A lack of agreement between FFQ assessment tools and nutrient data bases, 
highlights the limitations and difficulties inherent in dietary assessment of lutein and 
zeaxanthin. Finally, underestimation of MP readings by the MPS 9000 may pose some 
concern for practitioners in clinical practice with regard to advise on preventative health 
care and visual performance enhancement and/or preservation. 
 
Keywords:   age-related macular degeneration; heterochromatic flicker photometry; 
macular pigment; mesopic; photopic; visual acuity. 
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CHAPTER ONE 
Introduction 
 
1.1 Background 
 The Yellow colouration of the macula lutea is attributable to the presence of MP in the 
centre of the retina (Snodderly et al. 1984). MP consists of the xanthophylls, lutein and 
zeaxanthin and the retinal metabolite of lutein: meso-zeaxanthin (Handleman et al. 1988; 
Bone et al. 1997; Johnson et al. 2005). Although the definitive role of MP remains 
uncertain, several functions have been hypothesised and these include: (1) reduction of the 
effects of light scatter and chromatic aberration (CA) on visual performance (Nussbaum et 
al. 1981; Reading  & Weale, 1974); (2) non-optical enhancement of visual performance and 
comfort due to ocular, retinal and cortical health benefits; (Craft et al. 2004; Carboni et al. 
2010) (3) limitation of the damaging photo-oxidative effects of short wave (SW) light 
through selective absorption (Bone & Landrum, 1984); (4) protection against the adverse 
effects of photochemical reactions because of the antioxidant properties of these 
carotenoids (Snodderly, 1995). 
 
The selective accumulation of only three specific dietary carotenoids at the macula, 
suggests an exquisite biological selectivity for lutein, zeaxanthin and meso-zeaxanthin at 
the site of best vision in the human retina, and indicates a role for these carotenoids which 
is uniquely suited to this anatomic location. Lutein, zeaxanthin and meso-zeaxanthin are 
located at the macula to the exclusion of all other carotenoids in nature. Given that 
Darwinian natural selection confers advantage before and until the period of procreation, it 
follows that the biological selectivity of MP‘s accumulation in the retina primarily 
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represents an advantage in youth and middle age. The anatomic location, optical and 
antioxidant properties of MP have thus prompted two distinct lines of research, which seek 
to explore the definitive role of MP in vision and visual health. 
 
1.1.1 Visual performance 
The ‗optical‘ hypothesis posits that MP could improve visual resolution by absorbing SW 
light, which is easily scattered and poorly focussed. The yellow colouration of MP is such 
that it selectively absorbs blue green incident light with maximum absorption circa 460 nm, 
and with little or no absorption above 530 nm. Importantly given that peak retinal 
sensitivity is at 555 nm and the proportion of blue SW sensitive cones in the central macula 
is far lower than that of red and green (long and medium sensitive) cones, it is logical to 
suggest that the ‗optical‘ properties of MP are such that it attenuates the component of light 
that is least beneficial and potentially destructive (given that the effects of both light scatter 
and longtidunal chromatic aberration (CA) are non-linear and SW dominated to visual 
performance and experience (Bone et al. 1992). 
 
1.1.2 Age-related macular degeneration  
Although it is likely that the primary role of MP involves its contribution to visual 
performance, an alternative to this hypothesis is that MP protects the retina against light 
damage and as a powerful antioxidant protects the eye against age-related maculopathy 
(ARM) and AMD. AMD has received considerable attention from MP researchers, as it is 
the leading cause of visual loss in people over the age of 65 years in the Western world 
(Leibowitz et al. 1980). Although the aetiopathogenesis of AMD remains a matter of 
debate, there is a growing body of evidence to indicate that oxidative damage (Winkler et 
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al. 1999; Beatty et al. 2000), and associated inflammation (Hollyfield et al. 2010) play a 
role. Consequently, the possibility that the absorption characteristics and antioxidant 
properties of MP confer protection against AMD has been postulated (Snodderly, 1995; 
Landrum et al. 1997).  
 
The fact that MP is modifiable means that ongoing research into its role in prevention or 
progression of AMD, and optimisation of visual health is important. As we can see the 
function of MP may be to improve visual performance during life, as it acts as a SW light 
filter, and is a powerful antioxidant. Whether improved (and preserved into old age) visual 
performance is primarily due to its filtration effects or its antioxidant ability is still 
unknown. The long-term benefit of these effects however is that MP may improve the 
visual health of the eye, and may therefore retard the development of AMD, which is a late 
onset disorder. The ‗protective‘ and ‗visual performance‘ hypotheses of MP are, therefore, 
not mutually exclusive. 
 
1.2 Project Aims/Objectives 
The aim of this thesis is to provide an overview of the relevance of MP to eyecare 
practitioners, including its role in protecting the eye against age-related eye conditions such 
as AMD, and its role in visual performance. Given the inherent variability in the optical 
density of MP in population studies, and given the potential importance of this pigment for 
preventative eyecare systems, the current study sought to further explore the variety of 
methods available for measuring MP, including serum levels of lutein and zeaxanthin, 
dietary intake using FFQ‘s and clinical devices for the measurement of the optical density 
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of MP in the eye. Three separate studies were carried out, and will be explored in this 
thesis; 
a) The first section of this study was designed to identify and investigate relationships, 
if any, between MPOD and visual performance using a battery of techniques. A 
number of recent studies have reported positive and statistically significant 
associations between MP and several parameters of visual performance including 
visual comfort (Stringham et al. 2003), photophobia (Wenzel et al. 2006), veiling 
glare (Stringham & Hammond, 2007) and photostress recovery (Stringham & 
Hammond, 2007; Stringham & Hammond, 2008). The ‗optical‘ hypothesis of MP 
was originally discussed by Reading & Weale (1974) and later by Nussbaum et al. 
(1981) and includes MP‘s putative ability to enhance visual performance and/or 
comfort by attenuation of the effects of CA and light scatter via its light filtering 
properties (Walls & Judd, 1933). In this study we investigated the relationship 
between MPOD at various degrees of retinal eccentricity and clinically important 
parameters of central visual performance including BCVA, contrast sensitivity, 
glare sensitivity, subjective (questionnaire derived) visual function, hue 
discrimination, customised short-wavelength automated perimetry (cSWAP) and 
photostress recovery. 
b) Although MP‘s absorptive and transport characteristics have yet to be fully 
elucidated it has been shown that MPOD can be augmented through dietary 
modification. Another aim of this study was to assess dietary intake of lutein and 
zeaxanthin in a small sample population, using two different FFQs, and to analyse 
this data using two different nutrient databases. The validity of the dietary 
assessment tools and nutrient databases was subsequently assessed using nutrient 
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biomarkers; blood serum and MPOD. Valid measurements of retrospective lutein 
and zeaxanthin intake, as well as ability to track lutein and zeaxanthin intake 
longitudinally, are crucial components for elucidating the role of lutein and 
zeaxanthin in health and disease. 
c) Of the antioxidants found in the human retina, only the macular carotenoids can be 
quantified non-invasively. MPOD determinations, as opposed to blood serum may 
be more precise and indicative of long term ocular nutrient status (Snodderly et al. 
2004). In the absence of effective treatment strategies for non-neovascular AMD, 
interest has focused on prevention and/or retardation of progression, therefore, the 
ability to measure MP in-vivo could prove valuable in determining, the possible risk 
of developing AMD and in monitoring treatment. A reliable clinical method to 
measure and quantify MPOD, and changes in MPOD in response to dietary 
fortification and/or supplementation, would afford optometrists the capacity to 
detect low MP, and therefore monitor response to treatment protocol, in order to 
reduce the risk of AMD and/or improve visual performance. The MPS 9000 is a 
new commercial instrument for measuring MP, and it also employs the HFP 
technique. It is a portable device, designed to be minimally demanding for both 
patient and practitioner, enabling clinicians to quickly measure MP. While based on 
the same optical principles of HFP, significant design and methodological 
differences do exist. The current study, therefore, aims to assess the accuracy and 
repeatability of the MPS 9000 in relation to the gold standard, the Densitometer.  
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1.3 Expected Results 
It is important that optometrists and primary eyecare practitioners are aware of the 
functional role of MP. There is evidence to support the view that MP plays a role in 
preventing or retarding the progression of AMD (Bone et al. 1997; Age Related Eye 
Disease Study (AREDS), report no 8, 2001; Johnson et al. 2005). AMD is a late onset 
disorder and changes may be occurring in the eye decades before any visual signs or 
symptoms of the disease. MP is believed to be associated with reduced risk of development 
and progression of AMD and can be augmented, not only by eating food rich in these 
carotenoids, such as spinach, but also by dietary fortification with one of the many 
commercially available food supplements (Bone et al. 2003; Murray & Carden, 2008). A 
large part of this thesis will focus on the relevance of MP to primary eyecare practice, 
including the prevention of debilitating eye conditions such as AMD, and the optimisation 
and preservation of visual performance at youthful levels in an era of increasing life 
expectancy and increasing aged population. The current series of investigations aim to 
elucidate the nature of any expected visual performance benefits that might be associated 
with higher MPOD, the value (if any) of current means of assessment of dietary intake of 
MP carotenoids, and the validity of a novel MPOD measurement device currently marketed 
to primary eyecare practitioners. 
            
1.4 Research Benefits 
Optometrists and primary eyecare practitioners remain surprisingly ignorant about MP‘s 
potential role, both in relation to visual symptoms such as glare and photophobia, and in 
long term preventative eyecare practice. Increased awareness, coupled with coherent and 
structured implementation of clinical practice policies and guidelines may confer long-term 
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visual health benefits, which may translate as improved visual comfort during life, and also 
as a reduced risk of developing AMD in later years. At a community level, screening for 
lutein, zeaxanthin and MP levels would allow the identification and establishment of 
appropriate dietary requirements, both in the lower (risk factor) and the upper levels 
(preventive factor), and as a result it would be possible to determine the adequacy and 
efficacy of dietary intake, or nutritional interventions, with clinical impact on disease 
prevention and visual improvement.  
 
Using the information gathered from these studies, it may be possible to develop a clinical 
guide for optometrists, explaining the practical implications of MP and its constituent 
carotenoids, for optometric practice in preventative health care and visual performance 
enhancement, and outlining the most appropriate means of quantifying and assessing MP 
and MP carotenoid consumption in a clinical population. 
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CHAPTER TWO 
Anatomy and Physiology of the Retina 
2.1 The Retina 
The retina is the light sensitive layer which extends over the inner surface of the back of the 
eyeball, lying in contact with the vitreous internally and with the vascular layer, the 
choroid, externally.                                                                                             
 
Figure. 2.1 Schematic drawing of the human eye (Tunnacliffe, 1993). 
 
The gross anatomy of the retina is divided into the outer pigmented epithelium layer and 
the inner neural sensory layers. These layers form a functional unit essential for vision. The 
neural components of the eye are an extension of the forebrain, and thus form part of the 
central nervous system. The retina is approximately 310 microns with significant 
geographical and inter-subject variation (Yang & Du, 1999). Retinal thickness varies from 
0.56 mm near the optic disc to 0.1 mm at the ora serrata. It is thinnest at the centre of the 
fovea. The structure of the retina consists of ten layers (Figure. 2.2) which include: 
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      1.   The Retinal Pigment Epithelium (RPE) 
      2.   Photoreceptors-rods and cones 
3. Outer limiting layer 
4. Outer nuclear layer-rod and cone nuclei 
5. Outer plexiform or synaptic layer 
6. Inner nuclear layer-bipolar, horizontal and amacrine nuclei. 
7. Inner plexiform or synaptic layer 
8. Ganglion cell layer 
9. Optic nerve fibres-ganglion cell axons 
10. Inner limiting membrane 
 
 
Figure. 2.2 a) Schematic drawing of human retina (Heath and Young 2000) and b) 
histological section of human retina (Freeman and Hull 2003). 
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2.2 Retinal Pigment Epithelium  
Morphologically RPE cells form a highly polarised epithelial sheet that separates the 
choroid from the retina. It is a single layer of cells that act as a major barrier between the 
leaky blood vessels of the underlying choroid and the neural retina. The epithelial cells are 
bound together by junctional complexes with tight junctions that separate the cells into an 
apical half that faces the retina and a basal half that faces the choroid. The basal end of each 
cell is much infolded and rests on the basement membrane which forms part of Bruch‘s 
membrane. The apical end of the cells have multiple microvilli and these project between 
and surround the outer segments of the rods and cones. Some cells in the body are capable 
of ongoing replication, while others such as those of the RPE have very limited ability to 
divide before reaching cellular senescence (Gao & Hollyfield, 1992; Marshall, 1987; 
Boulton, 1991). The RPE cells are for the most part non-mitotic cells and the epithelium is 
currently believed to consist of a stable, non-dividing pool of cells (Tso & Friedman, 1967). 
 
2.2.1 Function of the Retinal Pigment Eipthelium 
The RPE performs highly specialised unique functions essential for homeostasis of the 
neural retina. The RPE cells provide the principal mechanism for transfer of nutrients 
between the choriocapillaris and the photoreceptors, which is essential for maintaining 
normal photoreceptor cell function and survival. The RPE cells are arranged in a regular 
hexagonal pattern and form a barrier that limits the flow of ions and prevents diffusion of 
large toxic molecules from the choroid capillaries to the photoreceptors. The RPE acts in 
the absorption of light passing through the retina and phagocytosis of spent outer segment 
discs (Young & Bok, 1969). RPE cells are also the principal storage depot for vitamin A in 
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the eye and these cells supply the essential visual cycle intermediate, 11-cis retinal, to the 
photoreceptors for the regeneration of rhodopsin (Berman, 1994).  
 
The RPE is an integral part of the visual cycle. The photoreceptor outer segments must 
undergo continuous turnover in order for normal photoreceptor cell function and survival to 
be maintained (Herron et al. 1969). Rhodopsin, phospholipids and other components of the 
disc membranes are transported to the base of the outer segments for assembly into new 
discs. These components are then displaced distally along the length of the rod outer 
segment, and finally small packets of terminal discs are shed. The outer segment tips shed 
in this process are rapidly phagocytosed by the pigment epithelium. Degradation of these 
ingested outer segments is achieved through a highly developed phagolysosomal system 
first described in human RPE by Feeney (Feeney, 1973).  
           
The continuous phagocytic load imposed upon RPE cells through life leads to a striking 
age-related accumulation, from about aged 40, of auto fluorescent lipofuscin granules 
(Feeney, 1973; Marshall, 1987). RPE lipofuscin is derived almost exclusively from 
phagocytosed outer segments (Boulton et al. 1989; Kennedy et al. 1995). With advancing 
age these particles may in some cases fill almost the entire RPE cell (Wing et al. 1978). 
Most of the discs appear to be degraded quickly in lysosomes of young healthy individuals, 
however, over time incompletely degraded membrane material builds up in the form of 
lipofuscin within secondary lysosomes or residual bodies (Boulton et al. 1989). In older 
individuals up to 25% of the volume of RPE cells may be occupied by lipofuscin, therefore 
room for normal cellular machinery is consequently limited. As a result, lysosomes and 
mitochondria of RPE suffer age-related alterations which, eventually, may lead to apoptotic 
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cell death. There is an age-related loss of RPE cells, particularly in the fovea and mid-
periphery, forcing compromised lipofuscin-engorged cells to provide metabolic 
maintenance for the retina. 
 
Figure 2.3 Diagram showing the relationship between the photoreceptor cells and the 
RPE. The outer segments undergo a continual process of renewal. Periodically, the 
tips of the outer segments are shed from the photoreceptors and are then 
phagocytosed by the RPE (Modified from Katz & Robison, 2002).      
 
2.3 Photoreceptor Layer 
Photoreceptors are highly specialised cells that are sensitive to light and responsible for 
converting light into a neural impulse. There are two main types of photoreceptors: rods 
and cones.  Rods are responsible for peripheral and scotopic vision, whereas cones operate 
best in photopic conditions and are responsible for central vision and colour perception. 
Cones are capable of high spatial and temporal resolution. The outer segments of both rods 
and cones contain discs with a double membrane and the visual pigments which capture 
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photons are mainly built into these discs and consist of aldehyde of vitamin A and various 
proteins (Steinberg et al. 1980; Adler and Martin, 1982; Papermaster et al. 1985). The 
photopigment in rods is rhodopsin and the photopigment in cones is iodopsin. The inner 
synaptic end of the photoreceptors transmits the effect of light to the bipolar and horizontal 
cells (Daw et al. 1990). Typically there are approximately 110 to 125 million rods and 6.5 
million cones in an eye. Overall rods are longer and thinner than cones (Heath & Young, 
2000).        
 
 Figure 2.4 The structure of a rod cell (Accessed from 
http://www.phys.utl.edu/~avery/course/3400/gallery/gallery-vision.html). 
 
The photoreceptor outer segments protrude into a unique compartment bounded by the RPE 
and Müller cells. The molecular composition of this compartment, the interphotoreceptor 
matrix (IPM), contains components secreted by rod and cone photoreceptors, Müller cells 
and RPE cells. In addition to transporting molecules among the cells bordering the IPM, 
various proteins and glycosaminoglycans provide a scaffold for the photoreceptor outer 
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segments and regulate the water and ion content of their environment (Hollyfield, 1999). 
RPE cells and Müller glial cells form the major component of the blood retinal barrier for 
the choroidal and retinal circulation, respectively. They regulate nutrient flow to 
photoreceptors and control the composition of the extra cellular environment surrounding 
rods and cones.  
        
There are three types of cones; the differing absorption spectra between their pigments give 
rise to colour perception. The SW class is the least populated cone type and is absent at the 
very centre of the foveola but has a peak intensity at approximately one degree. This in 
theory would have implications for reducing sensitivity to CA in the eye. The two 
remaining cone classes (medium and long wavelength cones) combine with the SW class to 
provide a typical range of sensitivity to wavelengths between 390 nm & 760 nm 
(Tunacliffe, 1993). Red-green cones seem to be more resistant than blue cones to aging and 
may also increase in size in AMD (Sarks et al. 1988; Curcio et al. 1996).  
 
 
Figure 2.5 Absorption spectrum of rods and cones. (Accessed from 
http://www.phys.utl.edu/~avery/course/3400/gallery/gallery-vision.html).    
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The small cone dominated fovea of only 0.8 mm (2.75
o
) in diameter is surrounded by a rod 
dominated parafovea (Curcio et al. 1990). In young adults, rods outnumber cones in the 
macula by 9:1. In the entire eye, rods outnumber cones 20:1. So the macula can be 
considered cone enriched but not cone dominated (Curcio et al. 2000). The retinal region 
with the highest acuity, the macula, has the highest cone density, rising to about 146,000 
cones per mm
2
 (Tunacliffe, 1987). 
 
Figure 2.6. Graph showing number of rods and cones per mm (Accessed from 
http://www.phys.utl.edu/~avery/course/3400/gallery/gallery-vision.html). 
 
In the maculas of older adults lacking grossly visible drusen and pigmentary change (i.e. 
they do not have AMD), the number of cones in the cone dominated part of the macula is 
stable at approximately 32,000 through to the ninth decade (Curcio et al. 1993). In contrast, 
the number of rods in the macula of the same eyes decreases by 30%. The greatest loss 
occurs in the parafovea (1-3 mm from the fovea at 3.5
o
-10
o
 from fixation). Psychophysical 
studies of photopic and scotopic sensitivity have identified that rods are at risk for 
38 
 
degeneration in aging and ARM and that scotopic impairment is greater than photopic 
impairment in older adults (Curcio et al. 2000).  
          
With respect to photoreceptor topography at different stages of ARM, the foveal cone 
mosaic of eyes with large drusen and thick basal deposits is surprisingly similar to that of 
aged matched controls (Curcio et al. 1996), and the total number of foveal cones remain 
normal. Furthermore, in eyes with late ARM, virtually all surviving photoreceptors in the 
macula are cones, a reverse of the normal predominance of rods. While rods gradually 
disappear with age, even without evidence of overt RPE disease, cones only begin to 
degenerate by advanced stages in non-exudative AMD (Curcio et al. 1993; 1996), and may 
finally result in disappearance of all photoreceptors in the presence of geographic atrophy 
(GA) or disciform degeneration (Sarks et al. 1988; Curcio et al. 1996). Although death of 
cone photoreceptors and consequent loss of vision are end points of AMD, it is far from 
clear whether the disease begins in these cells or elsewhere. 
 
2.3.1 Macular pigment   
Although MP is found throughout the tissue of the eye, it is concentrated in the macula 
lutea region of the retina, including the central retinal depression called the fovea, where 
cone photoreceptors reach their maximal concentration. The localisation of MP within the 
retina is in the fibres of Henle in the fovea and parafoveally MP is located in the inner and 
outer plexiform layers (Trieschmann et al. 2008). MP will be discussed in detail in chapter 
three. 
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2.4 The Inner Neural Sensory Retina (layers 3 to 10) 
 
2.4.1 The outer limiting membrane 
In the outer retina, the junctional complexes between Müller glial cells and photoreceptor 
inner segments, form the outer limiting membrane. It is not a true membrane structure but 
rather an artifact created by extensive interconnections between adjacent photoreceptors.  
 
2.4.2 The outer nuclear layer 
The outer nuclear layer contains the nuclei of the photoreceptors and their surrounding 
cytoplasm.  
 
2.4.3 The outer plexiform layer 
 Photoreceptor axons and synaptic processes extend up to the outer plexiform layer (a 
communication layer) where they synapse with the neural layers.  
 
2.4.4 The inner nuclear layer 
The inner nuclear layer contains the nuclei of 
    a) Bipolar cells, which communicate between one or more ganglion cells and one or 
more photoreceptors. They also may synapse with horizontal or amacrine cells. 
     b) Horizontal cells which may have short processes and one long process. They form 
lateral connections between photoreceptors, and between photoreceptors and bipolar cells.  
     c) Amacrine cells which communicate with bipolar cells, fellow amacrine cells, 
ganglion cells and occasionally provide a feedback loop to photoreceptors. 
     d) Interplexiform cells which communicate from ganglion cells to photoreceptors and 
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     e) Müller cells which are non-neural support cells (Heath and Young, 2000). 
There are many sub-types of bipolar cells which are important for summation and retinal 
processing. Horizontal cells are used in coding colour vision and they can act to dampen 
rod signal if the cone signal is strong and visa versa. Amacrine cells are large cells 
predominantly located in the retinal periphery.  
 
2.4.5 The inner plexiform layer 
The inner plexiform is thicker than the outer plexiform layer, except at the fovea where it is 
absent. It is a communication layer where impulses are relayed between bipolar, amacrine 
and ganglion cells. 
 
 2.4.6 Ganglion cell layer 
Ganglion cells are the only cell type in the ganglion cell layer and there are 1.2 million 
ganglion cells in the retina. Their cell size increases and the layer thickness decreases with 
retinal eccentricity. A 1:1 relationship between cones and ganglion cells exist at the fovea, 
compared to a 100:1 rod to ganglion cell relationship at the periphery. The difference in 
coupling ratios exemplifies the greater resolution at the fovea, which is important for the 
eye to extract the maximum image it can from the retinal image provided by the optics of 
the eye. The reduced resolution of the peripheral retina is economically matched in terms of 
biological demands to the reduced image quality provided by the eye‘s optics in the 
peripheral visual field. 
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2.4.7 The nerve fibre layer  
The nerve fibre layer contains the axons from ganglion cells. It takes a radial pathway 
across the nasal retina and an arcuate pathway across the temporal retina to the optic nerve 
head. The only exception is the papillomacular bundle where some axons in the central 
macular region take a radial path to the optic nerve head. The nerve fibre paths are strictly 
demarked between the superior and inferior retina by the horizontal raphe. Although the 
nerve fibres are unmyelinated, they are insulated by glial cells. 
 
2.4.8 The inner limiting layer 
The inner limiting membrane marks the boundary between the vitreous and the retina. A 
true basement is present and it is associated with condensing Müller cell membranes and a 
thickening of the vitreous basal laminar. The inner limiting membrane has variable 
adherence to both the sensory retina and the vitreous.  
 
2.5 Blood Supply to the Retina 
The retina receives vascular supply from both the choriocapillaris and the retinal 
vasculature system. The retinal vessels are absent centrally at the fovea. The central retinal 
artery enters the optic nerve some 10 to 15 mm behind the globe. On entering the eye the 
vessels branch into inferior and superior divisions which continue to subdivide and proceed 
to all parts of the retina, where, as capillaries, they supply the inner two-thirds of the retina. 
The outer third is supplied by transport across the pigment epithelium from the choroid. 
The retinal venous system exits the eye via the central retinal vein. The corresponding 
retinal venous branches have much the same distribution as arteries. 
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Figure 2.7 Showing blood supply to the retina (Accessed from Simple Anatomy of the 
Retina – webvisionhttp://webvision.med.utah.edu/book/part-i-foundations/simple-anatomy-
of-the-retina/) 
 
The choroid is supplied by the short posterior ciliary arteries, and these arteries are 
branches of the Ophthalmic artery. They form a rich anastomotic network that quickly 
empties large quantities of blood into the choriocapillaris (sinusoidal network). The 
choriocapillaris supplies the RPE and outer retinal layers. Four or five vorticose veins drain 
the choroid and pierce the sclera to join the Ophthalmic veins.  
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2.6 The Choroid 
The choroid is a thin layer lining the inner surface of the sclera. It is extremely vascular and 
its principal function is to nourish. The choroid extends from the optic nerve posteriorly to 
the ciliary body anteriorly. Its inner surface is smooth and firm and is attached to the 
pigmented layer of the retina. Its outer surface is roughened and is firmly attached to the 
sclera in the region of the optic nerve and where the posterior ciliary arteries and ciliary 
nerves enter the eye.  
The choroid may be divided into three layers. 
(i) The vessel layer (ii)) the capillary layer and (iii) Bruch‘s membrane. 
 
2.6.1 The vessel layer 
The external layer consists of loose connective tissue containing melanocytes in which are 
embedded numerous large and medium sized blood vessels. 
 
2.6.2 The capillary layer or choriocapillaris  
This intermediate layer consists of a network of wide bore capillaries with sac like 
dilatations. They are fed by arteries from the vessel layer and drained by veins into the 
vessel layer.  
 
2.6.3 Bruch’s membrane 
Bruch‘s membrane has five anatomic layers with known structure and function. The 
innermost layer (i.e. closest to the RPE) of Bruch‘s membrane is the RPE basal lamina, 
which serves as the anchoring surface for the RPE. Proceeding externally is the inner 
collagen layer, which is a dense collagen matrix that interconnects the basal lamina and 
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elastin layers of Bruch‘s membrane. Most of the dysfunction within AMD starts in the 
inner collagen layer. Drusen like material can accumulate either on the inner or outer aspect 
of the basal lamina layer. Next is the outer collagen layer, which is similar to the inner 
collagen layer at the ultrastructural level. Structural changes occur within the outer collagen 
layer as a function of advancing patient age, including collagen cross-linking. Lastly, the 
basal lamina layer separates the outer collagen layer from the choriocapillaris.  
        
 
 
                                             
 
Figure 2.8 Basement membrane, comprising the basal lamina and reticular lamina, in 
a diagram of a section through epithelial tissue. (Accessed from http://medical-
dictionary.thefreedictionary.com/Bruch's+membrane) 
 
Deposition of waste material occurs between the RPE and Bruch‘s membrane in the form 
of basal deposits. Basal laminar deposits accumulate between the RPE cell plasma 
membrane, and its basement membrane (Green & Enger, 1993; Green, 1999), whereas 
basal linear deposits accumulate external to the basement membrane of the RPE (e.g in the 
inner collagenous zone of Bruch‘s membrane). Basal laminar and basal linear deposits  
contribute to thickening of Bruch‘s membrane with age (Green & Enger, 1993). 
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2.7 The Macula  
The macula is recognised as the specialised region of the retina capable of high-resolution 
visual acuity (VA). Francisco Buzzi was the first to anatomically define the macula at the 
end of the 18
th
 century (Buzzi,1782) (Cited by Loughman et al. 2010). He described it as 
the yellow portion of the posterior retina, lateral to the optic nerve, with a depression in its 
centre. Wald (1945) documented the first xanthophylls extracted from the human retina and 
found they were concentrated in the macula. He suggested that the yellow pigment 
absorbed wavelengths between 430 and 490 nm, with maximum absorption at 465 nm. It 
has been established that the xanthophylls, lutein and zeaxanthin are responsible for the 
yellow colour and the antioxidant capabilities of these xanthophylls combined with their 
ability to trap SW light may serve to protect the outer retina, RPE and choriocapillaris from 
oxidative damage (Weale, 1951; Brown & Wald, 1963; Ruddock, 1963; Bone et al. 1985). 
Bone et al. (1985), identified lutein and its structural isomer, zeaxanthin as the specific 
xanthophylls in the retina, and Snodderly et al. (1984), located the xanthophyll pigment in 
the Henle fibre layer of primates.  
 
Anatomically the macula (macula lutea or central retina) is defined as that portion of the 
posterior retina that contains xanthophylls and two or more ganglion cells. This region is 
about 5.85 mm in diameter and is centered approximately 4 mm temporal and 0.8 mm 
inferior to the centre of the optic disc (Hogan et al. 1971). On the basis of microscopic 
anatomy, the macular area can be subdivided into several zones: the macula lutea (~5.85 
mm diameter), fovea centralis (~1.85 mm diameter) and the foveola (~0.35 mm diameter) 
(Kanski, 2003).  
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Figure 2.9 (a) Schematic drawing of human foveola (Kanski and Milewski 2002). (b) 
Histological section of human foveola (Heath and Young 2000). 
 
The fovea (fovea centralis) is a depression in the inner retinal surface in the centre of the 
macula and it is more heavily pigmented then the surrounding retinal tissue. The central 
floor of the fovea is called the foveola. It lies within the capillary free zone. A small 
depression in the centre of the foveola is called the umbo where the retina is only 0.13 mm 
thick. The anatomic subdivisions of the macula are ill-defined opthalmoscopically. The 
foveal reflex is present in most normal eyes and it lies just in front of the centre of the 
foveola. The macular area can also be described and divided in terms of different areas:  
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(i)Fovea containing foveola (ii) Parafovea (iii) Perifovea (Figure. 2.11). 
Figure 2.10 An anatomical view of the macula region as viewed in cross section 
(adapted from Thibos et al 2000). 
The foveola is surrounded by a wide ring zone, where the ganglion cell layer, inner nuclear 
layer and outer plexiform layer of Henle are thickest, and this is called the parafoveal area. 
This zone is in turn surrounded by the perifoveal area. 
 
2.7.1 Specialisation of the macula 
Most layers of the sensory retina are displaced sideways at the foveola to create the foveal 
pit. Thus, photoreceptors have unimpeded stimulation from light forming the retinal image. 
The small cone size and tight cell packing at the fovea, increases the spatial resolution of 
the visual system for on axis imaging (Heath and Young, 2000). 
perifovea diameter 5.85mm 
fovea  
diameter 
 1.85mm     
foveola diameter 0.35 mm     
parafovea  
diameter  
2.85mm    
a) 
b) 
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Figure 2.11 The central human fovea shown as graphics (Modified from Trieschmann 
et al. 2008). 
 
The fovea accounts for almost all of our useful photopic vision, even though it comprises 
less than 4% of the total retinal area. The retinal region with the highest acuity, the fovea, 
has the highest cone density and the central 100 µm of the foveola contain only red and 
green cones. Blue cone density is highest in a zone between 100 and 300 µm from the 
centre of the fovea. The foveola is entirely rod free. Rods, ganglion cells and all inner 
nuclear layer neurons are absent from the foveola so that light is directly incident on 
photoreceptors. 
 
The retina is principally organised on a vertical basis. Receptors transmit activity to the 
bipolar and ganglion cells and then to the higher brain centres. A given receptor may 
activate several bipolar cells, which may in turn activate more than one ganglion cell which 
causes a horizontal spread of the effect of the light stimulus. Horizontal and amacrine cells 
further increase the probability of horizontal interaction. There are three types of bipolar 
cells. Midget bipolars make contact with one cone only, whilst the flat bipolar connects 
with 6 or 7 cones. The third type, the rod bipolar, may make synapses with up to 50 rods 
(Tunnacliffe, 1987). There are two types of ganglion cells: the midget ganglion cell which 
connects with a midget bipolar cell and therefore has a very close relationship with a single 
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cone, and a diffuse type connecting with several bipolar cells. The single cone/midget 
bipolar/midget ganglion cell route is partly the basis of high VA achievable at the fovea. 
Midget ganglion cells probably only respond to cone stimulation, whereas diffuse ganglion 
cells respond to both rod and cone stimulation.  
 
The variable density and distribution of photoreceptors and ganglion cells across the retina, 
the differential light sensitivity of photoreceptors, and the convergence of information from 
the extra-foveal retina means that a hierarchy exists in the architecture of retinal processing 
and foveal information is given higher priority. This hierarchy continues back to the striate 
cortex, where a high percentage of cortical cells are dedicated to foveal information. The 
fovea is particularly important for functional vision (e.g. acuity); blindness results when 
this area is lost to disease.   
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CHAPTER THREE 
Macular Pigment 
The centre of the retina at the back of the eye contains a yellow pigment which gives this 
region its name, macula lutea (yellow spot). The yellow colouration of the macula is 
attributable to the presence of MP (Snodderly et al. 1984). Although all humans appear to 
have some quantity of MP within their retina, foveal concentrations tend to vary quite 
dramatically (Pease et al. 1987; Hammond et al. 1995). Lutein and zeaxanthin are 
introduced to the human body through dietary means alone, and although not considered to 
be essential micronutrients, they have powerful antioxidant and photoreceptive properties 
(Snodderly, 1995; Khachik et al. 1997; Landrum et al. 1997). Findings are currently 
emerging that higher levels of dietary and serum levels of lutein and zeaxanthin are 
associated with a lower risk of AMD (Seddon et al. 1994; Chakravarthy et al. 2009). The 
fact that MP is modifiable means that ongoing research into its role in prevention or 
progression of AMD is important. The functional role of macular carotenoids, have not 
been completely defined, however two major non-exclusive hypotheses have been 
proposed. The protection hypothesis has received the most attention and is based on the 
possibility that MP could reduce the cumulative effects of damage due to light and 
oxidation, and thereby retard the development of age-related eye disease. The optical 
hypothesis suggests that MP could influence visual resolution by absorbing SW light, 
which is easily scattered and poorly focused. The optical hypothesis is expanded further to 
include acuity, visibility and visual health hypotheses. These hypotheses are discussed in 
detail in section 3.8; 3.9.      
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3.1 Carotenoids 
De novo synthesis of carotenoids does not occur in animals and the MP of primates can be 
traced to its dietary origins. Lutein and zeaxanthin are two of the 600 plant pigments in the 
carotenoid class, and they belong to the xanthophyll family of carotenoids. There are 
between 40 and 50 carotenoids present in a typical western diet (Khachick et al. 1992; 
1997), but only 14 have been detected in human blood (Khachick 1992; 1997). The most 
prominent plasma carotenoids include lycopene, α-carotene, β-carotene, lutein and 
zeaxanthin (Khachick et al. 1997). Meso-zeaxanthin has been found in trace amounts in 
blood serum (Connolly et al. 2010); however until recently it had not, in the absence of 
supplementation, been detected or reported on in human serum. Lutein, zeaxanthin and 
meso-zeaxanthin are found in the retina (Bone et al. 1985; Khachik et al. 1997) to the 
exclusion of all other carotenoids in nature and are termed MP. Lutein and zeaxanthin are 
also the only carotenoids found in the lens of the human eye (Landrum & Bone, 2001). 
 
Lutein and zeaxanthin are found in a typical Western diet, of fruit and vegetables, although 
zeaxanthin is found in much smaller quantities than lutein (Sommerburg et al. 1998). In the 
diet lutein is found in highest concentrations in dark green leafy vegetables (spinach, kale, 
collard greens and others) (Sommerburg et al. 1998). Zeaxanthin is the major carotenoid 
found in corn, orange peppers, oranges and tangerines. The highest molar percentage of 
lutein and zeaxanthin are found in egg yolk and maize (Sommerburg et al. 1998). In serum, 
the ratio of zeaxanthin to lutein is 1:4 (Bone et al. 1997). Although meso-zeaxanthin has 
been identified in some less commonly consumed foods including fish (e.g. salmon and 
trout), shrimp, and turtle (Maoka et al. 1986), it is generally believed to be generated at the 
macula following a biochemical transformation of lutein (Bone et al. 1997; Johnson et al. 
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2005). Xanthophylls are a subclass of carotenoids, a large group of plant pigments 
responsible for the colour of bright fruit and vegetables. They act as energy sinks in plants 
and provide the essential first step toward photosynthesis in association with chlorophyll. 
Lutein and zeaxanthin differ from other carotenoids in that they each have two hydroxyl 
groups, one at each side of the molecule. Zeaxanthin is a stereoisomer of lutein differing 
only in the location of a double bond in one of the hydroxyl groups. The hydroxyl groups 
appear to control the biological function of these two xanthophylls (Johnson et al. 2005). 
Carotenoids are linear hydrocarbons and xanthophylls are the oxygenated form (Goodwin, 
1980). Meso-zeaxanthin, which represents the product of chemical processes involving 
lutein in the retina, will be discussed in section 3.2. 
  
3.2 Stereochemistry of Macular Pigment 
The yellow MP was shown in 1985, by Bone et al. and later by Handleman et al. (1988), 
using high-performance liquid chromatography (HPLC), to be composed of two 
chromatographically separable components, namely lutein and zeaxanthin. Subsequently 
MP was shown to be characterised by the presence of specific stereoisomers of these two 
carotenoids (Bone et al. 1993). 
       
While lutein is present as a single stereoisomer, [(3R,3'R,6'R)-β,ε-carotene-3,3'-diol], 
zeaxanthin occurs primarily as a mixture of three isomers; [(3R,3'R)-β,β-carotene-3,3'-
diol], [(3R,3'S)-β,β-carotene-3,3'-diol], with a much smaller amount of [(3S,3'S)-β,β-
carotene-3,3'-diol] (Bone et al. 2007). The first two predominant zeaxanthin isomers are 
referred to as zeaxanthin and meso-zeaxanthin respectively. 
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Lutein is the dominant carotenoid in the blood (Bone et al. 1993), whereas zeaxanthin and 
meso-zeaxanthin in particular, are less commonly consumed in a typical Western diet. 
Despite a lutein-zeaxanthin ratio of approximately 4 to 1 in human plasma (Bone et al. 
1997), and only trace amounts of meso-zeaxanthin have been detected in human serum 
(Connolly et al 2010), meso-zeaxanthin accounts for about one third of total MP at the 
macula, which is consistent with the finding that retinal meso-zeaxanthin is produced 
primarily by isomerisation of retinal lutein in the eye (Bone et al. 1993, Johnson et al. 
2005). This hypothesis is supported by the observation that lutein can be isomerised to 
meso-zeaxanthin by a base-catalysed reaction (Bone et al. 1997).  
 
Stereochemistry of Human Macular Carotenoids 
 
Figure 3.1 The structure of the major components of Macular Pigment (Bone et al. 
1993).  
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MP therefore refers to the accumulation at the macula of a single isomer of lutein and 3 
stereoisomers of zeaxanthin (RRZ, meso-zeaxanthin, and SSZ), to the exclusion of all other 
carotenoids which are found in the blood (Snodderly et al. 1984; Bone et al. 1993). 
 
3.3 Location of Macular Pigment 
The spectral distribution of lutein and zeaxanthin, were studied in the retinas of macaque 
monkeys and squirrel monkeys by Snodderly et al. (1991). Lutein and zeaxanthin were 
found to reach their highest concentration at the centre of the fovea, in the Henle fibre 
layer, with a sharp drop-off with increasing eccentricity from the macula (Snodderly et al. 
1991). Trieschmann et al. (2008) evaluated MP in the human retina of donor eyes and 
found comparable results with those obtained with primates (Snodderly et al. 1984; 1984). 
Within the central fovea, the carotenoids are most concentrated within the photoreceptor 
axons of the Henle nerve fibre layer (Snodderly et al. 1984). In the perifoveal region lutein 
and zeaxanthin are present in the outer segments of rod photoreceptors (Treischmann et al. 
2008). Meso-zeaxanthin is observed to reach its maximum in the central macula (Bone et 
al. 1993; 1997).  
 
  
Figure 3.2 Histology of human macular pigment  illustrating the spatial profile and 
pre-receptorial location of MP.The main location of macular pigment was in the layer 
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of the fibres of Henle in the fovea (a) and in the inner nuclear layer at the parafoveal 
site (b). (Modified from Trieschmann et al. 2008).  
 
MP density and distribution however varies considerably between individuals 
(Trieschmann et al, 2003; 2008), and it is not yet known if either or both the density and/or 
the distribution is important in protection of the retina.  
          
Although MP is found throughout the whole retina (Handleman et al. 1988; Bone et al. 
1988), these carotenoids reach their maximum concentrations at the foveola. Bone et al. 
(1997) reported that the proportions of meso-zeaxanthin:zeaxanthin in the central 3 mm of 
the macula was 0.83, which decreased with increasing distance from the fovea. The ratio of 
lutein to zeaxanthin and meso-zeaxanthin varies linearly with the ratio of rods to cones with 
increasing eccentricity up to approximately 6 degrees from the fovea (Bone et al. 1988). 
The hypothesis that zeaxanthin is found only in the rods is refuted by the fact that the fovea 
contains predominantly cones, as well as by the fact that squirrel monkey and macaque 
retina have their highest concentration of lutein and zeaxanthin in the central fovea 
(Snodderly et al. 1991). It is believed that at 7 degrees eccentricity retinal carotenoids 
become optically undetectable (Bone et al. 1988).  
 
3.4 Optical Density and Serum Levels of Macular Pigment 
There is a consensus among investigators that MP density varies between individuals 
(Hammond et al. 1997; Trieschmann et al. 2008), but there is good individual interocular 
agreement of MPOD, with mean differences of only 5% for zeaxanthin and 11% for lutein, 
between fellow eyes (Hammond et al. 1992; Handleman et al. 1991). Hammond et al. 
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(1996) conducted a prospective study to investigate the relationship between plasma, 
dietary and macular carotenoids. The investigators were able to draw some reasonable 
conclusions: 
   
(i) There are individual differences in the response to dietary modification with carotenoid 
supplements and there is dramatic variability of MPOD between individuals (Pease et al. 
1987; Hammond et al. 1992; 1997). It has been suggested that people who are less 
responsive to lutein supplementation may be so because of genetic differences, which 
results in reduced or less efficient lutein binding proteins in some people. Lutein-binding 
proteins have a high affinity to lutein and have been discovered in the retina of human eyes 
(Landrum & Bone, 2004). Hammond et al. (1997) found no retinal response in three people 
out of 11, despite dietary modification with spinach and corn for 14 weeks. Two retinal 
‗non-responders‘ showed substantial increases in serum lutein but not in MPOD. One 
serum and retinal ‗non-responder‘ showed no changes in serum lutein, zeaxanthin or β-
carotene and no change in MPOD. 
(ii) Serum levels of lutein and zeaxanthin reflect recent nutritional intake. MPOD on the 
other hand is said to have a slower biological turnover, as it reflects the local balance 
between pro-oxidant stresses and antioxidant defences in the retina (Nolan et al. 2007). A 
sudden change in diet will be reflected in much more rapid changes of serum 
concentrations of lutein and zeaxanthin, whereas it is unlikely to affect MPOD in the retina 
for several weeks. However, a recent study reported a significant increase in MPOD after 
only two weeks of supplementation (Connolly et al. 2010) and a study by Loughman et al 
(2011), observed a decline of 31% and 43%  of central (0.25 degrees) and average MPOD 
respectively, after a period of only 21 days of dietary exclusion of the MP carotenoids. 
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Macular concentrations of the carotenoids in the retina may not appear to be as consistent 
over long periods of time, in individuals on a relatively constant diet, as was originally 
thought (Bone et al. 1988), highlighting even more the importance of measuring MP in 
clinical practice.  
(iii) There are discrepancies between tissue and serum responses to lutein and zeaxanthin 
supplements, which suggest that blood levels of carotenoids in isolation, provide 
insufficient information when investigating the possible protective effect of carotenoids 
against retinal degenerative disorders. Although a positive and significant relationship 
exists between the density of MP and serum concentrations of lutein and zeaxanthin 
(Landrum et al. 1997), lutein/zeaxanthin ratios of blood and macula do not correlate and 
this is partly attributable to the stereochemistry of macular carotenoids (Bone et al. 1993), 
processes which influence digestion, absorption and transport of compounds in question, 
and accumulation and stabilisation of the carotenoids in the tissues. Because xanthophylls 
are fat soluble nutrients, bioavailability to tissues is dependent on a number of factors 
including nutrient source (whole food or supplement), state of food (raw, cooked or 
processed), extent of disruption of the cellular matrix via mastication and digestive 
enzymes, and absorption by the enterocytes of the intestinal mucosa (primarily the 
duodenum). Cooking of lutein/zeaxanthin foods may increase bioavailability by disrupting 
the cellular matrix and the carotenoid protein complexes (Castenmiller,1999). Non dietary 
factors affecting absorption and bioavailability of lutein and zeaxanthin include age, body 
composition, gender, malabsorption of fats, alcohol consumption, smoking and liver and 
kidney disease. 
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Lutein and zeaxanthin are also known to accumulate in liver, spleen and adipose tissue 
(Thomson, 2002). There is evidence of an inverse relationship between body fat and 
MPOD in humans (Johnson et al. 2000; Hammond et al. 2002), and a similar relationship 
with retinal lutein (not zeaxanthin) in female quail (Thomson, 2002), suggesting that fat 
and retina compete for lutein. 
 
3.5 Function of Macular Pigment 
Although the function of MP remains uncertain, several possibilities have been suggested. 
Blue light filtration effects, including glare reduction, minimisation of CA, contrast 
enhancement, improved fine detail distinction, and free radical scavenger by neutralising 
reactive oxygen species (ROS), are some of the major proposed functions of these ocular 
carotenoids (Whitehead et al. 2006). Two major but non-exclusive hypotheses regarding 
the function of MP exist and these include the ‗Protection‘ hypothesis and the ‗Optical‘ 
hypothesis.  
 
3.6 Oxidative Stress and Reactive Oxygen Species 
The ‗protection‘ hypothesis of MP is based on the possibility that MP could reduce the 
cumulative effects of damage due to light and oxygen and retard the development of age-
related eye diseases such as AMD.  
      
Oxidative stress is caused by an imbalance between the production of ROS and a biological 
systems ability to readily detoxify or easily repair the resulting damage. In aerobic 
conditions, ROS are generated at a very high rate. In the retina, the generation of ROS can 
occur as the by-products of cellular metabolism (Kukreja & Hess, 1992) or as a result of 
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photochemical reactions (Dargal, 1992). These molecules are highly reactive and will 
readily react with lipid, protein and nucleic acids, thereby resulting in impaired cell 
function or cell death (Halliwell, 1997). Most of the ROS are byproducts of normal 
physiological processes and are eliminated immediately by antioxidant systems. ROS form 
a natural by product of normal metabolism of oxygen and have an important role in cell 
signalling, however during times of environmental stress (UVand SW light, smoking or 
heat exposure), ROS levels can increase dramatically, which can result in significant 
damage to cell structures. This cumulates into a situation known as oxidative stress. 
 
3.6.1 Reactive oxygen species 
ROS is an umbrella term used to describe free radicals, hydrogen peroxide and singlet 
oxygen. Free radicals are molecules that contain one or more unpaired electron in their 
outer orbits, and examples include the superoxide anion (O2⁻•), the hydroxyl free radical 
(OH•), the hydroperoxyl radicals (HO₂•) and the lipid peroxyl radicals (Halliwell, 1991). 
Hydrogen peroxide (H₂O₂) and singlet oxygen (¹O₂) contain their full complement of 
electrons, but in an unstable or reactive state. Environmental factors such as cigarette 
smoking intense light exposure, irradiation, aging and inflammation are known to increase 
the production of ROS (Borish et al. 1987; Machlin & Bendich, 1987). In order to achieve a 
stable state, free radicals extract electrons from other molecules, which are themselves 
rendered unstable by this interaction, and a cytotoxic oxidative chain reaction results. 
Hydrogen peroxide, although containing no unpaired electrons, can generate free radicals 
through the Fenton reaction and singlet oxygen can damage molecules as it converts back 
to normal oxygen (Beatty et al. 2000). 
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Carbohydrates, membrane lipids, proteins and nucleic acids are all vulnerable to damage 
caused by ROS, and this damage is believed to contribute to the pathogenesis of many 
diseases, including ischemia, atheroma, diabetes, aging and Parkinson‘s disease (Davis, 
1991; Halliwell, 1991).  
 
3.6.2 Antioxidant enzymes 
 The antioxidant system in cells and tissues include enzymes (catalase, glutathione 
peroxidase and superoxide dismutase) and smaller antioxidant molecules, such as water 
soluble vitamin C and glutathione, and lipid soluble antioxidants, such as xanthophylls, 
retinoids and vitamin E, which back up the enzymatic system as direct scavengers (Beatty 
et al. 2000; Cai et al. 2000).  
 
3.6.3 Generation of reactive oxygen species in the retina 
The retina is an ideal environment for the generation of ROS for a number of reasons. The 
outer retina, especially membranes of the outer segments of the photoreceptors, has a high 
concentration of polyunsaturated fatty acids (PUFAs) that are susceptible to photo-
oxidation (De La Paz & Anderson, 1992). Oxygen consumption by the retina is much 
greater than by any other tissue and the outer retina has a high oxygen tension (70 mmHg), 
almost that of arterial blood. The retina is also subject to high levels of cumulative 
irradiation and the process of phagocytosis by the RPE itself creates oxidative stress, which 
results in the generation of ROS (Tate, 1995). The turnover of photoreceptors is high and 
the shed membranes have the highest concentration of PUFA‘s of any human tissue and are 
promptly phagocytosed by RPE. Peroxidation of these lipids can induce damage in the 
RPE. 
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A rich oxygen supply, combined with high-energy SW light stimulation, and a vulnerable 
substrate creates ideal conditions for oxidative damage. Another potential anatomical site 
for damage mediated by a photochemical response is the choriocapillaris.  
 
3.6.4 Retinal irradiation 
It has been shown that photochemical injury at the level of the RPE is related to 
wavelength, the threshold for damage being lowest for SW light region of the visible 
spectrum. Photochemical retinal injury was first described by Ham et al. (1978). The 
authors reported on the histopathologic findings of rhesus monkey retinas that had been 
exposed to blue light (441 nm) for 1000 seconds. It was noted that SW light resulted in 
damage to the photoreceptor outer segments and the generation of AMD like lesions in 
monkey retinas following exposure to light of varying wavelengths required 70-1000 times 
less power when using blue light compared to infrared wavelengths (Ham et al. 1978).  
 
3.6.5 Polyunsaturated fatty acids 
The photoreceptor membranes of both rods and cones contain a lipid bilayer. PUFAs, 
account for about 50% of the lipid bilayer of rod outer segment membranes and proteins 
make up the remaining 50%. PUFAs are particularly susceptible to free radical damage 
because their conjugated double bonds are convenient sources of hydrogen atoms, which 
contain one electron. The lipid radical combines with oxygen to form lipid peroxyl radicals 
and lipid peroxides, which can achieve a steady state only by stealing electrons from other 
PUFAs, thus creating a cytotoxic cascade of reactions that consume valuable PUFAs and 
produce damaged molecules (Beatty et al. 2000). 
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 Docosahexaenoic acid (DHA) is the most oxidisable fatty acid in the body, and it makes up 
~ 50% of the vertebrate rod photoreceptor phospholipid (Anderson et al. 1976). DHA 
contains six double bonds so the retina is inherently susceptible to lipid peroxidation. High 
levels of oxygen, delivered to the photoreceptor outer segments and the RPE from the 
choriocapillaris, coupled with the intense focus of environmental light on the macula, 
provides a highly permissive environment for the generation of reactive oxygen that can 
damage DHA (Hollyfield, 2010). Lipid peroxidation of membrane PUFAs results in loss of 
membrane function and structural integrity (Anderson & Krinsky, 1973).  
 
3.6.6 Retinal chromophores 
Chromophores or photosensitisers are molecules that absorb light to produce a chemical 
reaction that would not occur in their absence. Photochemical damage may be defined as 
injury arising from absorption of UV and visible light by a chromophore, resulting in the 
generation of ROS. The retinal chromophores include rhodopsin, melanin and lipofuscin.  
 
3.6.7 Lipofuscin 
Lipofuscin is a lipid-protein aggregate which accumulates within the lysosomes of a variety 
of metabolically active post-mitotic cells, especially the RPE (Eldred & Lasky, 1993). The 
RPE is unusual in the amount of retinoids and PUFA‘s that each of its cells must process 
through life. Waste by-products, which are not susceptible to the process of phagocytosis, 
contribute to the formation of lipofuscin. Lipofuscins have three defining characteristics. 
They consist of intracellular secondary lysosomes, they have a yellow auto fluorescent 
emission when excited by UV or blue light, and they accumulate during normal senescence 
(Katz & Robison, 2002). 
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The accumulation of lipofuscin with age within the RPE has been well documented (Wing 
et al. 1978; Feeney-Burns et al. 1984). Regional differences have also been noted with the 
highest concentrations in the macular region (including a dip at the fovea where MP is 
highest), and the lowest in the peripheral regions (Wing et al. 1978). Lipofuscin is likely 
composed of by-products of vitamin A metabolism, as well as products of lipid 
peroxidation (Feeney-Burns et al. 1984; Boulton, 1991). There is a growing body of 
evidence indicating that lipofuscin compromises RPE cellular function, and 
histopathological studies have demonstrated an association between high levels of 
lipofuscin and degeneration of RPE cells and the adjacent photoreceptors (Dorey et al. 
1989). Possible mechanisms exist whereby lipofuscin may disrupt RPE cellular activities 
include; metabolic processes may fail simply because of the reduction in functional 
cytoplasmic space which results from the presence of intracellular lipofuscin (Young, 1987; 
1988) and lipofuscin may actually induce oxidative damage of surrounding tissues, as it 
acts as a photosensitiser for generation of ROS (Boulton et al. 1993; Suter et al. 2000). 
 
Blue light induced generation of ROS by lipofuscin has been demonstrated in vitro by 
Rozanowska et al. (1995). Blue light damage to the RPE cells is proportional to the amount 
of light received and the amount of lipofuscin within the RPE cells (Sparrow et al. 2003). 
Lipofuscin has been established as the major chromophore of the RPE and that aerobic 
photo activation of lipofuscin forms several potentially cytotoxic ROS. N-retinylidine-N-
retinylethanolamine (A2-E) is a component of lipofuscin and there is strong experimental 
evidence that it can damage the RPE, is toxic to mitochondria and when exposed to blue 
light, induces apoptosis of cultured RPE cells (Suter et al. 2000; Sparrow & Cai, 2001). 
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Further studies have revealed that the lipofuscin mediated generation of ROS in response to 
irradiation is wavelength dependant, being greatest for the blue region of the visible 
spectrum (Rozanowska et al. 1995).  
 
3.7 Protection of the Macula by Macular Pigment 
Oxidative stress has been proposed as a major pathogenic factor in AMD (Beatty et al. 
1999). Exposure to light and oxidative stress induce photoreceptor death in vitro (Wiegand, 
1983). The process is accompanied by an increase in ROS and is diminished by use of 
antioxidants (Conn, 1991). It is likely that MP acts to protect the retina from photochemical 
damage both directly, by acting as a free radical scavenger (Snodderly et al 1984; 
Snodderly et al 1984; Khachik et al. 1997), and indirectly, by filtering out the potentially 
damaging SW blue light (Bone et al. 1992).  
 
The possibility that the absorption characteristics and antioxidant properties of MP confer 
protection against AMD has been postulated (Seddon et al. 1994; Snodderly, 1995; 
Landrum et al. 1997; Chakravarthy et al. 2009). Lutein, zeaxanthin and meso-zeaxanthin 
are oxygenated carotenoids (xanthophylls), and are present as the major diet-based 
compounds of MP (Landrum & Bone, 2001). Several studies examining the association 
between dietary intake of these carotenoids and AMD have yielded positive protective 
relationships. The risk of developing advanced AMD is lower among those reporting the 
highest lutein/zeaxanthin intake (Seddon et al. 1994; Mares-Perlman, 2001). Eyes with 
AMD have consistently been found to demonstrate low levels of MP (Eye Disease Case 
Control Study group (EDCCS), 1993; Beatty et al. 2001; Bone et al. 2001; Bernstein et al. 
2002). It is unclear however whether this is the cause or a consequence of the condition. 
65 
 
The Age Related Eye Disease Study (AREDS) demonstrated the effectiveness of 
supplementation with vitamins and minerals with antioxidant properties in preventing 
progression to advanced AMD among people with large drusen, GA or neovascular AMD 
in the other eye (AREDS, report no 8, 2001). 
 
The carotenoids as a family, have clear antioxidant properties, have been shown to react 
with singlet oxygen, free radicals and also to prevent lipid peroxidation (Khachik et al. 
1997). Oxidation products of lutein and zeaxanthin have also been identified in the retina 
(Khachik et al. 1997), suggesting that lutein and zeaxanthin may act as antioxidants to 
protect the macula against SW visible light. Chucair et al. (2007) demonstrated that lutein 
and zeaxanthin efficiently protect photoreceptors in culture from apoptosis induced by 
oxidative stress and also promoted photoreceptor differentiation. Interestingly, the average 
levels of MP have been reported as 32% lower in eyes with AMD than in normal age-
matched control eyes, among subjects not consuming high-dose lutein supplements 
(Bernstein et al. 2002). 
 
In-vitro experiments indicate that zeaxanthin is a more potent antioxidant, quenching 
singlet oxygen more efficiently than lutein by a factor of ~ 2 (Cantrell et al. 2003). The 
reason presumably due to the extended conjugation of zeaxanthin compared to lutein. The 
perpendicular orientation of zeaxanthin close to the oxidisable PUFA‘s, may also mean that 
zeaxanthin offers more protection than lutein (Bone et al. 1997). 
 
Almost 50% of total zeaxanthin in the human retina is in the form meso-zeaxanthin, which 
is not found in a typical Western diet. It has been reported that in association with a 
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zeaxanthin binding protein, pi-isoform of glutathione S-transferase, meso-zeaxanthin 
provides slightly better protection against lipid membrane oxidation than zeaxanthin 
(Bhosale & Bernstein, 2005); however without the binding protein the situation is reversed. 
Recently, Li et al (2010) demonstrated that a mixture of lutein, zeaxanthin and meso-
zeaxanthin (in a ratio of 1:1:1) quenches more singlet oxygen which would not be achieved 
by any of these carotenoids in isolation. By doing so they may reduce the levels of 
damaging free radicals, thus preventing the impairment of mitochondrial function and 
consequently avoiding the triggering of neuronal death (Chucair et al. 2007). Recent 
supplements on the market now contain meso-zeaxanthin along with lutein and zeaxanthin, 
because it is thought that it may be more advantageous to the macula to increase the ratio of 
total zeaxanthin compared to lutein.  
 
3.8 The ‘Optical’ Hypothesis of MP      
Following on from the ‗protective‘ hypothesis, MP‘s absorptive capacity and physical 
location within the retina has initiated the ‗optical‘ hypotheses of this pigment. The 
‗optical‘ hypothesis of MP was originally discussed by Reading & Weale (1974), and later 
by Nussbaum et al. (1981), and includes MP‘s reputed ability to enhance visual 
performance and/or comfort by diminishing the effects of CA and light scatter, via its light-
filtering properties. The theory that filtering defocused SW light could enhance VA (and/or 
contrast sensitivity) by attenuating the effects of CA and light scatter goes back as far as 
Schultze 1866, however empirical evidence has yet to be established to support this theory. 
Importantly, the effect of MP on retinal, ocular and cortical health may also translate into 
indirect (non-optical) improvements in visual performance and comfort, and should not be 
excluded in the assessment of the overall role of MP on vision (Loughman et al. 2010). In 
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addition to its role as a SW blue light filter, it has been established that MP is a powerful 
and effective free radical scavenger, which supports the view that MP may mitigate the 
damaging effects of ROS on the physiological function of photoreceptors and their axons. 
These factors combine to enhance visual performance.  
 
The ‗optical‘ hypothesis of MP may be related to at least one of the following properties: 
MP  may reduce visual discomfort by alleviating the effects of glare and dazzle; it may 
enhance visual contrast; MP may sharpen visual detail by the absorption of ‗blue haze‘ or it 
may enhance VA by lessening the effects of CA (Walls & Judd, 1932). Given its SW 
absorption characteristics and central location, MP retains ideal properties to improve 
visual performance  
      
The illumination experienced by people in the environment continually oscillates. Although 
adaptation facilitates performance over a wide range of ambient illumination levels, it does 
not mean however that we see equally well at all levels (Loughman et al. 2010). Eyes are 
very sensitive under dim conditions and can detect subtle changes in luminance, but acuity 
for pattern details and colour discrimination are poor. Visual parameters such as threshold 
visibility, colour appearance and VA are different at different illumination levels, and can 
change over the course of the day, and over the time course of light and dark adaptation.  
          
MP reduces sensitivity of the macular region to SW light by acting as a broad band filter 
(Reading & Weale, 1974). Evolution of the primate eye has ensured that almost all UVB 
(290-320 nm) and UVA (320-400 nm) light, is absorbed by the cornea and the crystalline 
lens respectively. Slightly longer wave light (400-500 nm) is then largely absorbed by MP, 
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which has a peak absorbance of 460nm, before reaching the macula (Snodderly et al. 1984; 
Bone et al. 1992). Aspects of MP location within the retina are central to the idea that it has 
a role to play in visual performance and many factors contribute to this assumption. 
(i) Although MP is diffusely distributed throughout the retina and other ocular structures 
(Davies & Moreland, 2004), it is mostly concentrated at the macula and remains optically 
undetectable beyond 7 degrees retinal eccentricity.  
(ii) MP is located at a pre-receptoral level, so that such absorptions are made prior to light 
stimulation of the underlying photoreceptors. The consequence of this is that the spectral 
distribution of light incident on the photoreceptors is altered. 
(iii) MP is also distributed throughout the photoreceptor cell and therefore each 
photoreceptor screens other photoreceptors as well as itself because of the lateral 
course of the axons (Snodderly et al. 1984).  
 
3.8.1 The ‘acuity’ hypothesis 
The original description of the spectral absorption characteristics of MP was made by Max 
Schultze, in 1866 (Schultze, 1866). He suggested that MP might improve VA  in broadband 
illumination by filtering out SW energy before absorption by the photoreceptors. The most 
long-standing and unproven hypothesis deals with the possibility that MP improves VA, by 
reducing the effects of longitudinal CA (Wald, 1945). Because the refractive index of the 
human cornea differs slightly from the crystalline lens and because the refractive index 
within the lens is not homogenous, the cornea and lens do not provide the equivalent of an 
achromatic doublet. As a result visible wavelengths (400nm-700 nm) are not all perfectly 
focused on the retina. The effect of longitudinal CA across wavelength in terms of blur is 
non linear i.e. shorter wavelengths are significantly more blurred than longer wavelengths. 
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When an emmetropic eye is in focus for middle wavelength light (555nm) (natural 
daylight), it will be myopic by ~ 1.2 D for SW light (460 nm), and slightly hyperopic, ~ 
0.50 D,  for long-wavelength light (650 nm) (Gilmartin & Hogan, 1985; Howarth & 
Bradley, 1986). Considering the spectral energy of average sunlight, and the photopic 
spectral sensitivity of the normal observer (Wyszecki et al. 1982), an eye would be in 
perfect focus for daylight only at 560 nm, therefore much of the SW region would be 
seriously out of focus. This effect is known as longitudinal CA. 
           
 
Figure 3.3 Longitudinal chromatic aberration-focal length for incident white light 
varies across wavelength (Modified from Loughman et al. 2007). 
 
Also, the wavelength dependency of the eye‘s focal length means the retinal image size is 
proportional to wavelength, that is, the longer the wavelength the larger the retinal image. 
This effect is known as lateral or transverse CA. If a disc of white light is imaged on the 
fovea, a violet-blue penumbra will result. Together, longitudinal and lateral CA is known as 
CA.  
          
Clearly both kinds of CA degrade the retinal image of any potential target. CA has been 
cited as possibly the most significant aberration affecting visual quality and can create up to 
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two dioptres of wavelength dependant optical defocus (Fig.3.4).The ultimate effect of such 
optical aberrations is that capacity limits are somewhat reduced. Visual acuity is also 
limited by diffraction and photoreceptor density in the eye (Smith and Atchison, 1997). 
Due to distortions created by the optics of the eye the image of a point source is distributed 
on the retina as a point spread function. An Airy disc pattern is formed from a point source 
due to the diffraction of light. Rayleigh‘s criteria is used to calculate the resolution of the 
eye for stimuli that are degraded by the optics of the eye. Retinal cone spacing can also 
limit VA, at least within the central 2 degrees (Green, 1970). Recent work on photoreceptor 
density and spatial resolution has shown that the receptor array in the human visual system 
can resolve in the order of 6/1 (20/3) or ~ 150 cycles per degree (Curcio et al.1990). Based 
on cone spacing a maximum of about 60 cycles per degree is possible, which is well above 
conventional clinical measures as this does not compensate for the optics of the eye and 
post receptoral neural processing. Because VA is limited by diffraction, aberrations and 
photoreceptor density, the neural limits of acuity are seldom achieved even by healthy 
normal individuals (Loughman et al. 2010). 
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Figure 3.4: Diagrammatic representation of the amount of blur induced by 
longitudinal CA when an eye is focused optimally for 555 nm. Note that the blue end is 
significantly more blurred than the red (Modified from Loughman et al. 2010 ). 
 
 The ‗acuity‘ hypothesis describes the concept that MP might improve VA for images 
illuminated by broadband (white) light by absorbing the poorly focused SW portion of 
visible light before this light is processed by the retina. In 1974, Reading and Weale 
presented a theoretical quantification of the absorbtion of SW light by MP, and concluded 
that its filtration of the aberrant part of the spectrum was appropriate to reduce CA to below 
threshold (Reading & Weale, 1974). Hence, it appears that the peak concentration of MP at 
the centre of the fovea is consistent with its role in minimising CA. 
 
The yellow nature of MP is such that it selectively absorbs blue-green incident light, with 
maximum absorption circa 460 nm and little or no absorption above 530 nm (Bone et al. 
1992). MP it appears, removes that component of light which has least benefit for photopic 
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vision from a performance perspective for a number of reasons; the number of SW sensitive 
(blue) cones are considerably less than long wavelength (red) sensitive cones at the macula; 
there is a complete absence of blue cones from the region of maximal visual performance, 
the foveola, and the peak retinal sensitivity lies at 555 nm. Images are not perceived to be 
degraded to the degree suggested by more than one dioptre of aberration because a pre-
retinal filter system may reduce the amount of blue light reaching the photoreceptors. This 
results in a visual system, that is most sensitive to middle and longer wavelength, with 
minimised CA and better acuity (Wooten & Hammond, 2002).  
         
Although individuals do not ordinarily notice the effects of CA on everyday vision, the 
negative effects of CA probably defines the upper limit of the eye‘s ability to resolve fine 
details (Thibos et al. 1991). The effects of foveal CA also varies widely between subjects 
(Howarth & Bradley, 1986), lending support to the idea that MP differences may contribute 
to these individual differences in contrast sensitivity. This interpretation is consistent with 
data showing that males have better acuity on average than females (Brabyn et al. 1979), 
and also tend to have higher average MPOD (Hammond et al. 1996; 2000). The ‗acuity‘ 
hypothesis predicts that for targets illuminated by broadband (white) light, an individual‘s 
VA should be related to the density of their MP. 
 
Historically spatial vision has been evaluated by acuity measures, that is, determining the 
finest discrimination possibly using very high contrast targets. In most clinical settings this 
is still the practice. Modern views of spatial vision, however, consider acuity as merely the 
upper limit of the more general contrast sensitivity function (CSF). In naturalistic 
conditions the mid and low spatial frequencies are certainly as important as the high spatial  
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frequencies, sometimes more so (Devalois & Devalois, 1988). Thus Schultze‘s original 
hypothesis linking MP, CA and acuity has been extended to include any measure of spatial 
vision where a sharpened image could improve performance. This certainly includes the 
entire CSF. For observers with low levels of MP, adding SW absorption with MP (either 
through diet and/or supplementation) or yellow lenses may improve spatial resolution as 
predicted by the ‗acuity‘ hypothesis.  
 
3.8.2 The ‘visibility’ hypothesis 
MP may also facilitate enhancement of detail by the absorption of ‗blue haze‘. Visible and 
non-visible particles, such as fog, smog, cloud, rain and haze aerosols, all contribute to light 
scatter. Wooten & Hammond (2002) describe why light scatter, especially that induced by 
haze aerosols, ‗critically determines how far one can see and how well details can be 
resolved so that aside from the optical and neural limits, scatter in the haze aerosols is the 
primary determinant of visual discrimination and range in the outdoors’. This haze aerosol, 
as it is called, scatters SW light more than other wavelengths and results in a bluish veiling 
luminance. Blue haze is a major factor that degrades visibility. 
           
It has been shown that compensation for the effects of light scatter could increase the 
visibility and discriminability of targets in natural settings (Wooten & Hammond, 2002). 
This could easily be achieved by increasing the density of MP. Problems caused by scatter 
are not consciously experienced by most people, but can become a significant symptom of 
which many patients complain. Patients with cataracts, corneal abnormalities and post laser 
refractive patients may all experience problems of light scatter. Scatter  does have an 
adverse effect on the visual experience of normals and those with ocular abnormalities 
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alike, and any means to reduce the effects of scatter can only be of benefit. MP may 
improve vision through the atmosphere by preferentially absorbing SW energy produced by 
blue haze and thereby increasing the contrast of targets with respect to their backgrounds. 
This proposed role of MP is called the ‗visibility‘ hypothesis. 
 
3.8.3 Photophobia 
Photophobia is eye discomfort in bright light, and is continually encountered in clinical 
practice. Glare and dazzle are maximal in high luminance or high contrast situations. MP 
may however increase the threshold for photophobia under normal viewing conditions, by 
absorption of blue light. By removing the highest energy light component, the impact of 
glare on visual performance is minimised. People with retinal disease, advancing age, and 
cataract often complain of glare. It is a symptom that people of all ages have problems with, 
and very often without obvious reasons for predisposition. A common reason though may 
be, less than normal amounts of MP.  
 
3.8.4 Optical and anatomic properties of macular pigment 
Evidence for the possibility that MP reduces glare may be inferred from its ‗optical‘ 
properties. The optical effect of MP is evidenced by two entoptic phenomenon, which are 
specific to the macula, namely Hadinger‘s brushes (Nussbaum et al. 1981) and Maxwell‘s 
spot (Magnussen et al. 2004).  
 
Because of their linear structure it is known that lutein, zeaxanthin and meso-zeaxanthin 
exhibit dichroic properties (Hemenger et al. 1982; Bone & Landrum, 1983; Bone et al. 
1998). Lutein is reported to be a superior filter of SW light, compared to zeaxanthin, due to 
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its orientation in the cell membrane, which is both parallel and perpendicular, whereas 
zeaxanthin and meso-zeaxanthin exhibit perpendicular orientation only. Since the cone 
axons radiate outwards from the centre of the fovea, forming the Henle fibre layer, the 
preferential alignment of MP molecules within those fibres cause an entoptic phenomenon 
called ‗Hadingers brushes‘ (Bone & Landrum, 1984). MP therefore has some of the same 
qualities as polarising sunglasses used for reducing glare. It is possible that MP could 
reduce glare by preferential absorption of polarised light and by absorbing forward intra-
ocular light scatter, before it degrades foveal vision. The collective effect of the three 
carotenoids together offers optimal filtration of SW light, as these carotenoids have 
different absorption spectra (Sujak, 1999). 
 
Maxwell‘s spot is another entoptic phenomenon which is due to preferential absorption of 
blue light by MP. A reddish spot can be seen in the centre of the visual field when a white 
surface is viewed by a normal observer through a dichroic filter transmitting red and blue 
lights. This phenomenon is attributed directly to the deposition of pigments at the macula. 
Magnussen et al (2004) have shown that the absence of short-wave-sensitive cones in the 
human foveola results in a blue scotoma which can be visualised as a negative afterimage. 
The afterimage has an annular shape with a lighter inner region that corresponds to 
Maxwell‘s spot, and a small bright spot in the centre, corresponding to the foveal blue 
scotoma (Loughman et al. 2010). MP distribution measured for the same observers 
corresponded closely to the lighter annular region of the afterimage.  
         
MP is certainly reduced in individuals with age-related macular disease and this may partly 
explain the problems with glare in this population. Given the substantial inter-individual 
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variability of MP levels, it is plausible that sensitivity to glare is increased in those with low 
pigment levels (Werner, 1990; Hammond et al. 1998; Hammond et al. 2001).  
         
Human visual performance tends to diminish with age. The decrease is very slow until 
approximately the fifth decade of life but seems to accelerate after that time. Most of the 
deterioration in performance can be traced to the slow degradation of the retina and lens. 
Wavefront-guided laser refractive eye surgery, blue filtering intra ocular lens (IOL) 
implants, blue filtering contact lenses and blue filtering spectacle lenses all attempt to 
improve or optimise visual performance.  
 
To  date there hasn‘t been a centralised objective to improve (or maintain) visual 
performance among normals, despite recognition of the optical limitations affecting vision. 
MP acts as an optical filter and it is believed that MP could improve visual performance 
through both optical effects (the ‗acuity‘ and ‗visibility‘ hypothesis), and by maintaining 
the health and functional integrity of the retina and lens (Hammond et al. 2001). 
 
3.9 Visual Health Hypothesis 
The established descriptions of the optical and glare hypotheses focus solely on the optical 
filtration properties of MP. However, MP may have a beneficial effect on visual 
performance and experience because it acts as a powerful antioxidant (Khachik et al. 1997). 
By mopping up free radicals, MP may attenuate or prevent long-term damage to the 
physiological function of the photoreceptors and their axons. Along with its SW filtration 
capacity, MP is an efficient antioxidant and by creating a healthier retina, has the potential 
to impact on visual performance, including glare and photostress recovery.  
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There is an inverse relationship between MPOD and lens density (Hammond et al. 1997). 
Also, the presence of lutein and zeaxanthin in substantial concentrations in the primary 
visual cortex (Craft et al. 2004), and the finding of better dark adapted cone sensitivities in 
association with higher MP (Carboni et al. 2010), combine to suggest a key role for MP in 
ocular and neurophysiologic health. The majority of studies investigating the effects of MP 
augmentation in ocular disease, including AMD, have reported a beneficial effect in vision 
(Richer et al. 2004, Chakravarthy et al. 2009). These findings may be due to the 
neuroprotective effect, along with, the optical properties of these carotenoids.  
       
Light absorbed by the RPE may result in the generation of phototoxic products and a slight 
rise in temperature which results in loss of pigment integrity. This results in a loss of blood 
retinal barrier with consequent leakage of systemic proteins reaching the photoreceptors, 
where membrane de-stabilisation of the discs in the outer segments occurs (Kennedy et al. 
1995, Curcio et al. 1996). Melanin, enzymes and antioxidants (MP) probably neutralise the 
phototoxic products normally but with excessive light exposure these mechanisms are less 
efficient (Ham et al. 1978, Taylor et al. 1990, Lam et al. 1990). When RPE cells are treated 
with lutein, phototoxic effects are reduced greatly (Boulton et al. 1993). The macular 
pigments, lutein, zeaxanthin and meso-zeaxanthin absorb SW light and also quench singlet 
oxygen. Because of these effects, MP is thought to reduce the potential for auto-oxidation 
in the central retina, thereby resulting in a healthier and more viable photoreceptor layer. A 
complex interplay between optical, neurological and physiological mechanisms underlies 
vision which can be uniquely affected by MP (Nolan et al. 2011). 
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3.10 Measurement of Macular Pigment 
MP can be measured in donor eyes or in live subjects. Ex-vivo techniques include autopsy 
analysis using HPLC (Bone et al. 1985), and micro densitometry (Snodderly et al. 1991). 
In-vivo techniques can be divided into two categories: Subjective psychophysical 
techniques and objective optical techniques.  
 Psychophysical: Colour matching or heterochromatic flicker photometry (HFP) 
using ‗‗maxwellian‘‘ and ‗‘free-view‘‘ systems.  
 Image-based: Fundus reflectometry and Auto fluorescence.  
 Signal based: Raman spectroscopy.   
 
Ex vivo techniques 
The main limitations of MP measurements in donor eyes include the need for expensive 
specialist equipment, and the laborious preparation and fixation of the tissues that is 
required if potential postmortem alterations in the spatial profile of the pigment are to be 
avoided (Snodderly et al. 1984). One obvious limitation is that postmortem measurements 
do not allow investigators to prospectively study MP and factors that influence it such as 
diet. 
 
In vivo techniques 
3.10.1 Fundus reflectometry 
In the imaging mode, fundus reflectometry measurement of MP is typically obtained at the 
fovea and parafoveal region using a fundus camera attached to a charge-couple device and 
a scanning laser ophthalmoscope (Kilbride, 1989). The method is objective and has the 
capability to map the spatial distribution of MP, but is based on the assumption that all the 
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reflected light that is detected has been attenuated by MP, however since other absorbers 
exist in the eye, it cannot be considered chemically specific. Imaging fundus reflectometry 
also requires pupil dilation in some implementations, expensive equipment and technical 
expertise which limit its widespread use.  
        
3.10.2 Auro fluorescence imaging (AFI)  
This method measures MPOD levels by determining MP‘s attenuation of the fluorescence 
of lipofuscin in the RPE. MPOD levels are calculated from the difference in lipofuscin 
fluorescence intensities at foveal and extrafoveal sites (typically 7 
o  
eccentricity) (Delori, 
2001). AFI has a number of distinct advantages in that it can map spatial variation in MP 
without pupil dilation, is objective, rapid, requires little training of the subject and 
minimises confounding scattering effects from the anterior ocular media.  
 
3.10.3 Signal based techniques 
Resonance Raman Spectroscopy (RRS): 
RRS measures the excitation of bond vibrations within molecules which is directly 
proportional to the concentration of MP compound existing in the irradiated macular area  
(Bernstein et al. 2002). One advantage of RRS as compared to HFP, reflectometry and AFI, 
is its high chemical specificity. RRS measurements of MP however have limitations. In 
particular absorbance or scattering of the lens can attenuate the Raman signal. Estimation of 
MP levels in older populations using this technology should therefore carefully take into 
account the status of the lens (Hogg et al. 2007).Wide pupil dilation is also generally 
required for measurement,and rather high levels of light are used, so an expensive laser 
light source is required. 
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3.10.4 Heterochromatic flicker photometer technique 
The most commonly used psychophysical technique utilises HFP to establish the optical 
density of the pigment at the foveal centre, which is proportional to its concentration. A 
detailed description of this procedure may be found in chapter five (section 5.3.7). HFP 
used for taking measurements of MP is reproducible, exhibits good test-retest reliability 
(Hammond et al. 1997), and shows good agreement with absorbance spectra generated 
from in vitro preparations of liposome bound zeaxanthin and lutein (Bone et al. 1992). A 
spatial profile of MPOD level is also possible with this technique. Although HFP may be 
minimally invasive as it does not require pupil dilation, and uses advantageously low light 
levels, it is a psychophysical procedure, necessitating both proper training of the subject 
and his or her attention while performing the measurement. Also subjects must have normal 
corrected or uncorrected VA to fixate the central and peripheral targets. 
 
The fact that MP can be enhanced has prompted interest in its measurement on a large 
scale. MP is modifiable through dietary changes and/or supplementation so accurate, 
repeatable and non-invasive methods of measuring MPOD are becoming increasingly 
important. The ability to measure MP in-vivo is therefore very valuable in determining the 
possible risk of developing AMD and in monitoring treatment. It is thought that an 
individual‘s MP level is not followed by a rapid decline following discontinuation of the 
modified diet, unlike serum levels of lutein and zeaxanthin. Studies have shown that it 
reflects long-term carotenoid consumption (Landrum et al. 1997). However, recent studies 
have shown that this may not be the case (Connolly et al. 2010; Loughman et al. 2011). A 
machine for measuring MP, which is accurate and reliable, would certainly prove useful as 
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it would provide a good indication of a person‘s overall MP status and a means of 
monitoring MPOD.  
            
HFP has recently been employed in the development of desktop devices for measurement 
of MPOD in clinical practice and commercially available devices include the MacuScope 
(Macuvision Europe Ltd, Solihull, United Kingdom) and the MPS 9000 (also known as the 
M:Pod and the QuantifEYE, Topcon, Newbury, Berkshire, UK) and a new clinical version 
of the Densitometer by Billy Wooten. HFP is an important and accessible clinical means to 
analyse MPOD and this method is now being applied to larger populations, therefore, the 
effects of individual differences in MP can now begin to be considered (Curran-Celentano 
et al. 2002).   
 
3.11 Dietary Assessment of Lutein and Zeaxanthin 
Mean daily intake of lutein and zeaxanthin combined, ranges from 0.8 mg to 4 mg per day, 
depending on the population studied and the method of dietary assessment used 
(Sommerburg et al. 1998; Landrum et al. 2001). A recent Irish study, involving 826 
subjects estimated mean lutein/zeaxanthin intakes of 0.6 - 2.4mg/day (Nolan et al. 2007). 
Based on the mean dietary intake and serum concentration reported in the above Irish 
study, subjects would need a dietary lutein/zeaxanthin intake of 5-8mg/day to achieve 
optimal serum levels. United States Department of Agriculture (USDA), recommend 4-
8mg/day, while research recommends 6-10 mg/day, both of which are achievable through 
dietary means (USDA, 2005). Lifestyle events and factors which indicate a need for more 
foods rich in these carotenoids include smoking and regular alcohol consumption, plus low 
intake of fruits and vegetables. Long-term inadequate intake of carotenoids is associated 
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with chronic disease including heart disease and various cancers (Block et al. 1992; 
Gaziano et al. 1995).  
         
3.11.1 Evidence that macular pigment can be augmented 
From animal studies, it has been shown that animals raised on lutein and zeaxanthin free 
diets, form no MP (Leung et al. 2004). Malinow et al. (1980) studied the retinas of macaque 
monkeys fed a carotenoid-free diet for more than three years and compared results with 
those of control primates on a standard diet containing lutein and zeaxanthin. Colour fundus 
photography and fundus fluorescein angiography indicated a total absence of MP in those 
animals not receiving carotenoids. A normal foveal appearance was evident in the control 
monkeys. Plasma lutein and zeaxanthin was undetectable in the primates deprived of 
dietary carotenoids. 
 
Neuringer et al. (2004) studied monkeys that were supplemented with either pure lutein or 
pure zeaxanthin and found that, although serum levels of lutein rose faster than those of 
zeaxanthin, by approximately 16 weeks both had stabilised at comparable concentrations, 
potentially indicating lutein and zeaxanthin had reached saturation levels. If the 
accumulation of lutein or zeaxanthin in the macula eventually reaches a saturation level, a 
slower rate of increase of optical density in subjects whose density is already high would be 
expected. The tendency for post supplementation optical density to remain elevated is 
consistent with previous studies (Landrum et al. 1997; Hammond et al. 1997), but not with 
others (Connolly et al. 2010; Loughman et al. 2011).  
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The ability to increase the amount of MP by dietary supplementation with lutein has been 
demonstrated (Hammond et al 1997; Landrum et al. 1997). Since lutein and zeaxanthin 
cannot be endogenously synthesised, a diet rich in these carotenoids is necessary to increase 
MP (Mares et al. 2006). Consumption of certain fruits and vegetables will increase dietary 
intake of lutein and zeaxanthin (Sommerburg et al. 1998). Hammond et al. (1997) reported 
that an average increase of approximately 20% in human MPOD was obtained after four 
weeks of a diet enriched in corn and spinach, but not in all subjects. Three types of 
response to corn and spinach supplements were identified out of 11 subjects. They reported  
eight retinal ‗responders‘, where subjects showed a significant increase in MPOD and 
serum lutein. There were two retinal ‘non-responders‘, in whom serum lutein increased 
significantly without a parallel increase in MPOD and finally there was one retinal and 
serum ‗non-responder‘, in which no significant rise in MPOD or serum carotenoids was 
noted (Hammond et al. 1997). 
 
In another study, two subjects who took a daily dose of 30 mg of lutein for 140 days had 
mean increases in MPOD of 39% and 21% in their eyes respectively (Landrum et al. 1997). 
The authors estimated that this increase in MPOD resulted in a 30% to 40% reduction in 
SW light reaching the photoreceptors, Bruch‘s membrane and the RPE. The persistence of 
raised MPOD following discontinuation of lutein supplements and return to pre-
supplementation serum levels of lutein prompted Landrum et al. (1997) to postulate a low 
turnover of carotenoids in the retina. 
 
The response to carotenoids however varies among individuals. Studies have suggested that 
individuals differ in their ability to absorb nutrients from food into their tissues. Some 
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individuals can have a relatively high intake of fruits and vegetables and high nutrient 
blood levels but low levels of retinal nutrients. Effective absorption of lutein and 
zeaxanthin from the alimentary tract depends on many processes including digestion of the 
food matrix, the formation of lipid micelles, and uptake of the carotenoids by mucosal cells 
and transport of the carotenoids to the lymphatic or portal circulation (Beatty et al. 2004). 
Hammond and coworkers measured MPOD in 88 subjects and correlated the results with 
serum levels of lutein and zeaxanthin and with dietary intake of carotenoids for males and 
females (Hammond et al. 1996). It was found that MPOD for males was 38% higher than 
for females and was positively and significantly related to dietary intake of carotenoids for 
males only (Hammond et al. 1996). In contrast, plasma lutein and zeaxanthin correlated 
significantly and positively with the density of MP and with dietary intake of carotenoids 
for both sexes. It was postulated that the greater MPOD in men may be as a result of the 
difference in the way carotenoids are metabolised by the male and female retina. 
 
More recently dietary supplements have included the third major carotenoid of MP, meso-
zeaxanthin. Landrum et al (2007) conducted a study with 10 subjects, who were given gel 
caps that provided 20 mg/day of meso-zeaxanthin and smaller amounts of lutein and 
zeaxanthin. The authors showed for the first time that meso-zeaxanthin is absorbed into 
serum following ingestion and that there was a significant increase in MPOD following 
predominantly meso-zeaxanthin supplementation compared to the placebo group. 
 
Connolly et al (2010) measured MPOD and serum levels of carotenoids in a group of 10 
subjects instructed to consume a formulation containing 7.3 mg of meso-zeaxanthin, 3.7 mg 
lutein and 0.8 mg zeaxanthin every day for an eight week period. The authors reported a 
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significant increase in serum concentrations of meso-zeaxanthin and lutein following 
supplementation with the above formula and a significant increase in MPOD after only two 
week of supplementation, highlighting that the turnover in the retina may not be at low as 
was originally thought (Landrum et al. 1997; Loughman et al. 2011). 
 
3.11.2 Dietary factors affecting macular pigment absorption 
Lutein and zeaxanthin are fat soluble substances and require the presence of dietary fat for 
proper absorption through the digestive tract. A minimum of 3g of fat in a meal is 
necessary for efficient absorption of carotenoids, except for lutein esters, which require >3g 
of fat/meal (Roodenburg et al. 2000). As a result, carotenoid status may be impaired by a 
diet that is extremely low in fat. Studies show that lutein is much better absorbed from egg 
yolk than lutein supplements or even spinach, as it is more bioavailable. Certain medical 
conditions that result in a reduction in the ability to absorb fat, such as crohns disease, 
celiac, cystic fibrosis or gall bladder disease may effect the absorption of these carotenoids, 
which would result in low concentration of lutein/zeaxanthin in the macula. Serum 
concentrations however can be used to rule out any malabsorption problems. Sublingual 
sprays are now available for people with these conditions. With these sprays lutein and 
zeaxanthin are absorbed directly into the bloodstream under the tongue, therefore bypassing 
the stomach. 
           
Dietary fibre has been shown to impair lutein absorption (Riedl et al. 1999), as it suppresses 
bile salt excretion, and therefore micelle formation. Other forms of dietary fibre such as 
wheat bran may decrease the absorption of lutein. The cholesterol lowering medications 
referred to as bile sequestrants also lower blood levels of carotenoids. The butter spreads 
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enriched with plant sterols such as ‗benecol‘ may also decrease the absorption of lutein and 
zeaxanthin. High density lipo proteins (HDL‘s) are known to be primary carriers of lutein 
and zeaxanthin (Viroonudomphol, 2003), and hence an individual‘s lipoprotein profile may 
influence the transport and delivery of these carotenoids to the retina, with a consequential 
impact on MP.  
       
The accumulation of MP carotenoids at the macula is variable, and affected by a multitude 
of previously defined factors (Snodderly et al. 1984). Apart from ocular tissue, adipose 
tissue is a major storage site in the body for these xanthophylls and as a result serum 
measurements of lutein and zeaxanthin have not been comparable to MPOD (Beatty et al. 
2008). Human MPOD however can be augmented with dietary modification and/or 
nutritional supplementation and the protective effect of MP, if any, can be investigated 
through experimental observation of MP levels. By measuring MPOD on a wide scale, it 
will be possible to analyse the effects of augmentation of MP on disease process and 
prevalence. 
 
3.11.3 Recommended daily allowance (RDA) 
Dietary modification (Hammond et al. 1997) or supplementation with purified supplements 
(Bone et al. 1988; Landrum et al. 1997) have been shown to increase MPOD. As lutein and 
zeaxanthin are fat soluble, they are not excreted daily from the body and hence there is an 
unknown potential for toxicity. Despite the absence of an RDA, set by the Food Safety 
Authority, lutein has been incorporated into dietary supplements since 1996. The majority 
of lutein supplements contain in the range of 6 - 25mg/day, well above the current average 
Irish intake. Toxicity levels of  lutein are to date unreported. However, when supplement 
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dosages are compared with RDA and Daily Recommended Intake (DRI) levels, they are 
however well above recommended levels. Most notably the fat soluble vitamins, with 
quantities of up to 40 times the DRI for vitamin E (no RDA set), 12 times the RDA for 
vitamin A, 10 times the RDA for zinc, 8 times the RDA for vitamin C, 2 times the RDA for 
copper and, 1.4 times the RDA for selenium (See Appendix A). High-dose zinc can cause 
gastric irritation or anemia (Johnson et al. 2007), vitamin A (as beta carotene) has been 
associated with an increased risk of lung cancer among smokers (Omenn, 1996), and 
increased risk of heart failure in at-risk populations who consume high levels of vitamin E 
supplements (Yusuf et al. 2000). More recently, an Irish study found lutein 
supplementation depressed the absorption and plasma concentrations of beta-carotene 
(Thurnham et al. 2008), suggesting that carotenoids may compete with each other for 
absorption. As a result of insufficient evidence and absence of an official RDA for  lutein 
and zeaxanthin, a food based rather than a compound based approach is recommended 
(Granado et al. 2003).  
 
3.11.4 Dietary sources of lutein, zeaxanthin and meso-zeaxanthin 
Lutein and zeaxanthin are found in a typical Western diet, in fruit and vegetables (e.g., 
spinach, corn, orange peppers, red grapes) (Sommerburg et al. 1998), whereas meso-
zeaxanthin has been identified in some less commonly consumed foods including fish (e.g. 
salmon and trout), shrimp, and turtle fat (Maoka, 1986). A healthy diet including these 
carotenoids is strongly recommended as many supplements are often well in excess of the 
recommended levels of certain minerals and vitamins, with some dosages carrying potential 
adverse effects. Achieving adequate lutein and zeaxanthin intake through dietary means 
would be a positive first step in maintaining eye health and avoiding degenerative 
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consequences of age-related eye diseases such as AMD. Foods which are high in lutein and 
zeaxanthin are outlined in Table 3.1. This table also highlights the number of portions a 
person would need to incorporate into ones diet, in order to achieve the daily recommended 
6 mg‘s of lutein and zeaxanthin. If dietary or lifestyle practices can enhance MP, improve 
quality of life and possibly delay or prevent vision loss, then decreased health care costs 
may be realised. Beneficial effects of MP may reside in its ability to protect against chronic 
and cumulative damage. In other words MP levels in youth and middle age are likely to 
determine the protection, if any, that this pigment confers against AMD. Lutein and 
zeaxanthin in the macula, as measured by MPOD, is affected by dietary intake more 
slowly, and can be used as a long term marker, over 2-3 months, of nutrtitional status 
(Granado et al. 2003).  
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Table 3.1 Lutein and zeaxanthin 6 mg/day exchanges. 
 
Food mg/100g 
Medium 
portion (g) 
Food (g) = 6mg 
exchange 
Choose 1 No. 
of portions 
needed to 
provide 6 mg 
Broccoli© 0.83 85 723 9 
Brussels Sprouts© 1.29 90 465 5 
Cabbage® 0.31 95 1935 20 
Carrots® 0.358 60 1676 28 
Corn© 1.8 146 333 2 
Green beans© 0.7 90 857 10 
Green peas© 1.35 70 444 6 
Minestrone soup © 0.15 220 4000 18 
Spinach © 7.043 90 85 1 
Spinach ® 11.938 90 50 1 
Tomatoes® 0.13 85 4615 54 
Fruit cocktail 0.112 115 5357 47 
Oranges 0.187 160 3209 20 
Orange Juice 0.105 160 5714 36 
Tangerine 0.243 60 2469 41 
Eggs 0.55 50 1091 22 
Kellogg’s Cornflakes 0.339 30 1770 59 
C = cooked R = Raw 
90 
 
Table 3.1: Lutein and zeaxanthin 6mg exchanges, highlighting the number portions 
needed in order to achieve the recommended 6mg of carotenoids a day through 
dietary means (Values calculated from data used in modified WISP nutrient data 
base; see chapter six).  
 
However, individual differences in MP may also be influenced by non dietary factors such 
as genetics, demographics and lifestyle characteristics. Concentrations of carotenoids in 
human serum and tissue are extremely variable and reflect not only diet and supplement 
use, but factors such as carotenoid chemistry, individual efficiency of absorption, fat intake, 
competition among carotenoids for absorption, cholesterol and lipoprotein status, metabolic 
status, body composition and BMI. A holistic approach needs to be taken with regard to 
MP. Diet is important, but so is knowing that these carotenoids are being absorbed, 
therefore serum measurements are also necessary. Because of the known existence of 
retinal ‗non-responders‘ it is important that we can measure MP in the eye to ensure people 
are benefiting from their protective and visual effects. 
         
 The appropriate age profile for subjects to be targeted for any protective effect that these 
retinal antioxidants/diet may confer against AMD is the 20 yr group and upwards, as 
changes are occurring in the retina on a microscopic level many years before AMD 
actually presents. We can subsequently relate our findings to established and putative risk 
factors for this condition (O‘Connell et al. 2008). Studies are needed to establish the 
optimal daily intake of lutein and zeaxanthin to maintain a healthy retina. At present, 
however, there are no definitively established physiologically significant cut off point for 
lutein in serum above which ‗protection‘ or ‗prevention‘ against chronic diseases are 
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ensured. Short and long term studies, using different protocols, doses and sources of lutein 
(diet and capsules) have shown that serum concentrations of lutein in the range of 0.6- 
1.05 mol/l, achievable through diet, produce optimal beneficial effects, including an 
increase in MPOD upon supplementation, (Hammond et al. 1997; Landrum et al. 1997; 
Johnson et al. 2000), and an improvement in visual performance in subjects with 
compromised visual function (Olmedilla et al. 2001; Richer et al. 2004). 
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CHAPTER FOUR 
Macular Pigment: It’s Contribution to Visual Health of the Eye and Visual 
Performance and Comfort. 
The current epidemic of AMD has directed researchers to investigate the ‗protective‘ 
hypothesis of MP in detail. This chapter will focus on the evidence which supports the view 
that people with low levels of MP are at a higher risk of developing AMD (EDCCS, 1993; 
Beatty et al. 2001; Bone et al. 2001; Bernstein et al. 2010). It has been proposed that MP 
protects the macula by two processes (Beatty et al. 2000). Its presence in the photoreceptor 
axons (Snodderly et al. 1984), together with the range of spectral absorbance (~400 – 500 
nm), provides MP with the ability to shield posterior tissues such as the photoreceptor 
segments and RPE from actinic blue light. Additionally its presence in the outer segments 
and RPE (Rapp et al. 2000), may mitigate the photo-oxidative damage caused by SW light, 
via its antioxidant and free radical scavenging properties. Evidence to support the view that 
MP enhances visual performance and comfort, by attenuating SW light, will be reviewed 
later in this chapter. This hypothesis however, remains largely unproven and poorly 
investigated.  
 
4.1 Age-Related Macular Degeneration 
Advanced AMD is the leading cause of irreversible vision loss in individuals more than 65 
years of age in the Western world, with the prevalence increasing over the last 50 years 
(Evans et al. 1996). It accounts for 8.7% of blindness world wide (WHO, 2002), and is the 
leading cause of registered blindness in Ireland (Kelliher et al. 2006). AMD results in a 
gradual breakdown of light-sensitive cells, in the macula, which results in the loss of central 
vision or straight ahead vision and not total or peripheral vision loss (Rosenfeld et al. 
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2009). The macula accounts for only 4% of the retina, however it contains a high 
concentration of photoreceptor cells, which are responsible for central vision, seeing colour,  
and distinguishing fine detail (Forrester et al. 1996).  
 
4.1.1 Classification of AMD 
In an effort to standardise disease definition and study methodology, the International 
ARM published in 1995 an international classification and grading system for AMD, in the 
hope of producing a common detection and classification system for epidemiologic studies 
(The International ARM, 1995). In that article, all age-related changes are referred to as 
ARM.  
 
ARM is characterised by any of the following macular findings: soft drusen; areas of 
increased pigment or hyperpigmentation associated with drusen; areas of depigmentation 
or hypopigmentation associated with drusen. Of note, hard drusen are not included in the 
definition ARM. AMD is reserved for the late stages of ARM. Dry AMD refers to GA and 
wet AMD is characterised by choroidal neovascularisation (CNV), detachment of the RPE, 
sub retinal hemorrhage, or retinal scarring (The International ARM, 1995).  
       
The disease entity AMD has also been described as either: Dry or Wet; Non-Exudative or 
Exudative; Early or Late. This terminology is commonly used in everyday clinical 
practice. 
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4.1.2 Early stage AMD  
Early AMD (or early/dry ARM as it is correctly termed) is defined as the presence of soft 
drusen (> 63µm) alone, associated RPE pigmentary changes alone or a combination of 
distinct/indistinct drusen with pigment irregularities and mild loss of VA (Ambati, 2003). 
Soft drusen precede macular degeneration, and can lead to RPE atrophy, with resultant 
overlying photoreceptor atrophy and vision loss (Gass, 1973; Bressler, 1990). When vision 
falls below or equals 20/30, the disease is termed non-neovascular or dry macular 
degeneration. GA is an advanced form of dry AMD. 
 
Figure 4.1 Comparison of the gross appearance of the two major drusen phenotypes 
observed at the funduscopic level. ‘‘Hard’’ drusen (A) tend to be smaller with 
relatively distinct margins, whereas ‘‘soft’’ drusen (B) are larger and typically have 
less distinct borders (Modified from Hageman et al. 2001). 
 
4.1.3 Late/dry AMD/advanced form of non-exudative AMD/GA   
In addition to drusen, there is a breakdown of light-sensitive cells and supporting tissue in 
the central retinal area. The dry form of AMD can be considered a typical 
neurodegenerative disease where a primary defect disrupts the function and viability of a 
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specific group of neurons: photoreceptors. The advanced form of non-exudative AMD, GA, 
is characterised by outer retinal and RPE atrophy with loss of choriocapillaris. As the 
disease progresses to a more advanced form, total loss of central vision may result (Bird et 
al. 1995). Focal hyper pigmentation along with the presence of five soft, large and 
confluent drusen is associated with an increased risk of progression of RPE atrophy and 
choroidal atrophy. These eyes have higher incidence of developing CNV (Sarks, 1980). 
Non-exudative AMD is the most common form of AMD accounting for 80% to 90% of 
cases overall (Kahn, 1977). 
 
4.1.4 Exudative AMD or wet AMD/CNV  
Although less prevalent than ‗Dry‘ AMD, ‗Wet‘ causes a more sudden and a greater central 
vision loss. The presence of sub retinal fluid, sub retinal hemorrhage, RPE detachment, or 
hard exudates indicates CNV, which heralds the onset of exudative macular degeneration 
(Klein, 1992). Choroidal capillaries, the mainstay of nutritional support for the outer retina, 
proliferate and extend through defects in Bruch‘s membrane and junctional complexes of 
the RPE layer into the sub retinal space. Disruption of the normal retinal architecture, 
serous and hemorrhagic detachment of the RPE and retina, pigment remodelling and 
disciform scarring contribute to the death of photoreceptors in the macular region (Bressler, 
1990; Green & Enger 1993). Cone loss is secondary to the abnormal growth of leaky blood 
vessels. CNV affects approximately 10% of the AMD patient population. CNV alone 
however represents 80% of the legal blindness from AMD. The loss of vision is rapid and 
severe and the chief method of diagnosis is angiography. 
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AREDS  have introduced the concept of staged disease severity with ARM 1, 2, 3 
representing combinations of drusen and pigmentary irregularities, and 4 when CNV or GA 
is seen (Fig 4.2) (AREDS, 2001; Hogg & Chakravarthy, 2010). 
.  
Figure 4.2: Disease severity scale with ARM 1, 2, 3 representing combinations of 
drusen and pigmentary irregularities, and 4 when CNV or GA is seen (Modified from 
Hogg & Chakravarthy, 2010). 
 
4.1.5 Geographic atrophy 
Retinal areas affected by GA involve the parafoveal and perifoveal retina early in the 
disease, sparing the foveal centre until late in its course (Sarks et al. 1988, Weiter et al. 
1988). The central sparing of annular macular degeneration also suggests that MP plays a 
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protective role against certain disease processes and it refers to an annular pattern of 
atrophy in the perifoveal region with sparing of the fovea, seen in RP and AMD (Sarks et 
al. 1988). There have been reports (some dating > 50 years) suggesting visual benefit in RP 
from lutein-containing medications (reviewed by Nussbaum, 1981). Dagnelie et al. (2000) 
assessed the effect of lutein supplementation in patients with RP. They reported moderate 
vision improvements in response to short-term lutein supplementation.  
          
Despite good VA, many patients with GA have difficulty in reading because of an inability 
to see a full enough central field as scotomas near the fovea and involving the foveal centre 
compromise visual performance. VA alone is an inadequate marker of visual function in 
patients with GA. Patients may complain that they can read small news print but not larger 
headline letters. For this reason, it is important to take into account that such patients may 
be able to read smaller letters on a Snellen chart even if they are unable to read the 20/400 
letter (Sunness et al. 1997). Patients with GA may also complain of having great difficulty 
recognising faces stemming from their inability to assimilate all features simultaneously. 
Glare problems, delayed or decreased dark adaption, loss of contrast are all common 
symptoms of retinal degenerations, and it has been suggested that such symptoms are due 
to low macular pigment levels, resulting in a failure to absorb scattered light which causes 
excessive photoreceptor bleaching by SW light components (Haegerstrom-Portnoy, 1988). 
             
Because GA can be clinically visualised in many patients before the development of 
moderate or severe vision loss, unlike CNV, there is greater potential for medical 
intervention to preserve visual function. While there is currently no definitive treatment to 
reverse the progression of GA, there are therapies for retarding disease progression. 
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Supplementation with dietary antioxidants has been shown to slow the progression of ‗Dry‘ 
AMD to the next stage over five years (AREDS, report no 8, 2001), but once dry AMD 
reaches the advanced stage no form of treatment, laser or other, can prevent vision loss. 
 
4.2 Circumstantial Evidence 
The evidence to support the hypothesis that MP protects against AMD may be classed as 
circumstantial, epidemiological, experimental or clinical. The term circumstantial refers to 
parallels between the risk of developing ARM and factors associated with low MPOD. 
These parallels include light iris colour (Hammond et al. 1996), cigarette smoking 
(Hammond et al. 1996), female sex (Hammond et al. 1996) and increasing lens density 
(Hammond et al. 1997). 
 
4.2.1 Iris colour 
Iris colour is a hereditary factor that may be associated with AMD (Weiter et al. 1985). 
Investigators have demonstrated an inverse relation between iris pigmentation and the risk 
for ARM (Weiter et al. 1985; EDCCS, 1992), however reports have not been unanimous, as 
the Beaver Dam Eye Study did not find any relationship between iris colour and the 
incidence and progression of AMD (Klein, 1998).   
 
In 1996, Hammond et al. reported a significant and positive relation between MPOD and 
iris pigmentation. Possible explanations to account for their findings include the possible 
shared tendency to accumulate melanin and retinal carotenoids, as both mechanisms co-
evolved in response to environmental stresses such as light and oxygen. In some studies Iris 
colour was used as an indicator for eye pigmentation. Blue eyed caucasions were found to 
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have higher retinal stray light values compared to pigmented brown eyed non-caucasions, 
leading to the conclusion that pigmentation is a source of variation in straylight in normal 
eyes (Ijspeert et al.1990, Elliott et al.1991). Van den Berg (1991) showed that this 
pigmentation dependence is partly caused  by variations in transmission of light through the 
ocular wall. For dark brown eyes of pigmented individuals, transmission was found to be 
two orders of magnitude lower than for blue eyed individuals. MP depletion may therefore 
occur as a result of increased oxidative stress in those eyes with light coloured irides 
because of increased light transmission (Van den Berg et al. 1991).  
 
4.2.2 Cigarette smoking            
In a recent review paper by Chakravarthy et al (2010) on the clinical risk factors for AMD, 
current cigarette smoking showed a strong and consistent association with late AMD. 
Significant increases in AMD were seen in a meta-analyses for current versus never 
smoked (included in this meta-analysis were six prospective studies, five case-control 
studies and five cross-sectional studies). In 1996, Hammond et al. reported their 
measurements of MPOD in 34 cigarette smokers and compared the results with those in 34 
non-cigarette smokers matched for age, sex, dietary patterns and overall pigmentation. It 
was found that tobacco users had significantly less MP (MPOD 0.16) than control subjects 
(MPOD 0.34). Further, smoking frequency was inversely related to MPOD (r=-0.448). It is 
known that smokers have lower concentrations of carotenoids in their bloods (Handleman, 
1999). One important deleterious effect of smoking may be increased oxidative stress to 
tissues. Therefore, as oxidative damage has been causally linked to CNV (Snodderly, 
1995), it is possible that a lack of macular carotenoids among smokers may shift the 
oxidant/antioxidant balance in favour of neovascular AMD (Hammond et al. 1996). 
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Inter-individual variation in MP density is high (Bone et al. 1988; Hammond & Fuld, 1992) 
and cigarette smoking has been found to be one of the major factors for this large degree of 
variability (Hammond et al. 1997). Smoking over 25 cigarettes a day has a more 
pronounced detrimental effect on MPOD (Hammond et al. 2005). Smoking increases 
oxidative burden (Ambrose & Barua, 2004), decreases plasma and tissue vitamin C, 
reduces retinal capture of zeaxanthin in heavy smokers (Nolan et al. 2007; O‘Connell et al. 
2008) and decreases HDL compared with non-smokers. To date smoking is the most 
consistently established modifable risk factor for AMD (Delcourt, 1998). 
 
4.2.3 Female sex  
 In 1996, Hammond et al. investigated the sex differences in MPOD, adjusted for age and 
caloric intake, and found that males had an average of 38% more MP than females. It has 
been suggested that lutein might accumulate in the retina more readily in men than in 
women. Although there was a positive correlation between serum carotenoids and the 
density of MP for both sexes, the relation was stronger for men (males r=0.62, females 
r=0.3). Such poor correlations between retinal, diet and blood carotenoids among females 
prompted the authors to suspect the presence of moderating variables, possibly hormonal 
interactions. Furthermore, higher levels of MP in men may be related to the lower level of 
body fat in men compared to women (Johnson et al. 2000). 
 
4.2.4 Crystalline lens density  
Hammond et al. (1997) have demonstrated an age-related inverse relation between MPOD 
and crystalline lens density (r=-0.47, p<0.001), and this supports the concept that ARM and 
age related cataracts share a common pathogenesis (Liu et al. 1989). Although the cause of 
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the inverse relation remains uncertain, it has been postulated that individuals with higher 
MPOD may also accumulate greater quantities of lutein and zeaxanthin in the lens, and the 
lenticular carotenoids may prevent or retard cataract progression through their antioxidant 
properties (Yeum et al. 1995). In a study by Olmedilla et al (2001), supplementation with 
lutein increased and maintained serum lutein levels, which was associated with an 
improvement in vision function in cataract and AMD patients. The authors postulated that 
the improvement in visual function in the patients with cataracts, may be a direct effect of 
the retina (macula), independent of cataract progression. Although there is no direct 
evidence for a shared mechanism of uptake of these carotenoids in the macula and the lens, 
the concept is supported by the finding that the lens and the macula both accumulate lutein 
and zeaxanthin to the exclusion of other carotenoids in the blood (Yeum et al. 1995; Shazia 
et al. 2004).  
 
4.3 Epidemiological Evidence 
Epidemiology is the cornerstone method of approaches to clinical practice and for 
preventive medicine. These studies are helpful in providing a perspective about whether the 
effect of carotenoids on eye diseases suggested by short-term animal experiments or human 
clinical trials can be generalised to longer periods in persons with differing circumstances. 
Inconsistent findings however have been found to date.  
        
The Eye Disease Case-Control Study (EDCCS, 1993) compared the frequency of possible 
risk factors among individuals with AMD to a cohort of control patients without the 
disease. They obtained personal, medical, physiological, biochemical and ocular data on 
421 subjects with AMD and 615 without the disease. Of the 21 biochemical variables 
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analysed, only serum carotenoid and serum cholesterol were found to be significantly 
associated with risk of neovascular AMD. Subjects were classified by blood level of the 
micronutrient (low, medium and high). Multivariate analysis identified a markedly 
decreased risk of neovascular AMD in those subjects with higher levels of serum 
carotenoids, and a markedly increased risk in those with high levels of serum cholesterol. 
Patients with carotenoid levels in the (medium and high) groups compared with those in the 
low group had markedly reduced risks of developing neovascular AMD, with levels of risk 
reduced to one half and one third respectively. The positive correlation between serum 
lutein and zeaxanthin and MPOD, coupled with the findings of the EDCC, support the view 
that macular carotenoids are protective for neovascular AMD.    
 
The EDCCS also evaluated dietary intake of vitamins A, C, E and the carotenoids in 356 
subjects with AMD using a food frequency questionnaire (FFQ), and compared the results 
with a control group which was statistically similar in terms of age and sex (Seddon et al. 
1994). No protective effect was found for consumption of vitamin C, E or preformed 
vitamin A (retinol), however a higher dietary intake of carotenoids was associated with 
reduced risk of AMD. After correcting for known risk factors for ARM and AMD, it was 
found that those in the highest quintile of carotenoid intake had a 43% lower risk for AMD, 
than those in the lowest quintile. Of the dietary carotenoids, lutein and zeaxanthin were 
found to be the most protective. 
           
The National Health and Nutritional Examination Survey (NHANES) was designed to 
measure the health and nutritional status of a cross sectional sample in the United States. 
They used interview based questionnaires to assess dietary intake of vitamins A and C for 
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178 subjects with ARM and compared the results with those of 2904 controls with healthy 
maculas (Goldberg, 1988). It was found that consumption of fruits and vegetables rich in 
vitamin A was inversely associated with ARM. A diet rich in fruit and vegetables however 
also contains high quantities of lutein and zeaxanthin (Sommerberg et al. 1998). The 
findings of the NHANES and the multicentre EDCCS provide strong evidence that 
antioxidant status is related to the risk of ARM/AMD, and that MP may play a protective 
role (EDCCS, 1992; Goldberg, 1988). 
 
Since the findings of Seddon et al. (1994), the relationship between lutein and zeaxanthin in 
the diet or blood and AMD has been investigated in several populations and higher intakes 
or blood levels of lutein and zeaxanthin have been associated with lower rates of certain 
types of AMD (Seddon et al. 1994; Mares-Perlman, 2001; Gale, 2003). 
 
4.4 Experimental Evidence 
Landrum et al. (1997) reported MP measurements using HPLC in 22 ARM and 15 control 
human donor eyes and found that eyes with ARM had significantly fewer carotenoids in the 
macula and whole retina than healthy eyes. It was noted that, 17 of the 22 diseased eyes had 
less MP than the mean of the control group. As the differences in carotenoid concentrations 
were consistent across the retina, the investigators concluded that lower MP levels are 
probably causally linked to ARM and not simply the result of the degenerative process of 
the macula.  
 
Bone et al (2001) determined whether there was an association between MPOD in the 
human retina and the risk of AMD. Retinas from 56 donors and 56 controls were examined 
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and the amount of lutein and zeaxanthin extracted from each tissue sample was determined 
by HPLC. Lutein and zeaxanthin levels were less on average for AMD donors compared to 
controls. Results are consistent with a theoretical model that proposes an inverse 
association between risk of AMD and the amounts of lutein and zeaxanthin in the retina 
(Bone et al. 2001). 
 
In 2001, AREDS showed that supplementation with a preparation of antioxidants and zinc 
slowed the progression of AMD to an advanced form by 25% over 5 years (AREDS, report 
no 8, 2001). AREDS, a double-masked clinical trial, enrolled 3640 patients, aged 55 to 80 
yrs, who had clinical evidence of extensive small drusen, intermediate drusen, non central 
GA, or advanced AMD in one eye and randomly assigned them to receive daily oral 
supplements containing either antioxidants (vitamin C, 500mg; vitamin E, 400IU and beta-
carotene, 15mg), zinc (80mg as zinc oxide and copper, 2mg as cupric oxide), antioxidants 
plus zinc or placebo. Average follow up was 6.3 yrs. Investigators observed that treatment 
with zinc alone or in combination with antioxidants significantly reduced the risk of 
progression to advanced AMD (AREDS, report no 8, 2001). Many retinal specialists 
recommend the AREDS formula, because of the overall lessening of risk of advanced 
AMD.  
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Figure 4.3. The estimated 5-yr probability of progression to advanced AMD was 
reduced (AREDS, report no 8, 2001) 
   
The Lutein Antioxidant Supplementation Trial (LAST), was the first trial to demonstrate 
improvements in visual funciton when supplementing with 10mg of lutein alone or in 
addition with other antioxidants (Richer et al. 2004). Results showed an increase in MPOD 
in subjects with and without AMD, and improved vision in patient‘s with advanced AMD. 
Improvements were also seen in contrast sensitivity and subjectively on amsler grid and 
glare recovery. Placebo control subjects achieved no such improvements. 
 
The Carotenoids and co-antioxidants in Age-Related Maculopathy study (CARMA) 
investigated the putative beneficial effects of supplemental lutein and zeaxanthin with co-
antioxidants in patients with AMD (Chakravarthy et al. 2009). It was a randomised, placebo 
controlled double blind study. BCVA was significantly better amongst subjects randomised 
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to supplementation but only at 36 months. In conjunction with existing evidence from 
AREDS, CARMA provides additional support for supplementation with lutein and 
zeaxanthin and co-antioxidants in the prevention of progression to late AMD. Figure 4.4 
shows a slower rate of progression to late AMD, in the active group compared to placebo. 
      
        
Figure 4.4. Morphological progression in study eyes (Chakravarthy et al. 2009) 
(Courtesy of J Nolan) (Figures on the X axis represent outcomes at six monthly 
intervals; figures on the Yaxis represent morphological changes to the retina).  
 
4.5 Clinical Evidence 
The accumulation of lipofuscin with age within the RPE has been well documented 
(Feeney-Burns et al. 1984, Wing et al. 1978) and regional differences have been noted with 
the highest concentrations in the macular region, however there is a dip at the fovea, where 
time
654321
C
u
m
 S
u
rv
iv
al
1.0
0.8
0.6
0.4
0.2
0.0
A-censored
P-censored
A
P
arm to which patient 
randomised
Kaplan Meier Survival
107 
 
MP is highest (Wing et al. 1978). The central sparing of annular maculopathy also suggests 
that MP plays a protective role against certain disease processes. Annular maculopathy, 
also known as bull‘s eye maculopathy, refers to an annular pattern of atrophy in the 
perifoveal region with sparing of the fovea, and is seen in AMD (Sarks et al. 1988; Weiter 
et al. 1988). Weiter and co-workers (1988) measured the size of central sparing in 45 
patients with annular maculopathy and compared results with the size of macular yellow 
pigment in 40 normals, using fundus fluorescein angiography and monochromatic 
photography. There was no significant difference between the mean diameter of the area of 
foveal sparing [0.34 (SD± 0.15) disc diameters] and the mean diameter of MP [0.31± (0.12) 
disc diameters]. The pattern of MP distribution corresponded exactly to the area of central 
sparing, and prompted the authors to suggest that ―the close approximation of these values 
suggested that macular yellow pigment contributed to the annular pattern through a photo 
protective mechanism‖. (Weiter et al. 1988). 
        
Topographic studies of atrophic AMD have shown that the region most vulnerable to 
damage lies between 2 and 4 degrees of eccentricity where the density of MP is low (Sarks 
et al. 1988), and that there is a focal reduction in RPE lipofuscin concentration at the very 
centre of the fovea where the macular carotenoids reach their peak concentrations (Wing et 
al. 1978). This evidence provides further support for the hypothesis that MP protects 
against ARM.  
 
To learn about the long-term effects of lutein and zeaxanthin on preventing earlier stages of 
AMD, it is necessary to look at long-term prospective studies to better understand the other 
determinants of MP levels. Currently the National Eye Institute has recruited 4,000 
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participants in its second study (AREDS I I), to assess the effects of the AREDS I nutrient 
formula. Lutein and zeaxanthin, along with omega 3 long-chain PUFA‘s  (350mg DHA and 
650mg EPA), will be examined in relation to the progression of AMD (not prevention), 
since there has been evidence to suggest that eating oily fish two times a week reduces the 
risk of AMD (Seddon et al. 2006). Results of this study are expected in 2012.  
 
4.6 Macular Pigment and Eye Disease Risk Factors   
Risk factors associated with the occurrence of AMD can be described as modifiable or non-
modifiable. Non-modifiable risk factors include age, female gender, iris colour, race and 
genetic background (Hammond et al. 1996; 1996; O‘Connell et al. 2008). Being aware of 
non-modifiable risk factors for AMD might encourage a person ‗at risk‘ to be extra vigilant 
about the modifiable risk factors for this eye disease, which include smoking, diets low on 
xanthophyll containing foods, obesity, cardio vascular disease (CVD) and  increased 
sunlight exposure (Mares-Perlman, 1995; Delcourt, 1999; Hammond, 2001; Richer et al. 
2004; Ambrose & Barua, 2004; O‘Connell et al. 2008). Smoking, previous cataract surgery 
and a family history of AMD are consistent risk factors for AMD. Cardiovascular risk 
factors are also associated with AMD (Chakravarthy et al. 2010). 
 
4.6.1 Cardiovascular disease/obesity 
There have been several studies investigating the proposed relationship between CVD and 
AMD, with both diseases sharing some common risk factors, including a raised blood 
pressure (bp) >160/95, physical inactivity, obesity and inflammation. The most compelling 
evidence is for obesity, as being a common denominator for risk of AMD and CVD. There 
is evidence of an inverse relationship between body fat and MPOD in humans (Hammond 
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et al. 2002; Thurnham et al. 2008), suggesting that lutein receptors in adipose tissue and 
retinal tissue compete for lutein. Johnson et al. (2000) reported a positive correlation 
between serum lutein and zeaxanthin and MPOD for males only, possibly explained by the 
higher percentage body fat often present in females. This may also explain the 
predisposition of women to AMD (Loane et al. 2007). Conversly, a recent Irish study 
suggested that a body mass index (BMI) >27, only effects serum and macular zeaxanthin 
concentration (and not lutein), however this result needs replication (Nolan et al. 2007).  
       
HDL facilitates increases in MPOD (Viroonudomphol et al. 2003), but HDL is reduced in 
obese subjects. Adipocyte HDL competes with retinal HDL, which is needed to transport 
lutein and zeaxanthin in the body (Seddon et al. 2003), and as lutein and zeaxanthin are 
transported primarily by HDL, low HDL may impair transport of these carotenoids. 
 
4.6.2 Sunlight exposure 
Cumulative exposure to light may cause gradual loss of photoreceptor cells in the macula 
(Weiter et al. 1985). Photo-oxidative damage by ROS induced by light may promote the 
development of AMD (Mares-Perlman, 1995; Delcourt, 1999). In 1976, Ham et al analysed 
light induced retinal damage as a function of wavelength by exposing rhesus monkey 
retinas to laser illumination and found that sensitivity to threshold damage rose 
exponentially with decreasing wavelength. Investigators calculated that 100 times less 
power  is required to produce retinal injury with blue light (440 nm) than with orange light 
(590 nm). 
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Ruffolo et al. (1984) investigated the influence of arterial oxygenation on photochemical 
damage of the retina of macaque monkeys, and found that elevated blood oxygen is 
associated with a reduced threshold for injury and more severe damage. The oxygen 
enhancement of blue light damage suggests that the basic mechanism of the photochemical 
injury is the photodynamic production of free radicals from the toxic combination of light 
and oxygen (Ruffolo et al. 1984).  
MP protects the region of the retina involved in vision from photo-oxidative stress by 
filtering out the potentially damaging SW light component of light, however MPOD varies 
greatly from one individual to another and low MPOD is generally regarded as a risk factor 
for AMD. MPOD is related to genetic makeup, prior history of light exposure and lifestyle 
factors.  
 
4.6.3 Nutrition and macular pigment 
In recent years, much research has focused on the concept of ‗optimal nutrition‘ and 
proponents of this idea have suggested that even though a balanced diet will provide 
sufficient amounts of vitamins to prevent deficiency, judicious supplementation of selected 
micronutrients may confer additional health benefits (e.g. avoidance of cancer, CVD). The 
potential role of nutritional supplements to reduce the incidence or severity of AMD has 
received a great deal of attention (Seddon et al. 1994; Snodderly, 1995; Bernstein et al. 
2010). The lack of an effective treatment for the majority of cases of AMD, coupled with 
the public‘s perception that over-the counter nutritional supplements are relatively 
harmless, creates the potential for widespread use of these supplements. Many studies have 
used serum levels of micronutrients to investigate the relationship of these micronutrients 
and AMD.  
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4.7 Macular Pigment and its role in Visual Performance and Comfort 
MP may protect against the development of AMD by defending the retina against 
cumulative and chronic photo-oxidative damage, however as AMD is a late onset disorder, 
the primary role of MP may rest more on its contribution to visual performance and 
comfort. The function of MP in the ‗protective‘ hypothesis is twofold. MP protects the eye 
against AMD by filtering SW light and it also acts as a powerful antioxidant. The 
traditional view of the optical (‗acuity‘and ‗visibility‘) hypothesis posits that MP‘s 
contribution to visual performance rests purely on its optical ‗filtration of SW light‘ 
properties. More recently though, the effect of MP on retinal, ocular and cortical health 
may translate into indirect improvements in visual performance and comfort, as MP also 
acts as an antioxidant. Improved visual performance may be due to either MP‘s SW 
filtration effects, but also because MP scavenges free radicals, and as a consequence MP 
may improve visual performance because the retina is healthier. The current available 
evidence on the impact of MP on visual performance will now be explored. 
  
4.7.1 The evidence 
The role of MP on visual performance and comfort may be as a result of its optical density 
and spectral absorption characteristics or due to biological effects on the retina and the 
crystalline lens (Loughman et al. 2010). The evidence supporting the role for MP in visual 
performance is largely associative and somewhat difficult to translate to a natural 
environment. Studies investigating the role of MP and visual performance can be divided 
into 
1) Populations with established eye diseases, however it is difficult to know if these 
findings can transfer to a normal population. 
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2) Studies involving normal subjects (lacking ocular pathlogy). 
4.7.2 Studies in subjects with retinal pathology 
Hereditary retinal degenerations: 
Glare and slow dark adaptation are common symptoms reported by patients with hereditary 
retinal degenerations. Low MP levels, which results in a failure to absorb scattered SW 
light, may result in excessive photoreceptor bleaching. Reduced contrast sensitivity could 
in part explain the symptoms of these patients. The SW filtration property of MP and its 
ability to mop up free radicals, suggests that MP may play an important role in retinal 
degenerative diseases, as it may help to preserve visual function in the longterm. 
 
RP results in a progressive degeneration of the retina, specifically the light receptors. The 
rods are involved earlier in the course of the disease and cone degeneration occurs later. 
Peripheral vision slowly constricts and central vision is usually retained until late in the 
disease. Ushers syndrome is a condition which affects both hearing and vision and the 
vision loss in this syndrome is RP. Finally, choroidermia is a condition resulting in the 
progressive degeneration of photoreceptors, RPE and choroid. A number of intervention 
studies investigated the relationship between visual function and MPOD in these 
conditions. 
        
Dagnelie et al. (2000) assessed the effect of lutein supplementation in patients with RP and 
reported moderate visual improvements following short-term supplementation with lutein. 
Subjects took 40mg of lutein for two months, followed by a dose of 20mg for four months. 
Mean VA improved by 0.7 dB and mean visual field area by 0.35 dB, although the largest 
gains were attained by blue-eyed participants. Aleman et al. (2001) investigated the 
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relationship between RP and Ushers syndrome and vision function in subjects 
supplemented with 20mg of lutein for 6 months. No significant improvement in visual 
function (measured as absolute foveal sensitivity) was found despite increases in MPOD. 
Duncan et al. (2002) investigated choroidermia. 13 subjects were supplemented for six 
months with 20mg of lutein and vision function was assessed, however no improvement in 
retinal sensitivity was noted. These studies highlight the difficulties inherent in assessing 
visual performance and MPOD. Dosage difference may however explain the discrepancy in 
findings here. 
 
4.7.3 Age-related macular degeneration 
Numerous investigators have explored the relationship between dietary and serum levels of 
MP and risk of AMD (Nolan et al. 2007), with respect to preservation of vision rather than 
enhancement. A number of intervention studies have however investigated the relationship 
between vision function and MPOD which will be discussed here. 
      
Richer (1999) assessed the effect of dietary modification with atrophic AMD and visual 
performance. 14 Subjects were put on a high lutein and zeaxanthin diet. Short-term 
enhancement of visual function in one or both eyes in terms of amsler grid testing, Snellen 
acuity, contrast sensitivity, glare recovery was demonstrated. Richer et al. (2004) went on 
to evaluate the effect of supplementation on visual performance in 90 subjects with atrophic 
AMD. It was a double blind placebo controlled trial, with two treatment groups and a 
placebo group. The first group supplemented with 10mg of lutein and the second group 
supplemented with 10mg of lutein and antioxidants. The investigators observed statistically 
significant improvements in VA. Snellen equivalent acuity improved 5.4 letters in the 
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lutein group and by 3.5 letters in the lutein plus antioxidant group. Improvements in 
contrast sensitivity and subjective measures in glare recovery were seen in both treatment 
groups but not in the control group. 
 
Bartlett & Eperjesi. (2007) investigated the effects of supplementation with lutein 
combined with vitamins and minerals on contrast sensitivity among patients with ARM and 
atrophic AMD. The authors reported no significant improvement in contrast sensitivity 
using a Pelli Robson chart, with 6mg/lutein and other antioxidant vitamins and minerals. 
Dosage levels for this study however were quite low and MPOD was not recorded at 
baseline. The authors suggest that lutein dosage may be an important factor in the 
effectiveness of ocular nutritional supplements. 
        
Chakravarthy et al (2009) investigated the effects of lutein and zeaxanthin supplementation 
with co-antioxidants on the progression of AMD. 433 subjects were randomly assigned to 
either the treatment or placebo group. Distance VA was found to be significantly better in 
the intervention group at 3 yrs follow up and progression of AMD was inversely associated 
with serum lutein (Neelam et al. 2008; Chakravarthy et al.  2009). Figure 4.5 illustrates 
visual improvement of almost 5 letters in the active group after three years. 
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Figure 4.5. The mean (95% CI) differential change in BCVA in study eyes between 
Treatment and Placebo Group. X axis is number of letters read (Change is from 
baseline to each visit). The Y axis represents outcomes at six monthly intervals (Beatty 
et al. 2009) (Courtesy of J Nolan). 
 
4.7.4 Cataract 
Olmedilla et al. (2003) explored the possibility that lutein supplementation might influence 
vision function in patients with age-related cataract. Visual performance was evaluated 
through VA and glare sensitivity measures. This randomised, placebo-controlled study 
revealed significant improvements in VA and glare sensitivity associated with increased 
blood serum lutein after supplementation. No such improvements were achieved in placebo 
controls or in those supplementes with α-tocopherol. The authors postulate that such 
improvements were not the consequence of any change in the crystalline lens, but possibly 
improved retinal function. A branch of AREDS looked at the effect of antioxidants and zinc 
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supplementation on visual loss in people with age-related cataract but found no significant 
effect (AREDS, report no 9, 2001). 
 
4.7.5 Studies in normal populations 
Photophobia and glare: 
Photophobia is a symptom many people complain of and it  results from exposure to light 
that is of sufficient intensity to produce discomfort. Clinicians are often presented with this 
phenomenon, often without any obvious reason for these symptoms. Because of MP‘s 
absorption characteristics, the ability to determine MPOD in clinical practice will prove 
invaluable as it may now be possible to determine an individual‘s threshold for subjective 
complaint of bright lights (photophobia). 
 
Photophobia involves an acute intolerance to light typically marked by some sort of 
behavioral aversion (squinting or closing the eyes). Thresholds for photophobia were 
determined at wavelengths from 440 to 640 nm by Stringham et al. (2003) for three 
subjects. Photophobia was assessed by means of electromyography. The authors showed 
that while subjects displayed a trend of increasing sensitivity with decreasing wavelength, 
they exhibited a notch which centered at 460 nm. A possible explanation for the 
pronounced notch found could be the absorption of light by MP, as the wavelength of peak 
absorption of MP is 460 nm (Wyszecki & Stiles, 1982). Stringham et al (2003) found that 
MP plays a major role in the attenuation of photophobia, substantially greater than what 
would be expected from spatial averaging of MPOD. For photophobia it appears that even 
small amounts of spatially integrated MP could prove to significantly reduce photophobia 
mediated by central viewing. 
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Such findings led to a subsequent study to test the direct relationship between MP and 
Photophobia. Wenzel et al. (2006) explored the relationship between baseline MPOD levels 
and photophobia thresholds as well as the effect of increasing MPOD on such thresholds. 
The authors found that individuals with higher MPOD were less susceptible to 
photophobia. The energy necessary to induce photophobia for a SW target relative to a long 
wavelength target was linearly related to MPOD. Furthermore increasing MPOD in 
subjects who consumed lutein supplements over a 12 week period, appeared to confer a 
predictable improvement in photophobia threshold. 
 
Recently Stringham & Hammond (2007) evaluated whether MP was related to visual 
performance under glare conditions. They looked at baseline visual performance under 
glare conditions by evaluating photostress recovery and grating visibility. Visual thresholds 
under glare conditions were strongly related to MPOD and photostress recovery time was 
found to be significantly shorter for subjects with higher MP. A subsequent trial, 
supplementing subjects with 10mg per day with lutein and 2mg per day with zeaxanthin for 
six months, investigated changes in visual performance associated with augmentation of 
MPOD. Most subjects exhibited improved photostress recovery and glare tolerance in 
association with an increase in MPOD (Stringham et al. 2008). Average MPOD increased 
from 0.41 to 0.57 and was shown to significantly decrease the deleterious effects of glare 
for both visual performance tasks.  
 
4.7.6 Spatial vision 
Engles et al (2007) evaluated the acuity hypothesis by measuring MPOD, gap and hyper 
acuity in 80 healthy subjects. 40 subjects were assigned to the gap acuity experiment and 40 
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to the hyper acuity experiment. Acuity measurements for both groups were taken under two 
conditions.  One condition consisted of mid-wavelength yellow light that is not absorbed by 
MP and the other consisted of a white light that was subject to CA because the blue portion 
would be absorbed by MP (Engles et al. 2007). No relationship between MP and resolution 
acuity or between MP and hyer-acuity in either illumination condition was found. Subjects 
employed in the Engles study however typically exhibited average to high MP levels, with 
few subjects exhibiting MP levels below 0.2 optical density. Reading & Weale (1974) 
suggested that due to the non-linear effect of CA, MPOD levels > 0.3 were probably 
superfluous to visual performance. 
 
In another study, the effect of lutein and antioxidant dietary supplements on visual function 
was assessed (Bartlett & Eperjesi, 2007). 46 healthy participants were randomised to 
placebo or active group (6mg lutein combined with minerals and vitamins). Visual function 
tests included distance and near VA, contrast sensitivity and photostress recovery time. No 
statistical significant difference between groups for any outcome measure was noted over 9 
or 18 months. The authors suggest that daily supplementation with 6 mg lutein combined 
with zinc and antioxidants may not be sufficient to effect a change in vision function. 
 
Loughman et al. (2010) in a cross sectional analysis involving some 142 young healthy 
subjects (COMPASS), observed statistically significant relationships between MPOD and 
best corrected VA, and also with photopic and mesopic contrast sensitivity at intermediate 
spatial frequencies. MP appeared to constitute up to 0.1 log unit refinement of high contrast 
VA (equivalent to 0.25 D or residual blur). Correlations between MPOD and VA and 
contrast sensitivity however, although statistically significant, account for only a small 
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percentage of the potential variability (r
2
 = 10%), and the authors suggested that these 
results should be interpreted with caution. 
 
The study investigating the relationship between MPOD and visual performance is 
discussed in chapter five. MPOD measurements and a battery of visual performance tests 
were performed on 51 young healthy subjects. This study formed one arm of a baseline 
study group for COMPASS. This was the first study to report an association between 
MPOD and contrast sensitivity in a young healthy population (not confounded by dietary 
supplementation or ocular pathology). Findings are consistent with those of Kvansakul et 
al. (2006), who reported that MP augmentation via supplementation enhances contrast 
acuity thresholds under mesopic conditions. Central MPOD (i.e. at 0.25
o
 and 0.5
o
 retinal 
eccentricity) in this study was found to be positively and significantly related to both 
mesopic and photopic contrast sensitivity at intermediate spatial frequency (i.e. 5.7 cpd), 
i.e. a spatial frequency to which the visual system is more highly tuned (Campbell et al. 
1968). See chapter five. 
 
4.7.7 Colour vision  
Colour vision and hue discrimination are more accurate at the fovea corresponding to 
increased cone density (Boyton, 1964). It would seem likely that MP influences colour 
vision through selective absorption of SW light, since the MP absorption spectrum ranges 
from about 400 nm to 500 nm and peaks at 460 nm (Snodderly et al. 1984). MP, which acts 
as a pre-receptorial filter, selectively absorbing SW light, thereby influencing the SW 
sensitive cones and as a result has the potential to alter colour vision (Davison et al (2011). 
Moreland & Dain (1995) reported that hue discrimination measured using the Farnsworth-
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Munsell 100-Hue test (FM 100) is indeed adversely affected primarily for blue 
wavelengths, by simulation of high MPOD using liquid notch filters containing carotene in 
a benzene solution. Comparing the results with those obtained with a neutral filter, they 
concluded that this effect was not simply the result of reduced retinal illuminance. 
 
Another study investigating the effects of dietary supplementation with macular carotenoids 
on MP found no correlation between the level of MP and red-green or yellow-blue colour 
discrimination thresholds. However a marginal improvement in red-green discrimination 
with increased MPOD was reported, supporting the theory that increasing MP levels 
improve chromatic discrimination sensitivity (Rodrigues-Carmona, 2006). 
  
Davison et al (2011) investigated the relationship between MPOD and colour sensitivity 
using a battery of techniques to quantify colour vision of colour-normal observers. Total 
error scores (TES) and % partial error scores (% PES) on the FM-100 were uncorrelated to 
MPOD, suggesting that dietary supplementation to increase MPOD is unlikely to adversely 
affect hue discrimination. Sensitivities on customised SWAP (cSWAP) using foveal targets 
were significantly inversely correlated with MPOD at both 1.75 and 3 degrees. Davison et 
al (2011) suggest that the association between MPOD and cSWAP may be a temporally 
limited effect to which the visual system normally adapts and that cSWAP may provide a 
clinical tool for assessing short-wavelength foveal sensitivity. 
 
These studies highlight the challenges inherent in investigating the role of MP in visual 
performance and comfort. Methological differences between studies and various influences 
of individual optical and neural architectures, all contribute to the difficulties in 
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establishing an association, if any, between  MP and visual function. The inter individual 
variability of MPOD (Hammond et al. 1997), makes interpretation of such studies more 
challenging, and it may be the case that having an MPOD level greater than 0.3 as 
suggested by Nussbaum et al (1981), might be surplus to requirements with regard to visual 
function. As far as spatial vision is concerned the effect of MP on visual performance, if 
any, appears small, at least in individuals with average MPOD. 
 
4.8 Preservation of Youthful Vision into Old Age 
Visual performance tends to decline from the age of about 50. Even with the appropriate 
optical correction, older adults do not possess the spatial resolving power of a young adult. 
As people grow older pupils get smaller, there is a loss of crystalline transparency, and as a 
consequence there is loss of retinal illuminance. MP is a SW light filter, and as a result 
protects the region of maximum VA by filtering out the most destructive component of 
light. However, the most important role of MP may rest on the potential of lutein, 
zeaxanthin and meso-zeaxanthin to retard the ageing process through their antioxidant 
properties. MP acts as an antioxidant both passively, in its ability to limit photo oxidative 
damage by filtering SW light at a pre-receptorial level, and actively due to its capacity to 
quench ROS. In subjects with reduced levels of MP, the cumulative and chronic effect of 
increasing exposure of the retina to SW light, coupled with a weaker capacity to quench 
free radicals, could accelerate degeneration of the ageing retina (Loughman et al. 2010) 
 
One of the more pronounced retinal losses with age is loss of SW sensitivity (Hammond et 
al. 1998). Reduced SW sensitivity is also found very early in the development of retinal 
disease. Hammond et al. (1998) have shown that higher MP seems to retard loss of SW and 
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scotopic sensitivity in the aged.  The authors measured MP and visual sensitivity using 
psychophysical methods in 27 older (aged 60-84 yrs) and 10 younger subjects (aged 24-36 
yrs) and compared the results (Hammond et al. 1998). As expected photopic sensitivity for 
blue and green light declined with age. For older subjects, however, photopic sensitivity 
was positively and significantly related to MPOD. The visual sensitivity of older subjects 
with higher density of MP was not significantly reduced compared with younger subjects. 
Subjects from the older group with lower levels of MP however had poorer sensitivity than 
subjects from the younger group. Better visual sensitivity and youthful levels of MP in 
older subjects appear to be associated in the study.  
 
Haegerstrom-Portnoy (1988) measured the spectral sensitivity of SW sensitive cones and 
medium and long wavelength sensitive cones at varying degrees of eccentricity for young 
and aged subjects. The results showed that SW cone attenuation varies as a function of 
eccentricity with less occurring foveally. This observed differential loss of SW cone 
sensitivity across the retina, indicates that these cones may be protected centrally by the 
screening effect of MP, as blue cone loss is least in the central zone of densest pigment 
(Shaban, 2002). 
 
Visual performance is typically much more variable in the mesopic range, where the 
influence of rods on spatio-temporal vision predominates and results in reduced contrast 
acuity. As rods are more sensitive to SW light (peak rod sensitivity lies around 498 nm in 
the blue-green spectrum), Kvansakul et al. (2006) postulated that SW light absorption by 
MP may reduce rod signals and thereby extend the superior characteristics of cone 
dominated vision into the mesopic range. They investigated the effect of increasing MPOD 
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through lutein and zeaxanthin supplementation on contrast acuity and found that regardless 
of whether groups were supplemented with lutein, with zeaxanthin or with a combination of 
the two, there was a trend towards improved performance. The improvement was 
statistically significant for the lutein group so that supplementation has now been shown to 
enhance visual performance at low illuminations. 
 
Glare is a problem many people complain of, particularly the elderly who may have 
developing cataracts or retinal degenerations. The findings that MP positively impacts 
photostress recovery, disability glare and visual discomfort has been shown (Wenzel et al. 
2006; Stringham et al. 2007; 2008), and is of huge clinical importance. However, the theory 
that MP can attenuate the effects of disability glare and visual discomfort, through its light 
filtration properties has only been demonstrated in a laboratory setting, under Maxwellian 
conditions. It is difficult to translate these findings to the real world and to date there are no 
studies which demonstrate this effect.  
 
The photostress investigation by Loughman et al (2010) was designed to test the 
neuroprotective and/or optical property of MP. The blue component in the photostress lamp 
was more comparable to everyday settings (i.e. it lacked a strong blue component like that 
used by Stringham et al 2007; 2008; Wenzel et al. 2006). While the nature of the lamp may 
be more in tune with blue light emission in natural environments, it may not have been 
enough to establish a relationship in this study. However the fact that the authors failed to 
find an association between MP and photostress recovery, in actual fact corroborates with 
the findings of Stringham et al (2007; 2008), in that the associations between MP and glare 
are strongly wavelength dependant (Loughman et al. 2010). There is a current trend for 
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change to compact fluorescent and light emitting diode installations, which typically emit 
significantly more blue light and are are therefore extending our exposure to SW light 
sources, which may render the role of MP for visual performance, if any, even more 
important. 
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CHAPTER FIVE 
The Relationship between Macular Pigment and Visual Performance 
5.1 Abstract 
Purpose 
To assess whether MP optical density (MPOD) is associated with visual performance.  
 
Methods 
 51 young (mean age 29 ± 6 SD years) healthy subjects were recruited into Dublin Institute 
of Technology (DIT). The spatial profile of MPOD (i.e. at 0.25, 0.5, 1, 1.75 and 3 degrees 
of retinal eccentricity) was assessed by customised heterochromatic flicker photometry 
(cHFP). Visual performance was assessed by psychophysical tests including best corrected 
visual acuity (BCVA), mesopic and photopic contrast sensitivity, glare sensitivity, 
photostress recovery time (PRT), Farnsworth-Munsell 100-Hue test (FM100), and 
customised short wavelength automated perimetry (cSWAP) at the fovea and at 1, 2, 3, 4 
and 5 degrees eccentricity.  
 
Results  
The mean (  SD) MPOD at 0.25
o
 eccentricity was 0.39 (  0.14) and was positively and 
significantly related to mean MPOD at all other degrees of eccentricity (r = 0.275 to 0.879, 
p ≤ 0.05, for all), with the exception of mean MPOD at 3o of retinal eccentricity (r = 0.088, 
p = 0.538). Pearson‘s correlation coefficient analysis showed a statistically significant 
positive relationship between BCVA and MPOD at 0.25
o
 and 0.5
o
 retinal eccentricity (r = 
0.345, p = 0.013, r = 0.317, p = 0.024, respectively). MPOD was also positively and 
significantly related to both mesopic and photopic contrast sensitivity (at 5.7 cpd), but this 
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relationship was confined to the central MPOD at 0.25
o
 retinal eccentricity (r = -0.394, p = 
0.004, r=-0.313, p=0.027) and was unrelated to MPOD at the more peripheral locations. 
cSWAP, PRT and blue-green colour discrimination were unrelated to MPOD across its 
spatial profile.   
 
Conclusions 
 Measures of central visual function, including VA and contrast sensitivity, are positively 
associated with MPOD. A longitudinal, placebo-controlled and randomised 
supplementation trial would however be required to ascertain whether augmentation of MP 
can influence visual performance.  
 
Key words 
Macular pigment optical density; mesopic; photopic; photostress recovery time; visual 
acuity; customised short wavelength automated perimetry. 
 
5.2 Introduction 
The macula is a specialised part of the retina and is responsible for high spatial resolution 
and colour vision (Hirsch & Curcio, 1989). The carotenoids lutein, zeaxanthin and meso-
zeaxanthin accumulate at the macula where they are collectively referred to as MP (Bone et 
al. 1993).  Lutein and zeaxanthin are of dietary origin, whereas meso-zeaxanthin is not 
normally found in a conventional diet, and is generated at the retina following lutein 
isomerisation (Bone et al. 1993; Neuringer, 2004).   
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AMD is a disease of the macula and results in the loss of central and colour vision. AMD is 
the most common cause of blindness in the elderly population in the developed world 
(Congdon et al. 2004). It is now understood that oxidative stress (Winkler et al. 1999; 
Beatty et al. 2000), and associated inflammation (Hollyfield et al. 2009), which are 
exacerbated in part by cumulative SW visible light exposure (Algvere et al. 2006; Fletcher 
et al. 2008), are important in the aetiopathogenesis of AMD. MP is a SW (blue) light filter 
(Bone et al. 1992), and a powerful antioxidant (Khachik, 1997), and is therefore believed to 
protect against AMD. This hypothesis, referred to as the ‗protective‘ hypothesis of MP, has 
been studied and reported on extensively (Loane et al. 2008).  
 
Beyond its ‗protective‘ hypothesis, MP‘s optical and anatomic properties have prompted 
the ‗optical‘ hypotheses of this pigment. The ‗optical‘ hypotheses of MP were originally 
discussed by Reading & Weale (1974) and later by Nussbaum et al. (1981) and include 
MP‘s putative ability to enhance visual performance and/or comfort by attenuation of the 
effects of CA and light scatter, via its light-filtering properties (Walls & Judd, 1933).  
 
Several studies have evaluated, and reported on, the role of MP in various aspects of visual 
performance including VA, contrast sensitivity, glare sensitivity, photostress recovery, 
critical flicker fusion frequency (CFF), and colour vision, amongst others (Wooten & 
Hammond, 2002; Stringham & Hammond, 2004; Hammond & Wooten, 2005; Kvansakul 
et al. 2006;  Stringham & Hammond, 2007; Engles et al. 2007;  Stringham & Hammond, 
2008; Bartlett & Eperjesi, 2008). However, the findings from these studies are inconsistent 
and, in some cases, lack validity as a result of inappropriate methodology.  
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In this manuscript, baseline data from the Collaborative Optical Macular Pigment 
Assessment Study (COMPASS) is presented, and as such represents a cross sectional 
evaluation of the relationship between MPOD and visual performance and comfort across a 
broad and refined range of functional tests.     
 
5.3 Materials and Methods 
5.3.1 Subjects 
51 healthy subjects volunteered to participate in this study, which was approved by the 
research ethics committees at DIT. Informed consent was obtained from each volunteer, 
and the experimental procedures adhered to the tenets of the Declaration of Helsinki. 
         
The study was conducted at DIT vision science laboratory. Self-selected recruitment of 
subjects (DIT: n = 51) was facilitated by poster and newsletter advertisement, and also by 
word of mouth. All subjects were aged between 18 to 41 years, in perfect general (self 
report) and ocular health, and with VA of at least 20/30 in the study eye. A typical study 
visit lasted approximately four hours. Those aspects of visual performance assessed, and 
their sequence, are presented in Table 5.1.  
 
Table 5.1:  Parameters assessed and their sequence for a typical study visit 
 
 
DESCRIPTION TIME (minutes)  
Information leaflet discussion and informed consent 10  
Collection of blood for serum carotenoid analysis 10  
Demographic, medical history, lifestyle and vision case 
history questionnaires 
20  
Spectacle refraction, visual acuity, and ocular dominance  25  
Colour vision  20  
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Glare sensitivity 10  
Visual function questionnaire 10  
Contrast sensitivity  25  
BREAK ~30  
Macular pigment optical density spatial profile 30 
Dietary questionnaire 30  
Short wavelength automated perimetry  15  
Photostress recovery  15  
Fundus and iris photography 10  
Total time: 260 
 
5.3.2 Demographic, medical history, lifestyle and vision case history questionnaires  
The following details were recorded for each volunteer using a demographic and lifestyle 
questionnaire: demographics; general health status; smoking (never, current or past); 
alcohol consumption (average alcohol consumption on a weekly basis); health exercise (in 
a typical week total time spent performing exercises); BMI [defined as kg body 
weight/height in m
2
]; blood pressure; ethnic background; marital status; education; 
occupation.
 
 
           
The following details were recorded using vision case history questionnaire: last eye 
examination; use of spectacles or contact lens use; history of ocular treatment or surgery; 
history of eye patching in childhood; family history of eye diseases; current problems with 
vision; eyestrain associated with computer use; headaches history (See Appendix H).  
 
5.3.3 Spectacle refraction, visual acuity, and ocular dominance 
Each subject underwent precise spectacle refraction by an experienced optometrist to 
determine refractive error and BCVA for each eye. A computer generated LogMAR test 
chart (Test Chart 2000 Pro; Thomson Software Solutions) was used to determine BCVA at 
a viewing distance of 4 meters, using a Sloan ETDRS letterset. BCVA was determined as 
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the average of 3 measurements, with letter and line changes facilitated by the software 
pseudo-randomisation feature. BCVA was recorded using a letter-scoring VA rating; with 
6/6 VA assigned a value of 100. BCVA was scored relative to this value, with each letter 
correctly identified assigned a nominal value of one, so that, for example, a BCVA of 
6/6+1 equated to a score of 101, and 6/6-1 to 99. The study eye was selected on the basis of 
ocular dominance, determined using the Miles Test (Roth et al. 2002), and with the 
dominant eye chosen as the study eye, except in cases of observed equi-dominance, in 
which case the right eye was selected. All subsequent tests were conducted with the 
subject‘s optimal subjective refraction in place. 
 
5.3.4 Glare sensitivity 
Glare sensitivity was assessed using a Functional Vision Analyser (Hohberger et al. 2007) 
(Stereo Optical Co. Inc. Chicago, IL) using the Functional Acuity Contrast Test (FACT) 
(Hitchcock et al. 2004; Terzi et al. 2005) and a customised inbuilt glare source. The test 
comprised linear, vertically oriented, sine wave gratings presented at five different spatial 
frequencies including 1.5, 3, 6, 12 and 18 cycles per degree (cpd). Nine circular patches 
were presented at each spatial frequency, the contrast of each patch decreasing by 0.15 log 
units from the previous. Gratings were tilted -15°, 0° or +15° with respect to the vertical, to 
keep them within the orientation bandwidth of the visual channel. The background was 
tapered into a grey field in order to keep retinal illumination constant and avoid ghost 
imaging. Baseline contrast sensitivity was determined on the basis of the lowest contrast 
compatible with accurate determination of patch orientation across all five spatial 
frequencies for mesopic (3 cdm
-2
) conditions, initially in the absence of a glare source. 
Subjects were asked to identify grating orientation, starting with the patch at highest 
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contrast, and continuing until identification was no longer possible due to reducing 
contrast. Subjects were instructed not to guess, but to respond ‗don‘t know‘ if patch 
orientation could not be correctly identified. 
 
Glare sensitivity was assessed using a radial glare source consisting of 12 white LED‘s 
arranged circumferentially in an oval pattern surrounding the grating charts (ranging from 
4.5° to 6° from central fixation). Two customised intensity settings were used to determine 
the effect of different levels of glare on contrast sensitivity. Glare source settings were set 
at a medium intensity of 42 Lux and a higher intensity of 84 Lux. All responses were 
entered into the Eye view software provided, and contrast sensitivity scores for no glare, 
medium and high glare conditions were determined for the respective spatial frequencies.  
 
5.3.5 Visual function in normal’s questionnaire   
A 30-part Visual Function assessment in Normal‘s questionnaire (VFNq30) was designed 
specifically for the study (See Appendix 5.1).The design was based loosely on a previously 
validated visual activities questionnaire (The Visual Activities Questionnaire, 1992), but 
adapted to suit a normal, young and healthy population sample. This questionnaire allowed 
the subject to quantify their visual performance using three separate metrics:  
(1) Situational Analysis – the subject was asked to rate their performance under 
specified, daily life situations. 
(2) Comparative Analysis – the subject was asked to rate their visual performance in 
comparison to their peers/friends/family. 
(3) Subject Satisfaction Score – the subject was also asked to rate their overall visual 
performance. 
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Each of the three metrics above is computed to give a performance score (x / 100) for 5 
different functional aspects of their vision including: 
-Colour Discrimination 
-Glare Disability 
-Visual Acuity 
-Light/Dark Adaptation 
-Daily Visual tasks 
 
5.3.6 Contrast sensitivity function 
A Dell Dimension 9200 computer and a Metropsis Visual Stimulus Generation device 
(VSG (ViSaGe S/N: 81020197), Cambridge Research Systems Ltd, Cambridge, U.K.) were 
used to generate and control the stimuli. The VSG provided 14-bit output resolution per 
phosphor. The stimuli were displayed on a 19
‘‘ 
View Sonic professional series p227f colour 
CRT flat screen monitor with a frame rate of 119.98Hz. The resolution of the monitor was 
set to 1024 x 769 pixels. Non-linearities in the screen luminance output were eliminated by 
gamma correction prior to testing using a photometer system (Opti-Cal; Minolta, Japan). 
The Metropsis software calculated the inverse curves required to correct for the monitor‘s 
non-linearities.  
 
The Metropsis contrast sensitivity system generated luminance modulated sine gratings 
(Gabor patches). The orientation of the stimuli was vertical. The Gabor patches were 
presented on the cathode ray tube (CRT) monitor and subtended a visual angle of 4.2 
degrees. The mean luminance was used as the background luminance. The Gabor had a 
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two-dimensional spatial Gaussian envelope and was radially symmetrical with equal 
standard deviations, δx and δy.  
 
Contrast sensitivity functions were determined under both mesopic and photopic 
conditions. Each subject was seated at a fixed viewing distance of 1.5m from the CRT 
monitor. Natural pupils were used throughout the experiment. The non-dominant eye was 
occluded. Testing was carried out in a light free (other than monitor generated background 
and stimulus light). The subject was dark adapted for 5 minutes and a five-minute training 
session was given prior to testing under mesopic conditions. Subject responses were 
recorded using a handheld responder (CR6, Cambridge Research Systems Ltd, Cambridge, 
U.K), which communicated with the VSG device via an infra red link. A four alternative 
forced choice testing system was used, with 4 possible target locations. The stimuli were 
randomly presented at 2 degrees spatial offset from the central cross target. The subject 
indicated the location of the target in relation to the fixation cross using the appropriate 
button on the responder box. The subject‘s contrast sensitivity was determined for 6 
different spatial frequencies (1.0, 3.1, 4.2, 5.7, 7.7 and 11.5 cpd) under both mesopic and 
photopic conditions, all at a mean luminance of 3cdm
-2
 (mesopic) and 100cdm
-2
 (photopic).  
 
A log scale staircase method was used to determine the contrast threshold. The first Gabor 
at a particular location was presented at an initial contrast level where it was anticipated 
that the observer would be able to detect the Gabor patch for that particular spatial 
frequency (initial contrast settings were informed by a brief pilot study involving 5 young 
healthy subjects). Subsequently, the contrast of the Gabor patch was varied using an 
adaptive staircase procedure, which was computer controlled and depended upon the 
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subject‘s responses. The stimulus contrast was reduced in steps of 0.3 log units until the 
subject did not detect the Gabor patch (first reversal). The contrast was subsequently 
increased by 0.15 log unit steps until the subject saw the Gabor patch and responded 
correctly (second reversal). The Metropsis software calculated the contrast threshold for 
each location and spatial frequency by taking the mid-point between the mean for peaks 
and troughs for 12 reversal points. The standard deviation was calculated by taking the 
deviations of the peak reversals from their peak means and using the average square of 
these deviations to calculate a peak variance. This method was repeated for the troughs. 
The square root of both variances were then calculated and averaged to provide the 
threshold standard deviation.   
 
For each subject, the Metropsis software plotted the inverse of the contrast threshold 
against the range of spatial frequencies tested to provide a contrast sensitivity function 
under both mesopic and photopic conditions.  
 
5.3.7 Photostress recovery  
PRT was calculated using a macular automated photostress (MAP) test (Dhalla et al. 2007; 
Dhalla & Fantin, 2005). MAP is a novel photostress method for the evaluation of macular 
function using the Humphrey® field analyser (Model 745i Carl Zeiss Meditec Inc. Dublin, 
CA, USA).  The foveal threshold feature of the field analyser was used to establish baseline 
foveal sensitivity as the average of three consecutive foveal sensitivity measurements 
recorded in decibels (dB), with each dB representing a 0.1log unit sensitivity variation.  
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Following baseline foveal sensitivity calculation, the subject was exposed to a photostress 
stimulus, which consisted of a 5-second exposure to a 300-watt, 230 volt tungsten lamp 
head from a viewing distance of one meter. The spectral irradiance in the wavelength range, 
300 nm to 800 nm, was measured using a Bentham DMc 150 double monochromator 
scanning spectroradiometer. The input optic consisted of a very high precision cosine 
response diffuser (f2 error < 1%) and the measurements were performed in 1 nm intervals. 
Calibration was carried out with reference to a quartz-halogen lamp traceable to the UK 
National Physical Laboratory. The illuminance at 1 meter was obtained by using the 
photopic weighting function. The spectral irradiance at 1 meter fixation distance from the 
photostress lamp is presented in Figure 5.1.  
 
Figure. 5.1. Spectral Irradiance at 1 m fixation distance from Arri 300 photostress lamp 
(Modified from Loughman et al 2010). 
 
Immediately post-photostress, a continuous and timed cycle of foveal sensitivity 
measurements were conducted and recorded for each subject. The reduction in foveal 
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sensitivity from baseline, along with the time taken to recover to baseline foveal sensitivity, 
was recorded.  
 
5.3.8 Macular pigment optical density 
We used the Macular Densitometer™ (Macular Metrics II, 12 River St, Rehoboth, MA 
02769, USA), a device developed and originally described by Wooten et al. (1999). The 
Macular Densitometer™ uses HFP to obtain a valid measure of MPOD at a given retinal 
location (Hammond et al. 2005). This method has recently been refined and is now referred 
to as customised HFP or cHFP (Loane et al. 2007; Stringham et al. 2008; Nolan et al. 2009) 
and is slightly modified from the device described by Wooten et al. 1999. The 
Densitometer uses light emitting diodes (LEDs) as light sources, but the luminance of both 
the green (550 nm) and the blue (460 nm) LEDs are varied in a yoked manner. This avoids 
any change of overall luminance. The illumination of the blue and green LEDs are 
alternated in square-wave counter phase. A stimulus of blue light close to the peak 
absorbance of the MP (460 nm) alternates with a green light which is not absorbed by MP 
(560 nm). This flickering stimulus is presented to the foveal centre where MP reaches its 
maximum concentration, and then to the parafovea, where MP is optically undetectable. 
The luminance of one light source (usually the blue light) can be adjusted by the subject, 
and the flicker can therefore be eliminated if the two wavelength components are matched 
in luminance. When viewing the flickering stimulus centrally, the intensity of the blue light 
must be increased to compensate for its attenuation by MP, if the end point of no flicker is 
to be reached. The average intensity of the blue light aimed at the foveal region at minimal 
flicker (Bfov)  is recorded. The test is then repeated with the stimulus aimed at an eccentric 
fixation point where it is assumed that the MPOD is negligible (Bref). The central MPOD 
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level is then calculated with the equation: MPOD = log (Bfov/ Bref). For the purpose of this 
study we measured MPOD‘s spatial profile across the retina (i.e. 0.25, 0.5, 1.0, 1.75 and 3 
degrees of retinal eccentricity).  
The target used to measure MPOD at 0.5 degree retinal eccentricity is a centrally loaded 
circular stimulus of 1 degree diameter, with a central fixation spot, at which the subject is 
encouraged to fixate. The 7 degrees reference target uses an eccentrically located red LED, 
5 minutes in diameter, as the fixation spot. This is presented to the left-hand side of a 
blue/green flickering circular disk. Both the central and reference targets are presented on a 
blue background test field. The wavelength of the blue background test field is 468 nm in 
the Densitometer. The Densitometer has the option to adjust the flicker frequency. This 
enables the investigator to customise the optimal flicker frequency (OFF) for each subject, 
which results in a more discrete end point for the test, thus minimising the variance 
between readings. Densitometer recordings are made under conditions of dimmed light 
(ambient illuminance: 4 lux, as measured with an Iso-Tech ILM 350 Lux Meter) at a 
viewing distance of 18.5 inches (47 cm) (Loane et al. 2007). 
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 Figure 5.2 Densitometer; showing the foveal test field on the left and the parafoveal 
test field on the right (for illustration only, not drawn exactly to scale) (Modified from 
Loane et al. 2007). 
 
5.3.9 Farnsworth-Munsell 100-Hue test (FM100) 
The FM100 test (X-Rite UK, Poynton) was administered under colour-corrected 
fluorescent lighting supplied by a pair of 15W 46 cm lamps (The Daylight Co, London, 
UK) providing minimum luminance of 94 cd.m
-2
 reflected from each colour sample as 
measured with a spot telephotometer. Maximum background luminance reflected from the 
supplied black sample trays was 12 cd.m
-2
. Colour temperature is rated at 6400
o
 K. Subjects 
were allowed to review the arrangement in each tray if they so requested. Individual error 
scores and total error scores (TES), summed across the visible spectrum and purple hues, 
were determined using the software supplied by the manufacturer. Partial error scores 
(PES) were used to assess hue discrimination specifically among blue and cyan hues using 
samples 50 to 68 and 36 to 54 respectively and were divided by TES to obtain percentage 
values (%PES). 
 
5.3.10 Customised short-wavelength automated perimetry (cSWAP) 
Foveal and parafoveal increment sensitivities were measured using an adaptation of the 
standard SWAP routine on a Humphrey Field Analyser 2i (Carl Zeiss Medetec, Jena, 
Germany). Yellow (530nm) background luminance was 100 cd.m
2
. Goldmann size V 
targets of 440nm and 200msec duration subtending 1.7 degrees at the eye were presented at 
0, 1, 2, 3, 4 and 5 degrees eccentricity (centered at these eccentricities; i.e. 5 degree target 
extended from 4.15 to 5.85 degrees eccentricity) from a fixation target. The number of 
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targets at each eccentricity beyond the foveal centre varied from 4 to 20. On each 
presentation, a single target was presented. Increment thresholds were obtained using the 
SWAP adaptive staircase full thresholding technique. Subjects were given 3 minutes to 
adapt to the background before testing began. Sensitivity for each eccentricity was the 
mean of values for all targets in the group at that eccentricity. 
 
5.3.11 Fundus photography 
Fundus photographs were obtained in both eyes using a NIDEK non-mydriatic fundus 
camera (AFC-230).  
 
5.3.12 Statistical analysis 
The statistical software package SPSS (version 18) was used for analysis. All variables 
investigated exhibited a typical normal distribution. Mean ± SD‘s are presented in the text. 
Pearson correlation coefficients were calculated to investigate bivariate relationships and 
partial correlation coefficients when controlling for confounding variables. We used the 5% 
level of significance throughout our analysis.  
 
5.4 Results 
The demographic, medical, lifestyle, anthropometric, and vision-related data of the 51 
subjects recruited into the study are summarised in Table 5.2. No subject was excluded 
from the study on the basis of fundus findings. The mean (± SD) age of the sample was 29 
(± 6) and ranged from 18 to 41 years. The mean (± SD) BMI was 25 (± 3.3) and ranged 
from 19.8 to 37.55.  
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Table 5.2:  Demographic, medical, lifestyle, anthropometric, and ocular related data for the 
entire study group. 
 
Characteristic n Characteristic n 
Sex  Family History of  
Male 16 Eye disease  
Female 35 AMD 9 
Medical History  Cataract 6 
Diabetes 1 Glaucoma 14 
High blood pressure 2 Retinal problems 1 
High cholesterol 3 None 27 
Angina 0 Smoking habits  
Stroke 0 Never smoked 32 
BMI  Ex smoker 9 
Desirable weight 
(BMI <25) 
29 Current smoker 10 
Overweight (BMI 
25-30) 
19 Exposed to second 
hand smoke 
0 
Obese (BMI >30) 3   
BCVA  Ocular dominance  
< 100 2 Right 28 
100 - 105 5 Left 33 
>105-109 33 Equi-dominant 0 
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>110 11   
 
*n = sample size; 
†
smoking habits: ex-smoker = smoked ≥ 100 cigarettes in lifetime but 
none in last 12 months; current smoker = smoked ≥ 100 cigarettes in lifetime and at least 1 
cigarette per week in last 12 months; exposed second-hand smoke = commonly exposed to 
second-hand smoke at home or in the work place 
 
5.4.1 Macular pigment optical density 
The mean ± SD MPOD at each degree of eccentricity and averaged across the retina is 
presented in Table 5.3 and Figure 5.3. The mean (  SD) MPOD (for the entire study group) 
at 0.25
o
 eccentricity was 0.39 (  0.14) and was positively and significantly related to mean 
MPOD at all other degrees of eccentricity (r = 0.275 to 0.879, p ≤ 0.05, for all), with the 
exception of mean MPOD at 3
o
 of retinal eccentricity (r = 0.088, p = 0.538).  
 
Table 5.3: Mean and SD‘s of MPOD at all retinal eccentricities: 
MPOD Eccentricity             Mean            SD 
MPOD 0.25
o
 0.39 ± 0.14 
MPOD 0.5
o
 0.31 ± 0.15 
MPOD 1
o
 0.17            ± 0.1 
MPOD 1.75
o
 0.03 ± 0.06 
MPOD 3
o
 0.05 ± 0.04 
Average MPOD 0.19 ± 0.08 
n = 51 
*° = degrees retinal eccentricity 
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†
MPOD = mean 
(± SD) macular 
pigment optical 
density 
 
 
 
 
 
 
 
 
Figure 5.3: A second-order decreasing exponential function fit the averaged subjects‘ 
profile data well. The curved line indicates the exponential best fit. Inverse second order fit; 
R
2
 = 0.97. 
 
There was no statistically significant association between MPOD at any degree of retinal 
eccentricity [or mean MPOD for the entire study group] and demographic and lifestyle 
factors (e.g. age, sex, BMI and smoking habits) [MLR: dependant variable = MPOD; p > 
0.05 for all; Pearson correlations: p > 0.05 for all correlations tested].This finding is 
unsurprising given the small sample analysed and the narrow age spread of our sample (20 
to 40 years).    
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5.4.2 Best corrected visual acuity and MPOD  
Pearson‘s correlation coefficient analysis showed a statistically significant positive 
relationship between BCVA and MPOD at 0.25
o
 and 0.5
o
 retinal eccentricity (r = 0.345 p = 
0.013,  r = 0.317 p = 0.024, respectively), and also with average MPOD across the retina (r 
= 0.331, p = 0.018). MPOD at all other degrees of retinal eccentricity and BCVA were not 
significantly correlated (p > 0.05, for all). The questionnaire derived VA index (VAI) also 
correlated significantly with MPOD at 0.25
o
 (r = 0.281 p = 0.046). The relationship 
between MPOD at 0.25
o
 of eccentricity and BCVA is presented in Figure 5.4.  
 
 
 
 
Figure 5.4: The relationship between MPOD at 0.25º and BCVA 
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5.4.3 Contrast sensitivity and MPOD  
Mesopic and photopic contrast thresholds were inversely and significantly correlated with 
central MPOD [e.g. mesopic contrast threshold @ 5.7 cycles/deg and MPOD at 0.25
o
: r = -
0.394, p = 0.004, Figure 5.5; and mesopic contrast threshold @ 7.7 cycles/deg and MPOD 
at 0.25
o 
: r = -0.343, p = 0.014]; [photopic contrast threshold @ 5.7 cycles/deg and MPOD 
at 0.25
o
: r = -0.313, p=0.027, Figure 5.6], but were unrelated to MPOD at the more 
peripheral locations [Pearson correlation matrix, Table 5.4]. Higher levels of MP were 
therefore associated with better contrast sensitivity at the spatial frequencies to which we 
are most finely tuned at both photopic and mesopic light levels. 
   
Figure 5.5: The relationship between MPOD at 0.25º and log contrast sensitivity at 5.7 cpd 
for mesopic conditions. 
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Figure 5.6: The relationship between MPOD at 0.25º and log contrast sensitivity at 5.7 cpd 
for photopic conditions 
 
Table 5.4: The Pearson‘s correlation coefficient (Pearson‘s r) for  MPOD at each 
eccentricity measured and log mesopic and photopic contrast thresholds at different spatial 
frequencies are shown in Table 5.4.  
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Spatial 
Frequency 
Mesopic 
MPOD @ 
0.25
o 
MPOD @ 
0.5
o  
 
 
MPOD @ 
1 
o 
MPOD @ 
1.75 
o 
MPOD @ 
3 
o 
Average 
MPOD 
1.0 0.033 0.103  0.179 0.324*  -0.086  0.134 
3.1  -0.031  0.014  0.094  0.171  0.168  0.064 
4.2  -0.288*  -0.272  -0.156  0.046  0.145  -0.217 
 5.7  -0.394**  -0.377*  -0.27  -0.069  0.105  -0.345* 
7.7  -0.343*  -0.329*  -0.242  0.041  0.156  -0.279* 
 11.5 -0.226  -0.183 -0.073  0.149 0.15  - 0.126 
 
Spatial 
Frequency 
Photopic 
MPOD @ 
0.25
o 
MPOD @ 
0.5
o  
 
 
MPOD @ 
1 
o 
MPOD @ 
1.75 
o 
MPOD @ 
3 
o 
Average 
MPOD 
1.0  -0.024 0.04 0.167 0.498**  0.068  0.134 
3.1  -0.19  -0.221  -0.202  0.218  0.05  -0.16 
4.2  -0.194  -0.172  -0.101 0.367**  0.154  -0.082 
5.7  -0.313* -0.3*  -0.284* 0.039  0.148  -0.269* 
7.7 -0.267 -0.272*  -0.197  0.252 0.007  -0.205 
11.5  -0.115  -0.121  -0.065  0.214  0.102 -0.056 
**correlation is significant at the 0.01 level, indicates p<=.01 without Bonferroni 
correction. 
*correlation is significant at the 0.01 level, indicates p<=.05 without Bonferroni correction. 
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P<=.001 with Bonferroni correction. 
MP = macular pigment  
 
5.4.4 Colour vision and MPOD 
There was no significant relationship between total error score (TES) obtained from the 
FM-100 hue test and MPOD at any degree of retinal eccentricity (r = - 0.181 to 0.111, p > 
0.05 for all), with the exception of the positive and significant relationship found between 
TES and MPOD at 1.75-degrees of eccentricity (r = 0.389, p = 0.005). 
 
There was no significant association found between MPOD at any degree of retinal 
eccentricity and blue/green (FM-100 hue caps no. 36 – 54 error scores) colour 
discrimination (p > 0.05, for all). However, MPOD at 1-degree of retinal eccentricity was 
inversely related to blue/green colour discrimination and approached statistical significance 
(r = -0.261, p =0.064). Likewise, there was no relationship observed between MPOD at any 
degree of retinal eccentricity and blue (FM-100 hue caps no. 50 – 68 error scores) colour 
discrimination (p > 0.05, for all). 
 
There was no significant relationship between the subjects colour satisfaction score derived 
from the VFNq and MPOD at any degree of retinal eccentricity (r = -0.110 to 0.033, p > 
0.05 for all).  
 
5.4.5 Customised short wavelength automated perimetry  
There was no significant correlation observed between cSWAP at any degree of retinal 
eccentricity with the most central MPOD‘s at 0.25, 0.50 or 1 degrees of retinal eccentricity 
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(p > 0.05, for all, Table 5.5). However, blue light sensitivity as assessed by cSWAP, was 
inversely and statistically significantly correlated with MP at 1.75 degrees of retinal 
eccentricity.  
 
Table 5.5: cSWAP and MPOD 
cSWAP MPOD @ 
0.25
o 
MPOD @ 
0.5
o 
MPOD @ 
1
o
 
MPOD @ 
1.75
o
 
MPOD @ 
3
o
 
Average 
MPOD 
cSWAP 
fovea 
0.012 -0.08 -0.205 -0.32* -0.159 -0.144 
cSWAP 1 -0.095 -0.11 -0.149 -0.403** -0.198 -0.196 
cSWAP 2 -0.005 -0.043 -0.206 -0.424** -0.183 -0.156 
cSWAP 3 0.094 0.072 -0.073 -0.238 -0.215 -0.021 
cSWAP 4 0.041 0.029 -0.048 -0.286* -0.224 -0.057 
cSWAP 5 0.027 0.009 -0.088 -0.229 -0.26 -0.075 
cSWAP 
Total 
0.014 -0.007 -0.118 -0.332* -0.224 -0.104 
 
**correlation is significant at the 0.01 level, indicates p<=.01 without Bonferroni 
correction. 
*correlation is significant at the 0.05 level, indicates p<=.05 without Bonferroni correction. 
P<=.001 with Bonferroni correction. 
MP = macular pigment  
cSWAP = Customised short wavelength automated perimetry  
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5.4.6 Photostress recovery time and MPOD 
There was no significant association between photostress recovery time (PRT) (seconds) 
and MPOD at any degree of retinal eccentricity (r = -0.239 to 0.066, p > 0.05, for all).  
 
5.4.7 Photostress sensitivity reduction  
There was no significant association between photostress percentage reduction and MPOD 
at any degree of retinal eccentricity (p > 0.05 for all), with the exception of a significant 
inverse association at 3-degrees of retinal eccentricity (MPOD at 3-degree of retinal 
eccentricity and photostress recovery time: r = -0.332, p = 0.017).  
 
Questionnaire based assessment of visual performance as affected by glare showed no 
correlation with either photostress recovery time or percentage visual loss immediately 
post-bleaching (p > 0.05, for all). 
 
 The absence of a strong blue light component in the photostress lamp (Figure 5.1), 
employed in this study may partially explain the absence of any association between MP 
and photostress recovery time. While the nature of the lamp may be more in tune with blue 
light emission in natural environments, the SW component perhaps, may not have been 
strong enough to establish a relationship in this study.  
 
5.4.8 Subjective glare assessment and MPOD 
There was a positive association between the questionnaire based subjective glare 
assessments (i.e. questionnaire situational analysis, comparative analysis and overall 
subject satisfaction score) and MPOD at the more central locations, with positive 
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associations found between MPOD at 0.25-degrees and comparative analysis (r = 0.288, p 
= 0.041), MPOD at 0.25-degrees and overall subject satisfaction score (r = 0.279, p = 
0.047). Positive and statistically significant associations were found between MPOD at 1-
degree and average MP with overall subject satisfaction score for glare (r = 0.307, p = 
0.028 [Figure 5.7], and r = 0.286, p = 0.042 respectively). Higher MP levels were therefore 
associated with better subjective glare performance. 
 
Figure 5.7: Glare subjective satisfaction score and MPOD at 1 degree of retinal 
eccentricity 
 
5.4.9 Validation of visual function questionnaire in normal’s (VFNq) 
The correlations between BCVA and acuity assessed by questionnaire (i.e. situational 
analysis, comparative analysis, overall subject satisfaction score) were positive, with a 
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significantly significant correlation found between BCVA and both situational analysis and 
subject satisfaction score acuity (r = 0.490, p = 0.000 [Figure 5.8] and r = 0.274, p = 0.05, 
respectively). 
 
Figure. 5.8: Relationship between BCVA and visual acuity assessed by questionnaire 
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5.5 Discussion 
Given the central, pre-receptoral location (Snodderly et al. 1984; Trieschmann et al. 2007), 
and the optical and antioxidant properties of MP (Bone et al. 1992), it is reasonable to 
hypothesise that MP would impact on visual performance, via its potential to attenuate CA 
and light scatter (Walls & Judd, 1933; Reading & Weale, 1974; Nussbaum et al. 1981; 
Wooten & Hammond 2002), or through its capacity to improve retinal function (Richer et 
al. 2004; Chakravarthy et al. 2009). In this study, we investigated the relationship between 
MPOD at various degrees of eccentricity (i.e. at 0.25, 0.5, 1.0, 1.75 and 3 degrees of retinal 
eccentricity) and clinically important parameters of central visual performance including 
BCVA, contrast sensitivity, glare sensitivity, and photostress recovery.  
 
We report that MP (at O.25 and O.50 degree retinal eccentricity) is positively associated 
with BCVA in our study population, which suggests that MP plays a role in the 
optimisation of VA under photopic conditions in the more central locations. This finding 
however is all the more provocative given that subjects in the current study were young, 
free from ocular pathology, and uniformly demonstrated high VA. It is important to point 
out that extensive efforts were made by the study investigators to probe the limits of VA, so 
that even the most subtle contributions of MP to visual performance might be detected. 
This was facilitated by customisation of the vision test charts (i.e. inclusion of additional 
letter sizes to allow testing to a limit equivalent to 20/8) and recruitment of an experienced 
optometrist to perform functional evaluations. BCVA among the study participants ranged 
from a minimum of 99 (6/6-1) to a maximum of 110 (6/4).  
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This finding is, however, somewhat at odds with previously reported investigations of the 
‗acuity hypothesis‘. Engles et al. (2007) explored the relationship between MPOD and both 
gap and vernier acuity under ―photopic‖ conditions (Engles et al. 2007). They reported that 
neither gap acuity nor vernier acuity was significantly related to MPOD. Their findings 
however are not directly comparable to the results described here, and for a number of 
reasons. Specifically, their adopted background luminance levels were in the low photopic 
range (i.e. 17cd/m
2
 for the achromatic condition, and 15.7cd/m
2
 for the chromatic 
condition), and were less appropriate for evaluation of photopic visual function. Also, gap, 
vernier and recognition acuity measures are not directly interchangeable, so it is entirely 
plausible that findings with relation to the acuity hypothesis might differ when different 
visual attributes are assessed. Indeed, one might argue that the assessment of vernier acuity, 
a form of hyperacuity subserved by mechanisms other than basic ocular optics, was perhaps 
not the most appropriate methodology to assess the impact of a purely optical filter (i.e. 
MP) on visual performance. Despite the aforementioned methodological differences, the 
conflicting outcomes do serve to emphasise the challenges inherent in the evaluation of the 
role of MP on visual performance, particularly by associative means, as has been reported 
by Loughman et al. (2010). 
 
We also report that central MPOD (i.e. at 0.25 degrees and at 0.5 degrees of eccentricity) is 
positively and significantly related to both mesopic and photopic contrast sensitivity at 
intermediate spatial frequency (i.e. 5.7 cpd) and MPOD at O.25 degrees was also positively 
and significantly related to mesopic contrast sensitivity at 7.7 cpd but not photopic contrast 
sensitivity, although it did approach significance. Central MP appears to influence 
sensitivity at spatial frequencies to which the visual system is highly tuned Campbell et al. 
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(1968). However, in the current study there were some obvious outliers which weakened 
the relationship once they were removed. Although the association is weak, there is a trend 
and for photopic conditions, this finding might be attributable to the attenuation of the 
effects of CA and light scatter, whereby image refinement potentially cause lateral 
inhibitory surround responses to be dampened, and the resultant ganglion cell response 
optimised (Kuffler, 1953). Under mesopic conditions, it is more likely that enhanced visual 
performance is a consequence of the selective diminution of rod mediated signals. While 
rod and cone photoreceptors operate interactively in the high mesopic conditions employed 
here (Kuffler, 1953), rods remain optimally sensitive to SW‘s than cones (explaining the 
Purkinje shift in peak retinal spectral sensitivity towards blue under mesopic conditions). 
The pre-receptoral absorption of SW light by MP might, therefore, serve to attenuate rod 
activity and allow cone-mediated vision (which typically exhibits better contrast sensitivity) 
(Puell et al. 2004) to dominate further into the mesopic range. This theory is supported by 
the limited nature of the relationship observed between MP and contrast sensitivity, 
confined to the most central anatomic locations where MP is highest and cone activity 
predominates.  
 
Of note, this is the first study to report on the association between MP and contrast 
sensitivity in a young healthy population (not confounded by dietary supplementation or 
ocular pathology). Our findings are consistent with those of Kvansakul et al. who reported 
that MP augmentation, via supplementation, enhances contrast acuity thresholds under 
mesopic conditions (Kvansakul et al. 2006).   
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Finally, we found that MPOD was not related to either glare sensitivity or photostress 
recovery, as assessed here. These findings conflict directly with a number of recent studies, 
which have reported positive and statistically significant associations between MP and 
several parameters of visual performance including: visual discomfort, (Stringham et al. 
2003), photophobia (Wenzel et al. 2006), veiling glare (Stringham & Hammond, 2007), and 
photostress recovery (Stringham & Hammond, 2007; 2008). The cited series of 
experimental analyses are consistent with the rationale whereby MP attenuates the effects 
of SW (blue) light, which is both valid and important. Fundamental methodological 
differences may, however, explain the differences between those reports and our 
observations. 
 
Firstly, all the above studies employed a Maxwellian-view optical system to generate and 
present stimuli. While the rationale for doing so remains sound, in that it eliminates pupil 
diameter and pupil responses as a potential confounding factor, it is difficult to extrapolate 
their findings into a natural environment, outside of the laboratory, where changes in pupil 
diameter for example, are a natural consequence of the luminance changes typically 
observed on a daily basis, and may confer some level of protection against the deleterious 
effects of glare and excessive light stimulation. However, adoption of a natural pupil 
introduces other difficulties. Most importantly, the individual variation in pupil size, and 
the consequential variation in retinal illuminance, clouds the interpretation of MP‘s 
contribution to visual performance under glare conditions. It should therefore be conceded, 
that for a cross-sectional evaluation, the natural pupil poses different analytical problems in 
a comprehensive evaluation of the role of MP, if any, in terms of its contribution to visual 
comfort and glare attenuation.  
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Secondly, the studies cited above invariably employed stimuli containing a strong SW 
(blue) light component. Again, there is an obvious rationale for doing so, as MP 
predominantly absorbs SW light.  However, the concept of the environmental validity of 
such stimuli must again be questioned. Specifically, the most common light sources 
employed in industrial, commercial and home lighting systems typically contain 
significantly less SW light than those employed in cited studies. Tungsten and tungsten-
halogen filament lighting systems, in fact, contain a minimal SW light component. The 
absence of a strong SW light component in the photostress lamp, employed here, may 
partially explain the absence of any association between MP on PRT observed in our study 
(see Figure.5.1). It is worth noting, however, that the current trend for change to compact 
fluorescent and light emitting diode installations, which typically emit significantly more 
SW light (unpublished data from our laboratory suggests a two-fold increase in SW (blue) 
light irradiance for compact fluorescent bulbs compared to tungsten), may render the role of 
MP for visual performance, if any, ever more important. 
 
In conclusion, visual performance, as assessed by VA and contrast sensitivity measures, 
appears to be associated with MPOD. However, photostress recovery and visual 
performance under glare conditions were unrelated to MPOD using the stimuli and tests 
employed here. The lack of consistency between our findings and those of others possibly 
reflects the difficulties inherent in investigating the role of MP with respect to visual 
performance using a study of cross sectional design. 
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VA has been shown to relate to quality of life (Datta et al. 2008), and is important in our 
highly visual society, where the demands for high quality visual resolution are constant. 
Contrast sensitivity correlates with various functional vision tasks such as mobility 
orientation, balance control, driving, face perception and reading performance (Owsley & 
Sloane, 1987; Owsley et al. 2002), and has been established as an important measure of 
visual function, which is related to quality of life (Owsley & Sloane, 1987). These 
associations between MP and visual performance are likely to apply equally and possibly 
more substantially, in an older population, where, for example, the incidence of driving 
accidents and falls directly relate to visual performance (Owsley et al. 2002).  
 
In summary, a placebo controlled, randomised, lutein-based supplementation trial, designed 
to investigate if augmentation of MPOD enhances visual performance and/or comfort, is 
required to more adequately address this critical research question, and fully explore the 
proposed visual performance hypotheses of MP. 
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CHAPTER SIX 
Validation of Two Food Frequency Questionnaires to Assess Dietary Lutein and 
Zeaxanthin in Irish Adults 
 
6.1 Abstract 
Purpose 
The McCance and Widdowsons nutritional database (WISP) does not include values for 
lutein and zeaxanthin. This study aimed at modifying the database to include nutritional 
data for these two carotenoids. The database was then used to assess the accuracy of two 
self-administered Food Frequency Questionnaires (FFQs), to estimate dietary lutein and 
zeaxanthin intake in an Irish population. The study also aimed at assessing the 
comparability of this database with an existing nutrient database. 
 
Methods 
This cross-sectional study included 3 men and 19 women from DIT. Participants were aged 
18-54 years and were all of Irish origin. Dietary intake of lutein and zeaxanthin was 
assessed by two different FFQs, the first of which was previously validated to assess 
overall habitual dietary intake in a Scottish population, and the second a brief nutrient 
specific FFQ, validated to assess lutein and zeaxanthin dietary intake in an Italian cohort of 
women. Dietary data was analysed using two different lutein and zeaxanthin databases. 
Serum concentrations of lutein and zeaxanthin were quantified by HPLC. MPOD was 
measured psychophysically using HFP. Demographic data, lifestyle data, and general 
health status, were also recorded by questionnaire, with particular attention directed toward 
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factors affecting bioavailability and absorption of dietary lutein and zeaxanthin along with 
risk-factors (established and putative) for AMD.  
 
Results 
When dietary intake of lutein and zeaxanthin was assessed using the Scottish Colloborative 
Group (SCG) FFQ and modified Italian FFQ and analysed using modified WISP, 
differences of up to 4.88mg/day indicated a poor level of agreement. A similar lack of 
agreement was found between the modified WISP nutrient database and the Medical 
Research Council (MRC) nutrient database, with dietary intake differing by up to 
4.22mg/day depending on the database used for dietary analysis. Dietary intake of lutein 
and zeaxanthin measured with the SCG FFQ and analysed using the modified WISP and 
MRC nutrient database correlated significantly with serum nutrient values (r=0.597, 
P=0.024), (r=0.590, P=0.026) respectively, but there was no significant correlation between 
the Italian FFQ and serum (r=0.288, P=0.317). A strong correlation was found between 
serum nutrient values and MPOD (r=0.734, P=0.003).    
  
Conclusion 
A poor lack of agreement found between the dietary assessment tools and nutrient 
databases reinforces the limitations and difficulties inherent in dietary assessment and the 
lack of comparability between previous studies which differ in study design. The strong and 
statistically significant correlation found between serum nutrient values and MPOD would 
suggest that serum biomarkers are a more comparable and accurate alternative from dietary 
intake assessment, when investigating risk of AMD. 
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6.2 Introduction  
To date there has been a lack of treatment options for dry AMD resulting in a growing 
interest in the potential role of lutein and zeaxanthin intake in the pathogenesis and 
treatment of AMD (Nolan et al. 2007; O‘Connell et al. 2008). Accurate assessment of 
lutein and zeaxanthin is fundamental for advancing research in this area. Valid 
measurements of retrospective lutein and zeaxanthin intake, as well as ability to track lutein 
and zeaxanthin intake longitudinally, are crucial components for elucidating the role of 
lutein and zeaxanthin in health and disease. The methods that can be employed to measure 
dietary lutein and zeaxanthin will depend upon whether lutein and zeaxanthin is the only 
nutrient to be studied, or whether lutein and zeaxanthin intake will be evaluated together 
with assessment of energy and/or other nutrient consumption.  
 
In clinical settings, practitioners can use estimates of usual lutein and zeaxanthin intake to 
determine appropriate treatment for individuals. These recommendations may involve 
providing dietary guidance and/or advice on lutein and zeaxanthin supplementation. 
Methods are therefore needed to estimate lutein and zeaxanthin intake of Irish adults 
accurately and efficiently, using approaches that are not overly burdensome for 
respondents, researchers, or clinicians. 
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Dietary intake is typically self-reported and only crudely quantified, even with the best 
developed methodologies, and as a result is subject to both bias and error. Owing to their 
relatively lower administrative costs and time and the ability to assess usual and longer 
term intake, FFQs have historically been the method of choice for collection of dietary 
intake data for epidemiologic studies (Cade et al. 2002). More recently, their use in other 
research and clinical settings has become more common as FFQs have been used to 
measure usual lutein and zeaxanthin intake (Nolan et al. 2007; O‘Connell et al. 2008). 
These instruments are however commonly criticised for imprecise and biased estimates 
(Briefel et al. 1992) which may contribute to the failure of epidemiologic studies to show 
significant associations between diet and disease (Liu et al. 1987).  
                
Few lutein and zeaxanthin specific FFQs have been developed and validated to date. As a 
result general FFQs have been used in their absence (Nolan et al. 2007). However FFQs 
designed for assessing total diet, such as those of Block and colleagues (Willet et al. 1985; 
Block et al. 1990) although validated, might not be suitable for all circumstances. Often 
these FFQs require optical scanning, making them impractical when estimates of intake are 
needed promptly for study enrolment or treatment decisions. In addition, total diet FFQs 
can be unnecessarily long when used for estimating only one nutrient, and they might not 
be as valid for assessing intake of a single nutrient as a trade-off for estimating intake of 
numerous nutrients in epidemiological studies (Cade et al. 2002). Also FFQ‘s developed 
for assessing lutein and zeaxanthin specifically may not be appropriate for estimating these 
carotenoids in Irish adults for a number of reasons. FFQs that were designed for particular 
populations (e.g. Italian women) might not be valid for use with other populations (Ward et 
al. 2004). FFQs developed in other countries might not reflect food eaten by adults in 
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Ireland (Cena et al. 2007). Finally, the high variability in food content and the limited 
quality and quantity of the food and nutrient composition data for lutein and zeaxanthin, 
also affects the ability to accurately interpret findings (Holden et al. 1999). It has been 
hypothesised that lutein and zeaxanthin concentration in food varies with time and 
according to geographical origin, however studies have demonstrated conflicting results. If 
the hypothess is true, the carotenoid database used to analyse dietary intake would need to 
be up to date and developed using foods from the country of origin of the population being 
studied. This is not always possible due to the limited availability of carotenoid databases. 
Those that do exist are often not comparable and hence reducing the comparability with 
previous studies (Granodo et al. 1996; Scott et al. 1996; O‘Neill et al. 2001).  
 
Accurate assessment of individual intakes of lutein and zeaxanthin are crucial in the 
evaluation of the relative roles in eye health and disease. It was only in 1993, with the 
release of a new database on carotenoids by the USDA (Mangels et al. 1993) that dietary 
carotenoid intake, for the five major carotenoids found in human plasma, was compared 
with their respective values from food sources for the first time (Forman et al. 1993). 
Before that, due to the absence of databases for carotenoid fractions, carotenoid intake was 
based on conversion of vitamin A values to estimated carotene intake (Coates  et al. 1991; 
Bolton-Smith et al. 1991; Ascherio et al. 1992). In addition, the nutritional composition of 
many of the more traditional foods has changed. The introduction of new cultivars, 
adoption of new feeding practices, and technological changes in food processing are all 
capable of altering the composition of food. An example includes the recent development 
of more highly coloured yellow vegetables, with a resultant increase in carotene content. 
Therefore, the most up to date databases should be used. Accurate assessment is also 
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difficult given that current databases generally report these carotenoids as a combined 
value. Xanthophyll carotenoid databases often consist of foods based on their xanthophyll 
content and not on their frequency of consumption. When lutein and zeaxanthin are 
considered together it makes it difficult to determine their respective roles in eye health.  
 
Some researchers currently examining the relationship between dietary intake of lutein and 
zeaxanthin and risk of AMD are using a general FFQ, which was not developed with 
lutein/zeaxanthin specifically in mind (Nolan et al. 2007). A more specific brief Italian FFQ 
(Cena et al. 2007) has more recently been developed, which correlated well with plasma 
levels and with intakes assessed by 7 day records. In the current investigation, the 
comparability of the two FFQ‘s is examined. Dietary lutein and zeaxanthin intake is 
subsequently analysed using two different databases. The validity of the questionnaires and 
nutrient databases are determined using biomarkers; serum lutein and zeaxanthin and 
MPOD. As both questionnaires previously performed well when compared with dietary 
records, the hypothesis would be that both questionnaires would perform well when 
compared with each other, regardless of the nutrient database used. 
 
6.3 Materials and Methods 
6.3.1 Subjects 
Subjects were recruited as a result of an information sheet circulated around DIT or through 
word of mouth. 19 women and 3 men from an Irish student population  in DIT, volunteered 
to participate in the study, which was authorised by the Research Ethics Committee of DIT. 
Written information mapping the principles of the study was provided to each subject and 
informed consent was subsequently obtained from each subject prior to enrollment in the 
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study. Subjects in the age range between 18 and 60 years were included.. There were no 
other exclusion criteria. All 22 volunteers recruited were included in the study.  
6.3.2 Study design  
The study design is illustrated in Figure. 6.1. This cross sectional study entailed the 
modification of a nutrient database and a brief Italian FFQ, completion of two FFQs, a 
demographic questionaire, measurement of MPOD, obtaining a blood sample, blood 
pressure and BMI calculation. Completion of all parts of the study took approximately one 
hour 20 minutes per subject. During their visit, subjects were invited and instructed to 
complete two FFQs, the first of which was previously designed and validated to assess 
habitual dietary intake and the second, a modified version of a brief FFQ previously 
designed and validated to assess specifically lutein and zeaxanthin intake among the Italian 
female population aged 20-25years (see section 6.3.5 and 6.3.6). Subjects also underwent a 
short clinical examination, checking blood pressure, weight, height and visual health. A 
blood sample was collected from 15 subjects. Blood samples were not taken from 7 
subjects due to extraction difficulties. MPOD measurements were taken using the Macular 
Metrics Densitometer
TM
, which is a validated psychophysical method for measuring MP. 
As carotenoid intake has been shown to have a wide seasonal variation, the biomarker 
information was collected on the same day as the FFQ administration and completion. 
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Figure 6.1: Study Design 
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6.3.3 Demographic details questionnaire 
Demographic data, lifestyle data, and health status, were recored by questionnaire, with 
particular attention focused towards risk factors for AMD. The risk factors investigated 
included age, sex, blood pressure, cholesterol, personal and/or family history of eye 
disease, cigarette smoking history, including frequency and quantity of cigarettes smoked, 
along with exposure to second hand smoke; alcohol intake including frequency and 
quantity, physical activity, BMI (calculated by kg/m
2
) and blood pressure (mmHg).
  
 
6.3.4 Food frequency questionnaire 
Before the analysis criteria for acceptable data quality, including limitations of FFQ‘s, were 
carefully considered. Common limitations of FFQs include questions left blank and over 
estimation of dietary intake. Overestimation of intake was minimised, particularly in the 
SCG FFQ, by encouraging subjects to read all foods listed in each food group before 
deciding frequency and quantity of consumption. All questionnaires were immediately 
reviewed with the subject to ensure no spaces were left blank.  
 
6.3.5 Scottish collaberative group (SCG) FFQ 
A self-administered, semiquantitative FFQ developed by the SCG was used as the first tool 
for dietary assessment. The questionnaire which was previously validated (Masson et al. 
2003), was designed to estimate a subjects habitual diet over the previous 2 to 3 months. 
The questionnaire comprised 166 commonly eaten food types or drink, grouped into 19 
selections with three additional sections labelled ‗Other foods and drinks‘ ‗vitamin, mineral 
and food supplements‘ and ‗other‘. Subjects were asked to specifiy two things; (1) 
frequency of consumption of each food, on a weekly or monthly basis. Less than monthly 
167 
 
consumption was denoted by ‗rarely‘ and nutritional contribution was considered negligible 
(2) Quantity consumed by specifying how many portion ‗measures‘ per day they consumed 
of each food. A ‗measure‘ was designed to be a small portion so that a single standard 
potion of a food would often be more than 1 measure. A coloured photograph, depicting 
examples of food meaures equal to 1 measure accompanied each questionaire, along with 
detailed written and verbal instructions and an example of how to fill in the questionaire. 
Questionnaires were completed in 23-35 minutes (See Appendix D). 
 
6.3.6 Modified Italian FFQ  
An interview assisted quantitative 32-item FFQ, originally developed and validated (Cena 
et al. 2007) to assess dietary intake of lutein and zeaxanthin in Italian women, was modified 
to suit the Irish diet. Modification included the exclusion of three foods originally listed 
from the FFQ (collards, green turnip and tangerine juice) which did not feature commonly 
in an Irish diet, and the inclusion of six important lutein and zeaxanthin food sources (green 
peppers, turnip, eggs, kelloggs cornflakes, celery, herbs/spices) which featured more 
regularly (O‘Neill et al. 2001). The questionnaire was originally designed as a quantitative 
questionnaire to assess lutein and zeaxanthin intake over the previous month, involving an 
interview. Brief written and verbal instructions were again provided. Subjects were asked to 
answer two questions; (1) frequency of consumption, either as ‗never consumed‘ or on a 
daily, weekly or monthly basis and (2) number of standard portion measures consumed. It 
is well known that FFQ‘s and food records may have common sources of errors such as 
recall bias of portion sizes and over/under reporting (Cade et al. 2002). In order to minimise 
this, the same food photograph was used to illustrate the quantity of food equivalent to one 
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portion measure for both FFQs. However, this might bias the results of the Bland Altman 
Plot and reinforce Pearson‘s/Spearmans correlation (See Appendix E). 
 
6.3.7 Macular pigment optical density measurement 
MP was measured psychophysically using the Macular Densitometer™ (Macular Metrics 
II, 12 River St, Rehoboth, MA 02769, USA), a device developed and originally described 
by Wooten et al. (1999) to measure MPOD. This technique utilises the principle of HFP 
and for this study MP measurements were taken centrally (0.25 degrees retinal eccentricity) 
and peripherally (7 degrees retinal eccentricity) (See section 5.3.7 for a detailed destription 
of this procedure). 
 
6.3.8 Analysis of serum samples   
Blood samples (6-8 ml) were collected from 15 patients on the same day as MPOD 
assessment. Serum was separated from blood by centrifugation at 15, 000 revolutions per 
minute (rpm) for 10 minutes, and then aliquoted into two light-sensitive micro centrifuge 
tubes and stored at minus 70
o
 Celcius until time of analysis. The following method is a 
precedure used by Nolan et al (2007). A 400µL aliquot of serum was pipetted into a light-
sensitive micro centrifuge tube (1.5 mL total capacity). Ethanol (300 µL) containing O.25 
g/L butylated hydroxytoluene (BHT) and 200µL internal standard (α-tocopherol acetate) 
were added to each tube. Heptane (500µL) was then added and samples were vortexed 
vigorously for 2 minutes followed by centrifugation at 2000 rpm for 5 minutes (MSC 
Micro Centaur, Davison & Hardy Ltd. Belfast, UK). The resulting heptane layer was 
retained and transferred to a second labeled light-sensitive micro centrifuge tube, and a 
second heptane extraction was performed. The combined heptane layers were immediately 
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evaporated to dryness under nitrogen. These dried samples were reconstituted in 200µL 
methanol (containing 0.25 g/L BHT), and 100 µL was injected for HPLC analysis. Agilent 
1200 series was used (Agilent Technologies Ltd. Dublin, Ireland) system with photodiode 
array detection. A 5 micron analytical/preparative 4.6 x 250 mm 201TP specialty reverse 
phase column (Vydac, Hesperia, CA) was used in line guard column. The mobile phase 
consisted of 97% methanol and 3% tetrahydrofuran. The flow rate was 1 mL/min and the 
total run time was 15 minutes. DSM nutritional products (Basel Switzerland) provide total 
lutein (TL) and total zeaxanthin (TZ) standards to operate response factors which were used 
to calculate serum concentrations of TL and TZ. An internal standard: α-tocopherol acetate 
was made up in ethanol (O.25 mg/L) was used to standardise all extractions for HPLC 
analysis and was also used for quantification purposes. All chromatograms were integrated 
manually by drawing a baseline and dropping perpendicular lines to quantify the peaks of 
interest. All carotenoid peaks were integrated and quantified using Agilent ChemStation 
software (Nolan et al. 2007).  
 
6.3.9 Data input and coding 
Each subject was given a reference number for anonymity purposes. Completed personal 
detail questionnaires, were entered into a Microsoft Excel spreadsheet. Categorical data 
was coded, and open ended questions were entered directly. The Excel spreadsheet was 
exported into the SPSS software package, version 18, and after some manipulation of the 
data, the final database was created.  
 
Dietary information obtained from the SCG FFQ and modified Italian FFQ were coded and 
entered into Microsoft Excel. Daily nutrient intakes were determined from weekly 
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estimates and data entered into a food and nutrient software package (WISP V 3, Tinviel 
Software, 2006) and output was obtained for each method and for each subject. The SCG 
FFQ was analysed using a second nutrient database developed by the MRC Human 
Nutrition Research (Cambridge, UK), which was designed specifically for analysis of this 
questionnaire. 
 
6.3.10 Modification of WISP 
Every effort was made to ensure that the most up to date information on lutein and 
zeaxanthin was used. An extensive search of the literature and existing carotenoid 
databases was conducted, to identify estimation of lutein and zeaxanthin content of the 569 
individual foods, which were designed to make up the 166 commonly eaten food types in 
the SCG FFQ and the 32 individual foods in the Modified Italian FFQ. Sources of data used 
included the United States National Nutrient Database (USDA) (1998);  Perry et al. (2009); 
O‘Neill et al. (2001) and Nutrientdata.com (2009). The information in Nutrition Data.com 
is derived from the USDA's National Nutrient Database for Standard Reference and is 
supplemented by listings provided by restaurants and food manufacturers, such as 
Kellogg‘s. Since only O‘Neill et al. derived data from Ireland, and since it is thought that 
carotenoid content varies geographically, this database would have seemed like the most 
suitable to use. However, total carotenoid intake estimated by O‘Neill et al. (2001) using 
this database tended to be 3 to 4 times higher than that calculated by previous investigators. 
This was explained in part by the potential inaccuracy and the dietary assessment tool used 
(Granado et al. 1996; Scott et al. 1996; O‘Neill et al. 2001). Despite this however, in the 
absence of other Irish or European carotenoid databases, Irish data from O‘Neill et al. 
(2001) was included in the modification of the database. Confusion as to which analysis 
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uses cis/trans carotenoid information makes it difficult to make a comparison between 
databases and to determine the most reliable and accurate database to use. Therefore, one 
database alone cannot be deemed the most reliable and a combination of all four were used 
for this study. 
          
All four databases were used to estimate the lutein and zeaxanthin combined contents of the 
569 and 32 foods included in the SCG and modified Italian FFQ. 75 foods were deemed to 
be sources of lutein and zeaxanthin using this approach. The WISP database was 
subsequently modified for lutein and zeaxanthin as a combined nutrient value, as the 
majority of published databases to date contain only information on lutein and zeaxanthin 
combined. The 44 FFQs in total were analysed using the modified database and dietary data 
were exported to a SPSS database.  
 
6.3.11 Data cleaning of the SCG FFQ 
The ratios of energy intake to basal metabolic rate (BMR) were calculated to identify mis-
reporting (Goldberg et al. 1991). As only the SCG FFQ assessed total energy intake, 
under/over-reporting could not be evaluated for the modified Italian FFQ. The cut off ratio 
was set at 1.35, as 1.35 x BMR is the minimum energy expenditure compatible with a 
normally active lifestyle (Goldberg et al. 1991). However, as this would result in the 
exclusion of 11 subjects (50%), all subjects were included in the study. It does serve 
however, to reinforce the difficulties inherent in retrospective FFQ analysis. 
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6.3.12 Statistical analysis 
The statistical software package SPSS (version 18) was used for analysis. The mean and 
SD‘s are given for normally distributed data. The following variables were tested as 
potential effect modifiers for the correlation between dietary lutein/zeaxanthin intake and 
corresponding biological markers: age, sex, BMI category (Kg/m
2
: <25, 25-29.9, 30), 
smoking status (never, former, current), alcohol intake per week, physical activity, and fruit 
and vegetable intake.  
(1) Preliminary analyses at all phases were performed to ensure no violation of the 
assumptions of normality. Concurrent agreement of the SCG FFQ, the modified 
Italian FFQ, the WISP database and the MRC database, along with the validity of 
both FFQs, with biological markers was assessed using several methods: To 
determine overall association: Pearson Product-moment correlation. 
(2) A paired samples t-test was performed to compare means and test for statistical 
significance. 
(3) To determine agreement: Bland-Altman plots including limits of agreement and 
coefficients of repeatability (Bland et al. 1986) were calculated for the SCG FFQ 
and the modified Italian FFQ. The limits of agreement define the limits within 
which 95% of these differences are expected to fall (mean of difference  1.96 
standard deviations of the difference). The differences between the two FFQs were 
plotted against the average of the two FFQs creating a Bland Altman Plot. This was 
repeated to assess agreement between the two nutrient databases. 
(4) Joint classification of nutrient intake assessed by the two FFQ was assessed using 
quintiles of intake for lutein and zeaxanthin from the SCG FFQ and the modified 
Italian FFQ, respectively. The proportion grossly misclassified applied when one 
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dietary assessment method classified the individual‘s intake into the lowest quintile 
and the other method classified it into the highest quintile. Quadratic weighted 
Kappa values were calculated comparing quintiles of intake for each nutrient from 
the SCG FFQ and modified Italian FFQ.  
 
6.4 Results 
6.4.1 Demographic data 
The demographic profile of the study population is presented in Table 6.1. Because 
only 3 subjects were males, the data was not split by gender. The study population 
consisted of 19 females and 3 males aged 18-54 years. Only one subject reported a 
previous diagnosis of high cholesterol. No previous history of eye disease was reported. 
Mean daily intake of lutein and zeaxanthin varied from 1.68mg/day (SD±1.16) to 
1.76mg/day (SD±1.87), depending on the dietary assessment tool and nutrient database 
used for dietary assessment and analyses. Mean serum concentrations of lutein and 
zeaxanthin were (1.02ug/ml (SD±0.33) and mean central MPOD was 0.59 (SD±0.19); 
mean total MPOD was 1.77 (SD±0.676).  
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Table 6.1 Demographic characteristics of sample population (n=22). 
 Mean % SD   Mean  % SD 
Age 24.5 9.49 BMI (Kg/m
2
)   
Sex n  18.5-24.9 15 68.2 
Male 3 13.6 25-29.9 6 27.3 
Female 19 8.4 >30 1 4.5 
Exercise (mins/wk) 212.7 144.5 Smoking Status   
MPOD Total 1.775 0.676 Never 18 81.8 
MPOD Central 0.591 0.19 Current 3 13.6 
   Former 1 4.5 
L and Z intake 
     (mg/day) 
  Alcohol Consumption   
SCG FFQ 
(WISP database) 
1.68 1.16 None 0 0 
SCG FFQ 
(MRC database) 
1.76 1.87 1 unit 2 9.1 
Modified Italian 1.51 1.41 6-10 units 4 18.2 
   >10 units 10 45.5 
Fruit Intake (g/day)   Vegetable Intake 
(g/day) 
  
SCG FFQ 352 188 SCG FFQ 183.9 118 
Modified Italian 61 49.9 Modified Italian 135.9 75.6 
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L and Z = Lutein and Zeaxanthin.   
BMI = Body mass index;  MRC = Medical research council.  
Mean and Standard Deviation (SD) Number (n) and %. 
 
6.4.2 Comparability of the two FFQ’s 
 Comparison of group means 
The mean daily intake of lutein and zeaxanthin estimated by the SCG FFQ and the  
modified Italian FFQ were1.68mg/day (SD±1.16) and 1.51mg/day (SD±1.41) 
respectively (analysed using modified WISP database). In order to see, to what extent 
both FFQs were in agreement, data were plotted in a scatter diagram [Fig.6.2 (a)]. The 
mean difference in intake by the two methods was 0.168mg (SD±1.2). A paired 
samples t-test revealed no statistical significant difference in mean intake 
estimated by the two FFQs, (t= 0.634, P = 0.533).  
 
6.4.3 Correlation between both FFQs  
In order to see to what extent the two methods were associated, Pearsons product 
moment correlation was computed. There was a positive significant association 
between both FFQs [SCG FFQ and modified Italian FFQ analysed using modified 
WISP], (r = 0.546, p=0.009). 
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Fig.6.2(a) Correlation between lutein and zeaxanthin intakes assessed by the SCG 
FFQ (analysed using modified WISP) and the modified Italian FFQ. 
  
6.4.4 Assessment of agreement between FFQs: Bland-Altman Plot 
Figure 6.2(b) illustrates how well the two methods were likely to agree on an individual 
basis. The difference between lutein and zeaxanthin intake assessed by the two FFQs 
were plotted against the average of the two measurements. The 95% limits of agreement 
were calculated. The mean difference is close to zero, so there is little evidence of 
overall bias. Wide limits of agreement indicated that both methods differed by up to 
4.88mg for some subjects. From the Bland Altman plot it can be seen that as the lutein 
and zeaxanthin intake of individuals increased, so did the magnitude of error between 
the modified Italian FFQ and the SCG FFQ. 
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Fig.6.2(b) Differences between lutein and zeaxanthin intakes assessed by the SCG FFQ 
(analysed using modified WISP) and the modified Italian FFQ plotted against the 
average of the two measurements (Bland Altman Plot). 
 
6.4.5 Comparability of the two nutrient databases 
Comparison of group means: 
The mean daily intake of lutein and zeaxanthin estimated by the SCG FFQ, using the 
modified WISP nutrient database was 1.68±1.16 and using the MRC nutrient database 
was 1.76±1.87. Fig. 6.3(a) shows a scatter diagram, representing the association 
between dietary intakes assessed by the SCG FFQ and analysed using two different 
databases. On average the mean difference between the two databases was 0.08mg 
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(SD±1.076). A paired samples t-test revealed no statistically difference in means 
between the two databases, (t=-0.365, P=0.719). 
 
6.4.6 Correlation between the nutrient databases 
A pearsons product moment correlation was calculated, (r=0.85, p=0.001), indicated a 
significant, strong, positive correlation between the two databases.  
 
 
Fig 6.3(a): Correlation between lutein and zeaxanthin intake using the SCG FFQ 
analysed using WISP database and the MRC database. 
 
6.4.7 Assessment of agreement between databases: Bland Altman Plot 
Figure 6.3(b) presents a Bland Altman plot, which illustrates how well the two 
databases were likely to agree on an individual basis. The mean difference between 
lutein and zeaxanthin intake analysed by the two databases were plotted against the 
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average of the two measurements. The mean difference is close to zero, so there is little 
evidence of overall bias. Wide limits of agreement represented a potential variation of 
up to 4.22 mg/day depending on the nutrient database used. From the Bland Altman 
Plot it can be seen that as the lutein and zeaxanthin intake of individuals increased, so 
did the magnitude of error between the modified WISP nutrient database and the MRC 
nutrient database. 
 
 
Fig. 6.3(b) Differences between lutein and zeaxanthin intakes analysed using the 
modified WISP and the MRC database plotted against the average of the two 
measurements (Bland-Altman Plot). 
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Table 6.2 Shows the relationships between the study parameters for the entire study 
group. 
 
 
Table 6.2. Pearson‘s Product moment correlation Matrix showing relationships between 
the study parameters for the entire study group     
 SCG FFQ  SCG FFQ  Italian FFQ Serum L+Z MPOD 
 (WISP) (MRC) (Modified)     
SCG FFQ  1     
(WISP)      
SCG FFQ  0.850** 1    
(MRC)      
Italian FFQ 0.546** 0.730** 1   
(Modified)      
Serum L+Z 0.597* 0.590* 0.288 1  
MPOD 0.205 0.350 0.161 0.734** 1 
      
*Correlation is significant at the 0.05 level (Pearson‘s correlation: two tailed) 
**Correlation is significant at the 0.01 level (Pearson‘s correlation: two tailed). 
 
6.4.8 Classification into quintiles of consumption 
In this study, the number of subjects correctly classified within one quintile category by 
both FFQ‘s for estimated lutein and zeaxanthin intake analysed using the WISP 
database were 4 (18%) respectively. There was no gross misclassification. Weighted 
kappa values were poor (0.32) representing poor agreement. Despite no gross 
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misclassification between the two FFQ‘s, the relatively low proportion of subjects 
similarly classified, would suggest a poor capacity for both FFQ‘s to classify 
individuals into the same quintile of consumption. When comparing dietary lutein and 
zeaxanthin analysed using the two different databases, only 9 (41%) were correctly 
classified into the same quintile of consumption with no gross mis-classification. 
 
6.4.9 The relationship between dietary lutein and zeaxanthin and serum 
Mean serum lutein and zeaxanthin values was 1.01 g/ml (SD±0.33). Table 6.2 
demonstrates that serum lutein and zeaxanthin concentrations were significantly 
correlated with the dietary intakes obtained from the SCG FFQ only. The modified 
WISP database showed similar correlations (r=0.597, p=0.024) to the MRC nutrient 
database (r=0.590, p=0.026). No significant relationship was found between dietary 
intake analysed by the modified Italian FFQ and serum concentration of lutein and 
zeaxanthin (r=0.288, p=0.317). The strength of the relationship was increased between 
the three sets of dietary data and serum lutein and zeaxanthin when BMI, alcohol intake 
(g/day) and smoking status were controlled for. 
 
6.4.10 The relationship between dietary lutein and zeaxanthin and MPOD 
Mean total and central MPOD calculated was 1.775 (SD±0.676) and 0.59 (SD±0.19). 
Table 6.2 demonstrates non significant correlation coefficients for both questionnaires, 
analysed using the modified WISP database and MRC database with MPOD. Similar, to 
the relationship with serum, correlations were strengthened when controlling for BMI, 
alcohol intake (g/day) and smoking status. 
 
 
182 
 
6.4.11 The relationship between serum lutein and zeaxanthin and MPOD 
The relationship between serum values and MPOD total yielded a strong correlation of 
(r=0.734, p=0.003) (Table 6.2). The strength of the relationship was improved after 
adjusting for BMI, alcohol intake (g/day) and smoking status.  
 
6.4.12 Analysis of sources of lutein and zeaxanthin in the Irish population 
Lutein and zeaxanthin dietary intake, estimated from the SCG FFQ, was split into 17 
different food groups and % of lutein and zeaxanthin contributed by each food group 
was calculated. As expected food groups contributing most substantially to lutein and 
zeaxanthin intake, included vegetables (44%), fruit/ fruit juices (20%), breakfast cereals 
(8%), potatoes (5%), breads (4%) and miscellaneous (3%). Vegetable intake estimated 
by both, the SCG and modified Italian FFQ, was positively and significantly correlated 
with estimated lutein/zeaxanthin intake (r = 0.712, p=0.001; r = 0 .693, p=0.001), but 
not MPOD, although it did approach significance for the SCG FFQ (r=0.419, p=0.052). 
Fruit intake from the SCG FFQ and the modified Italian FFQ was not significantly 
correlated with lutein and zeaxanthin intake, but fruit intake from the Italian FFQ was 
significantly related to MPOD (r=0.436, P = 0.042), but not for the SCG FFQ. Mean 
weights of foods consumed in these food groups were also calculated. The average 
consumption of fruit and vegetables estimated by the SCG FFQ were 352g (SD±188) 
and 184g (SD±118) respectively. This was approximately 3 times greater than that 
estimated by the modified Italian FFQ (Table 6.1).  
 
 
 
 
183 
 
6.5 DISCUSSION 
The purpose of this study was to assess dietary intake of lutein and zeaxanthin in a 
small sample population, using two different FFQs, and two different nutrient 
databases, and subsequently to assess the validity of the dietary assessment tools and 
nutrient databases, using nutrient biomarkers; blood serum and MPOD. A small sample 
size was a major limitation of this study, given that a sample size of >50 subjects is 
needed to allow the limits of agreement calculated in the Bland Altman plot to be 
estimated precisely (Cade et al. 2002). Therefore, as with any study, interpretation and 
extrapolation of results must be done so in a cautious and educated manner. Instead, 
results should be used as a guide to help direct future research in the area. 
            
Results of this study showed a positive relationship between lutein and zeaxanthin in the 
diet, serum and macula. These findings are consistent with previous intervention 
studies, which have shown that dietary lutein and zeaxanthin fortify the MP in the eye, 
forming a layer of tissue that protects the macula from age-related damage (Bone et al. 
1997; Johnson et al. 2005). There was a strong positive relationship between serum 
nutrient concentration and MPOD. Again this is supported by previous findings which 
indicate that the extent of MP enhancement is dependent upon the lutein and zeaxanthin 
in the blood serum level achieved (Hammond et al. 1997; Bone et al. 2002). However, 
the nature of the relationship between lutein and zeaxanthin in the diet, blood, and 
macula is not a simplistic one but is confounded by many variables including proceses 
which influence digestion, absorption, and transport of the compounds in question, and 
accumulation and stabilisation of the carotenoids in the tissues. Regardless of the 
confidence in the method for dietary assessment, it is not possible to control for the 
extent to which interpersonal variation of these variables will influence the relationship 
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between lutein and zeaxanthin in the diet and its consequent accumulation in the blood 
and macula, whereas biomarkers, serum and MPOD are independent, to a certain extent 
of these influences. 
 
Mean dietary intake of lutein and zeaxanthin assessed by the SCG FFQ and the 
modified Italian FFQ, and analysed by modified WISP, was 1.67 ±1.16mg/day and 1.51 
±1.41mg/day respectively which fell approximately 3-5mg short of the daily 
recommended intake of 6mg/day, however results were consistent with previous Irish 
findings (Nolan et al. 2007). Despite the use of several different dietary assessment 
tools and nutrient databases, previous researchers have found a high level of consistency 
in estimated intakes of lutein and zeaxanthin, suggesting comparability between studies 
and hence a good level of agreement between the different dietary assessment tools and 
nutrient databases. For example, the estimated dietary intake in the Irish and Italian 
population cohort, using the SCG FFQ and the brief Italian FFQ have been analysed 
using separate nutrient databases (Nolan et al. 2007; Cena et al. 2007). Estimated 
dietary intake ranged from 1.1mg/day to 1.6mg/day, differing by a negligible 
0.5mg/day. Both studies found significant correlations between dietary intake and 
serum concentrations, suggesting validity of their chosen dietary assessment tools and 
nutrient databases. However, Wirfalt et al (1998) highlighted a limitation compromising 
the comparability of studies. Both FFQs differ in terms of design and neither have been 
validated in an Irish population [validation studies are not necessarily transferable to 
another population (Plummer et al. 2003)]. The modification of the Italian FFQ here, 
makes previous validation invalid (Castenmiller, 1999) so neither of the FFQ‘s can be 
considered a validated dietary assessment tool for use in an Irish population. 
Additionally, the fact that the SCG FFQ was previous designed and validated as a 
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general FFQ and not specifically with lutein and zeaxanthin in mind, would leave 
results yielded by its use questionable.  
 
On average, the SCG FFQ and the modified Italian FFQ performed well against each 
other, with a negligible mean difference in estimated lutein and zeaxanthin intake of 
0.168mg/day. Although there was a positive and significant correlation between the two 
FFQ‘s, the two FFQs demonstrated poor agreement. The wide limits of agreement 
calculated in the Bland Altman Plot Figure. 6.2(b) indicate that on an individual level 
the two methods differ in estimation of lutein and zeaxanthin intake by up to 4.88 
mg/day, with differences increasing for highest consumers of lutein and zeaxanthin. 
Given that the range within which most differences lie is approximately 3 times the 
average Irish daily intake and 3 times larger than those calculated by previous 
researchers (Cena et al. 2007), it is possible to conclude that any false assumption of 
good comparability between the two FFQs, may lead to false associations between 
dietary factors and disease or disease related markers. As limits of agreement must be 
interpreted clinically and not statistically, more studies are needed to establish a 
reference range within which limits of agreement should lie when establishing the 
comparability or validity of FFQs. In this instance analyses using the Bland Altman plot 
served to highlight the potential danger of using mean difference or correlation 
coefficients alone to determine comparability of two methods. Where one method may 
produce a consistently higher level of output than another, a strong correlation would 
persist, despite a lack of agreement at an individual level. In the absence of such 
information, correlation coefficients continue to be the main method of comparison 
between studies, with >90% of studies having calculated correlation coefficients and 
<10% calculating limits of agreement (Cade et al. 2002). The lack of association is also 
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reinforced by the failure of the two FFQs to classify 18 (81%) subjects into the correct 
corresponding quintile of consumption, which has been identified as the most important 
quality of the FFQ (Hodge et al. 2009). 
 
On average, the SCG FFQ analysed using modified WISP and the MRC nutrient 
database performed well against each other, with a negligible mean difference in 
estimated lutein and zeaxanthin intake of 0.084 mg/day. There was a significant strong 
positive correlation between the two FFQ‘s when analysed using the different nutrient 
databases, however, this result again is misleading, as on an individual level the two 
databases did not agree. The wide limits of agreement calculated in the Bland Altman 
Plot Fig. 6.2(b) indicate that the two methods differ in estimation of lutein and 
zeaxanthin intake by up to 4.22 mg/day, with differences increasing for highest 
consumers of lutein and zeaxanthin. The lack of agreement found between the two 
nutrient databases is unnecessarily reducing comparability of studies even further. 
While FFQs are well known for their limitations, and, as in the current study, have been 
found to vary substantially in accuracy (Sebring et al. 2007), the high degree of 
variability between databases is less appreciated. According to O‘Neill et al. (2001) ‗the 
validity of all food intake data in terms of nutrient intakes is based on the availability 
and accuracy of food composition data’. 
             
In addition to the absence of a ‗gold standard‘ lutein and zeaxanthin dietary assessment 
tool, there is, similarly an absence of a ‗gold standard‘ database. This renders the 
assessment of the validity of questionnaires difficult. Inaccurate information may lead 
to false associations between dietary factors and disease or disease related markers. 
Validation of the questionnaires against a ‗gold standard‘ is necessary to determine 
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which method is providing the most accurate information. Studies prior to 1993 used a 
database developed based on limited analytical data and extrapolation of values for 
similar foods (Coates et al. 1991). The more recent studies have used the database 
originally developed by the USDA and the National Cancer Institute by Mangels et al. 
in 1993 and updated in 1998, either alone or in combination with other data. Several 
studies have examined individual associations between dietary carotenoids, and plasma 
carotenoid concentrations (Brady et al. 1996; Coates et al. 1991; Forman et al. 1993; 
Peng et al. 1995; O‘Neill et al. 2001; Nolan et al. 2007; Cena et al. 2008). Previous 
researchers have found when databases have been compared they yielded different 
quantitative estimates, but similar correlations with blood concentrations (Ritenbaugh et 
al. 1996; Vandenlangenberg et al. 1996). Correlations reported by these studies range 
from 0.09-0.76 for lutein and zeaxanthin. The variation in databases leading to such 
differences in quantitative estimates but good agreement with blood concentrations may 
be explained by an absence of consistency in reporting cis/trans form of the carotenoid, 
bioavailability from the food, cooking method, ripeness, or country of origin.  
 
Given that most dietary assessment methods carry considerable limitations and error 
and are subject to several forms of bias, with the possible exception of extensive diet 
diaries (e.g.14-21 days in length) or direct behavioural observation, no dietary 
assessment method can be deemed a gold standard (Briefel et al. 1992). In the absence 
of such a gold standard, this study used two nutritional biomarkers, [serum 
concentration of lutein and zeaxanthin and MPOD (reflecting lutein/zeaxanthin status in 
the eye)], to determine the validity of the two FFQs. As carotenoids are not 
homeostatically regulated, and the only source of these in serum and macula is diet, 
MPOD and serum biomarkers are assumed to be independent of respondent bias and 
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they represent a useful measure of the relative validity of the intake measure. 
Determining the threshold of acceptable validity coefficients between self-reported diet 
and biomarkers is often difficult i.e. deciding on how strong a correlation is needed to 
establish validity, since MPOD and serum lutein and zeaxanthin are influenced by 
factors other than food intake. Accurate interpretation of data correlating dietary intake 
of lutein/zeaxanthin and serum concentration of lutein/zeaxanthin in epidemiologic and 
clinical studies requires knowledge of biological and non-dietary factors influencing the 
relationship between lutein and zeaxanthin in foodstuffs, blood, and macula. Rock et al. 
identified demographic characteristics (age, sex, race/ethnicity, education), BMI and 
lifestyle factors (exercise, sun exposure, smoking and alcohol consumption) to be 
significantly associated with dietary lutein and zeaxanthin intake, while processes which 
influence digestion, absorption, and transport of the compounds in question, and 
accumulation and stabilisation of the carotenoids in the tissues will influence serum (a 
short term marker of dietary intake) and macular concentrations (a long term marker of 
dietary intake) of lutein and zeaxanthin (Rock et al. 2002).   
 
Mean serum nutrient concentration (0.101 ± 0.33 g/ml) was consistent with previous 
Irish findings (0.102 ± 0.045 g/ml) (Nolan et al. 2007). As recommended intake of 
lutein and zeaxanthin based on serum levels, results would indicate that on average, this 
study population would require an additional 3.8 - 6.6 mg/day to achieve optimal serum 
levels in the range of 0.350 - 0.600 g/ml (Appendix B). This study found significant 
correlations for dietary intake assessed by the SCG FFQ only with blood concentrations, 
consistent with correlations found by previous researchers (Rock et al. 2002). The 
strongest correlation with serum lutein and zeaxanthin was for dietary intake analysed 
using the modified WISP but there was also a moderate correlation with the MRC 
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database. Assuming that higher correlations of dietary variables with serum levels can 
be interpreted as an indication of greater validity, it appears that the SCG FFQ is more 
accurate than the modified Italian FFQ and the modified WISP database produces 
somewhat more valid estimates of lutein and zeaxanthin intake than the MRC database 
when estimating intake in an Irish population. The inclusion of more up to date data 
(Perry et al. 2009), and the inclusion of population specific data (O‘Neill et al. 2001) 
represent likely explanations for the increased validity of the modified WISP database.  
          
As expected, given that fruit and vegetables are lutein and zeaxanthin rich sources, their 
intake contributed most significantly to lutein and zeaxanthin intake. Previous studies 
also reported a strong correlation between both fruit (r = 0.54) and vegetable (r = 0.61) 
consumption and blood serum concentrations of lutein and zeaxanthin (Cena et al. 
2007), and were confirmed in the current study, with serum concentration correlating 
with vegetable consumption estimated by the SCG FFQ, although not for fruit 
consumption. This may be explained in part by the potential over-reporting of fruit 
consumption by the SCG FFQ, which estimated an average consumption of 4.5 servings 
of fruit/day, 3.5 portions more than that found to be the average intake in an Irish 
population subgroup studied by Thurnham et al. (2008). Given the semi quantitative 
design of the SCG FFQ, where frequency of consumption is based on standard portion 
size rather than open questions on quantity of food consumed, it is vulnerable to 
overestimation of food consumption (Molag et al. 2007). Additionally, the number of 
fruits listed in the questionnaire may in part account for the overestimation of intake as 
it has been shown that the longer the list of detailed food items belonging to a given 
main food group (e.g. many different types of vegetables), the higher the total level of 
consumption reported (Haraldsdottir, 1993). When actual consumption of fruit and 
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vegetables is monitored, very few account for most of the carotenoid intake, suggesting 
that the modification of the SCG FFQ, to include a shorter list of fruits would be 
sufficient. However, as Ireland is quickly becoming a multicultural nation, it may be 
argued that such an extensive list is needed to provide a common questionnaire for all 
cultures and dietary habits when assessing nutrient intake in an Irish population.  
             
Similarly, fruit and vegetable consumption estimated by the Italian FFQ showed no 
significant correlation with serum. This may be explained, in part, by the brief, nutrient 
specific design of the questionnaire. The food list consists of 32 rich sources of lutein 
and zeaxanthin, commonly eaten by the Italian population. Those listed tend to be eaten 
only occasionally and by a relatively small proportion of the Irish population e.g. 
vegetable juice, tomato juice, papaya and watermelon. In addition a limited list of foods 
does not permit recipes or specific ingredients to be imputed for analysis. Despite this 
however an estimate of approximately two portions of fruit and vegetables was 
reported, which would seem, to be an overestimation of actual intake, which would 
comply with previous findings indicating, as found with the SCG FFQ, that when 
subjects are presented with a long list of items in a specific food group, the risk of over-
reporting is increased. 
 
While the crude quantification of dietary intake, and the inaccuracies of nutrient 
databases are predictive of the relationship between dietary intake and serum 
concentration of lutein and zeaxanthin, it is important to consider other components of 
the diet such as dietary fat (Seddon et al. 2003), fibre (Riedl et al. 1999), food source 
(Hof, 1999), and food preparation or processing (Castenmiller, 1999), can influence 
lutein/zeaxanthin bioavailability or serum response. These factors could potentially 
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influence the observed relationship between dietary intake and tissue concentrations of 
lutein and zeaxanthin. Certain medications such as statins can lower blood levels of 
carotenoids. Butters and margarines enriched with plant sterols such as ‗Benecol‘ and 
‗Flora Pro Active‘ may decrease the absorption of carotenoids. Given the relatively 
young mean age of this subject population, consumption of these products was not 
controlled for, however, given their increased popularity and frequency of consumption 
among the Irish aging population (Hearty et al. 2008), their potential to confound the 
relationship should not be ignored. Never the less, Rock et al (2002) found that, neither 
fat, fibre nor cholestra were predictive of serum lutein/zeaxanthin concentration in the 
general population. Unfortunately, other than the recording of reported known digestive 
or absorptive idiosyncrasies, the scope of this present study did not permit for the 
control of potential confounders affecting the relationship between dietary intake of 
lutein and zeaxanthin and serum concentrations, and therefore, it could be expected that 
controlling for factors affecting the bioavailability of lutein and zeaxanthin, along with 
the transport of lutein and zeaxanthin in the serum (LDL/HDL), would have 
strengthened the correlation (Rock et al. 2002; O‘Connell et al. 2008). Smoking status 
and alcohol consumption, due to potential direct effects on metabolism and turnover of 
these carotenoids (Handleman et al. 1999), were controlled for, strengthening the 
relationship between dietary intake and lutein and zeaxanthin concentrations in the 
serum and macula. In previous studies associations between circulating lutein and 
zeaxanthin concentrations and MPOD or risk for eye disease, determinants have 
sometimes (Mares-Perlman et al. 1995, O‘Connell et al. 2008) but not always (Bone et 
al. 2001) been considered in the analysis, and again may contribute to inconsistencies in 
results.  
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Both FFQ‘s failed to show a significant relationship between MPOD and dietary intake. 
Previous researchers have showed inconsistent results; however the majority have found 
a significant relationship (Bone et al. 2000). The absence of significance may in part be 
explained by small numbers of subjects (n<50), which was deemed to be the most likely 
explanation for a lack of significant findings in previous studies (Hammond et al. 1995; 
Beatty et al. 2001). Two other factors, that might help explain the modest diet-macula 
correlations, some of which have already been mentioned, include vagaries in dietary 
and biochemical assessment, and a limited understanding of carotenoid metabolism. 
Despite previous findings of no seasonal variation in dietary intake of these carotenoids, 
the inclusion of a significantly younger population group than that used in previous Irish 
studies (mean age 24yrs), and the knowledge of a lack of dietary routine in younger 
population groups, may have biased the relationship between dietary intake and MPOD. 
It has been previously suggested, that interpersonal variation in terms of efficiency of 
metabolism, absorption, transport and stabilisation, may be the primary determinant of 
MPOD and not dietary intake of lutein and zeaxanthin (Bone et al. 2000).   
 
With a highly significant correlation coefficient of (r = 0.734), serum concentrations
 
of 
lutein/zeaxanthin were found to be more strongly related to MPOD than
 
to dietary 
intake, which is consistent with previous findings by other researchers (Hammond et al. 
1996; Bone et al. 2000; Mares et al. 2006). Thus, more direct assessments of dietary 
intake and lutein/zeaxanthin
 
status, such as serum concentrations of lutein/zeaxanthin 
and
 
MPOD, may provide a clearer picture of the
 
relationship between lutein and 
zeaxanthin and risk of AMD. Individualised dietary intake requirements (Appendix B) 
based on serum concentrations, would serve to eliminate vagaries inherent with dietary 
assessment and analyses, while automatically controlling for digestive and absorptive 
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idiosyncrasies. Unfortunately lutein and zeaxanthin levels in serum are not routinely 
determined in clinical settings, constituting an important gap in relation to the dietary 
requirements and distribution of lutein and zeaxanthin in serum in patients at risk of 
AMD. 
 
While this study would favour the use of the SCG FFQ for assessing dietary lutein and 
zeaxanthin intake, it appeared to severely under-report energy intake, with over half the 
study population falling below the Goldberg cut-off for under-reporting. However, the 
fact that fruit and vegetable intake was estimated to be 3 portions more than that 
reported in previous Irish populations, would imply that the SCG FFQ underestimated 
non lutein and zeaxanthin rich foods such as protein and fat, a common limitation of 
FFQs (Schaefer et al. 2000), rather than fruit and vegetables, the main providers of 
lutein and zeaxanthin, which seemed to be over-reported.  
 
When choosing a dietary assessment tool, practical issues related to the administration 
of FFQs should be examined. The length of time needed for an individual to complete 
each FFQ should be considered: about 35 minutes for the SCG FFQ and <10minutes for 
the modified Italian FFQ. Analysis times and required resources also vary among the 
two FFQs. The SCG FFQ requires 40 minutes for analysis, or alternatively optical 
scanning in Scotland, which may take several days, where as the modified Italian can be 
analysed in 10 minutes. However, while a nutrient specific questionnaire, such as the 
modified Italian FFQ, would seem to be the optimal choice in terms of practicality, its 
apparent lack of accuracy found in this study would indicate that the number of items on 
a FFQ should not be reduced just because of the length of the food list, as doing so 
might reduce the validity of the FFQ (Cade et al. 2002). In contrast, Wirfalt et al 
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reported that ‗less detailed information may be sufficient when categorising individuals 
on nutrients present in a few foods consumed, providing that the questionnaire includes 
sufficient number and quality of food sources’ (Wirfalt et al. 2007). Therefore, with the 
correct modifications to the questionnaire, to make it population specific, as well as 
administering the questionnaire with interview assistance, as originally intended by 
Cena et al, the modified Italian FFQ, has the potential to be the optimal choice of FFQ, 
both practically and in terms of accuracy (Cena et al. 2007). 
 
A potential limitation of the modified WISP nutrient database relates to the reporting of 
lutein and zeaxanthin as a combined value. However, this in part, was due to the limited 
availability of data which report the nutrients as separate values. Additionally, as both 
serum and MPOD provided a reading of both nutrients together, it was sufficient, for 
the scope of this study to report the nutrients combined as a single value. An important 
point worth mentioning is that considering meso-zeaxanthin is now believed to be the 
more potent antioxidant of the three carotenoids, no tool exists to assess dietary intake 
of this carotenoid (as it is not commonly found in many foods). 
                 
The development of the carotenoid database, modified WISP, contains, to our 
knowledge the most up to date information available on lutein and zeaxanthin, while 
being population specific. Additionally this study provides evidence for the potential 
danger of using dietary assessment methods for purposes other than those identified 
through the validation procedures. Most importantly this study highlights the lack of 
comparability between studies using different dietary assessment tools and nutrient 
databases (Granado et al. 1996; Scott et al. 1996; O‘Neill et al. 2001), and may provide, 
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in part an explanation for inconsistent results found by researchers investigating the 
relationship between dietary intake of lutein and zeaxanthin, serum values and MPOD. 
 
In summary, dietary intake of lutein and zeaxanthin assessed using the SCG FFQ and 
the modified Italian FFQ was not comparable. Similarly dietary intake of lutein and 
zeaxanthin analysed using the modified WISP database and the MRC nutrient database 
was not comparable. While the evidence from this study would favour the use of the 
SCG FFQ and the modified WISP database, the short modified Italian FFQ would 
appear to have the potential to provide accurate estimates of intake, if limitations 
identified were addressed through revisions in administration and a food-list update. 
While dietary assessment methods may be appropriate and useful for estimating lutein 
and zeaxanthin exposure on a community or group basis, evaluation of nutrient 
exposure by dietary means is ultimately reliant on the availability of reliable data on 
food composition. Therefore, concerted efforts should be directed toward improving 
data, with the aim of developing a ‗gold standard‘ lutein and zeaxanthin database which 
would enhance the validity of estimates of dietary intake of lutein and zeaxanthin. Such 
a milestone, within the field of AMD would provide researchers with a higher degree of 
precision needed to assess their respective roles in eye health. 
 
None of the available resources are currently adequate for research or clinical practice 
so alternatives are required. In the meantime, serum lutein and zeaxanthin, when 
assessed repeatedly, and prospectively on a long-term basis, may be a good indicator of 
healthy eating habits related to AMD. On a community level, screening of lutein and 
zeaxanthin concentrations in serum would allow the identification and establishment of 
appropriate dietary requirements, both in the lower (risk factor) and the upper levels 
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(preventive factor) of requirements, and to determine the adequacy and efficacy of 
dietary intake, or nutritional interventions, with clinical impact on disease prevention. 
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CHAPTER SEVEN 
An Evaluation of a Novel Instrument for Measuring Macular Pigment Optical 
Density: The MPS 9000 
 
7.1 Abstract 
Purpose  
Of the antioxidants found in the human retina, only the macular carotenoids can be 
quantified non-invasively (albeit in a collective fashion), thus facilitating study of their 
role at the retina. The aim of this study was to evaluate concordance between MPOD 
values recorded on a commercially available instrument, the MPS 9000, with those of 
an already validated HFP instrument. Also, we assessed and compared test-retest 
variability for each instrument. 
 
Methods  
MPOD at 0.5
o 
retinal eccentricity was measured using two different heterochromatic 
flicker photometers, the MPS 9000 and the Densitometer
TM
 in 39 healthy subjects. Test-
retest variability was evaluated separately for each instrument by taking three readings 
over a one-week period in 25 subjects. 
 
Results  
In terms of MPOD at 0.5 degrees eccentricity, there was a strong positive correlation 
between the MPS 9000 and the Densitometer (r=0.68, p<0.001); however, a paired 
samples t-test showed a significant difference in terms of mean values, with a bias 
towards lower MPOD values being yielded by the MPS 9000 (t= -4.103, p<0.001). 
Bland Altman analysis indicated only moderate agreement between the two instruments. 
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Test-retest variability, expressed in terms of the coefficient of repeatability, ranged from 
0.18 to 0.21 for the MPS 9000 and from 0.11 to 0.12 for the Densitometer.  
 
Conclusion  
These results show that the MPS 9000 consistently yields MPOD readings which 
represent an underestimate of actual values, and are subject to a substantial amount of 
test-retest variability.  
 
Keywords 
Age-related macular degeneration; MPS 9000; MPOD; densitometer, heterochromatic 
flicker photometry; macular pigment. 
 
7.2 Introduction 
AMD is the most frequent cause of blindness among individuals ≥ 55 years in 
developed countries, (Leibowitz et al. 1980; Attebo et al. 1996; Friedman et al. 2004) 
and with increasing longevity the incidence of AMD is rising. The therapeutic options 
for AMD are limited, although improving. Treatments, however, tend to be exclusively 
aimed at the neovascular, or wet, form of AMD, which until recently included only laser 
photocoagulation (Macular Photocoagulation Study Group, 1993), with or without 
photodynamic therapy, and macular translocation surgery (Ciulla et al. 1988). In the 
recent past, however, substantial progress has been made in the management of the 
neovascular form of the disease using intra-vitreal injections of anti-vascular endothelial 
growth factor (or anti-VEGF) therapy (Avery et al. 2006). Although vision loss with 
wet AMD is more sudden and severe, the non-neovascular form, including the atrophic 
type, is more prevalent and accounts for approximately 90% of cases (Richer et al. 
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2004). At present, there is no consensus with respect to the management (including risk 
analysis and/or prevention) of these more common non-neovascular forms of the 
condition, which may, at least partly, reflect our incomplete understanding of AMD‘s 
aetiopathogenesis. 
  
In the absence of effective treatment strategies for non-neovascular AMD, interest has 
focused on prevention and/or retardation of progression. The Age-Related Eye Disease 
Study (AREDS) has shown that the risk of vision loss in cases of early AMD can be 
reduced with antioxidant supplements.  Further, MP composed of lutein and zeaxanthin, 
two hydroxycarotenoids, which are entirely of dietary origin, and the retinal metabolite 
of lutein: meso-zeaxanthin, (Bone et al. 1997; Johnson et al. 2005) is believed to be 
associated with reduced risk of development and progression of AMD. MP can be 
augmented, not only by eating food rich in these carotenoids, such as spinach, but also 
by dietary fortification with one of the many commercially available food supplements 
(Bone et al. 2003; Murray & Carden, 2008). Epidemiological studies have observed an 
inverse association between the prevalence of AMD and a diet rich in lutein and 
zeaxanthin, (Seddon et al. 1994; EDCCS, 1993) and furthermore, eyes with AMD have 
consistently been shown to have significantly lower levels of MP when compared to 
those without AMD (EDCCS, 1993; Beatty et al. 2001; Bone et al. 2001; Bernstein et 
al. 2010).  
 
The evidence in support of the view that MP plays a role in preventing or retarding the 
progression of AMD rests on its ability to limit photo-oxidative injury in the inner retina 
through its pre-receptoral absorption of SW light, (Snodderly et al. 1984; Snodderly et 
al. 1984) and/or the antioxidant properties of these carotenoids as they act as free radical 
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scavengers in the retina (Snodderly, 1995). Although all humans have some MP in the 
retina, the optical density and spatial distribution of MP have been shown to vary 
dramatically between individuals, (Pease et al. 1987; Bone et al. 1992; Hammond et al. 
1995)
 
with consequential large inter-individual variation in pre-receptoral SW light 
absorption and antioxidant activity in the retina.  
 
Several methods for measuring the optical density of MP have been developed, thereby 
enabling the investigator to detect changes in MP concentration and distribution over 
time, and therefore able to study the response to dietary modification or fortification. 
Unsurprisingly, there is a growing demand for a valid, reproducible, user-friendly 
instrument that measures MPOD.  
 
HFP was the first, and remains the most widely used, technique for measuring MPOD 
in vivo (Snodderly et al. 1984; Pease et al, 1987; Hammond et al. 1997; Hammond et al. 
2005; Nolan et al. 2008; Rougier et al. 2008; Stringham et al. 2008). HFP is a 
psychophysical method, which requires the subject to make iso-luminance matches 
between green and blue flickering lights, which are typically perceived as the point of 
cessation of flicker. The log ratio of the amount of blue light absorbed centrally, where 
MP peaks, to that absorbed at a peripheral retinal locus (the ‗reference point‘, where 
MPOD is assumed to be optically undetectable), gives a measure of the individual‘s 
MPOD. This method (using the Densitometer) has been validated against the absorption 
spectrum of MP in vitro (Bone et al. 1992; Hammond et al. 2005). The MPS 9000 is a 
relatively new HFP instrument that has been developed for clinical use (Van der Veen et 
al. 2009; Schechtman & Karpecki, 2008). It is evident from the literature, however, that 
while based on the same basic optical principles of HFP, significant design and 
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methodological differences do exist. We report a concordance study between the newly 
available commercial instrument, the MPS 9000, and the validated and conventional 
research instrument for measuring MPOD, the Densitometer. We also measured and 
compared test-retest variability for the two instruments.  
 
7.3 Materials and Methods 
This study was conducted at DIT, Dublin, Republic of Ireland. Subjects were recruited 
by word of mouth. Informed consent was obtained from each volunteer after the 
provision of a detailed information sheet. Ethical approval was granted by the research 
ethics committee at DIT, and the experimental procedures adhered to the Declaration of 
Helsinki. Inclusion criteria required participants to be aged 18 years or older, have no 
clinical signs of ocular pathology, and log MAR VA of better than 0.2 in the study eye.  
 
The study eye was selected on the basis of corrected distance visual acuity (CDVA), the 
eye with the better CDVA being selected, (Stringham et al. 2008) and in cases of equal 
CDVA, the dominant eye was selected. A computer generated Log MAR test chart 
(Test Chart 2000 Pro; Thompson Software solutions) was used to determine CDVA at a 
viewing distance of 4 meters, using a Sloan ETDRS letterset. Subjects were requested to 
wear non-tinted normal distance correction spectacles if required. An ocular health 
examination was conducted by ophthalmoscopy to rule out any ocular pathology.  
 
MPOD was measured at 0.5 degrees eccentricity on each instrument, on the same day, 
in 39 subjects to determine instrument concordance.  In order to assess test-retest 
variability for each instrument, 25 subjects had MPOD measured (again at 0.5 degrees 
eccentricity) on three occasions over a one-week period on each instrument, 50 subjects 
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were recruited for this part of the investigation, 25 were randomly assigned to the MPS 
9000 and 25 were randomly assigned to the Densitometer. All data were collected by a 
single operator.  
 
The instruments used in this study were the MPS 9000, (Tinsley Precision Instruments 
Ltd, Croyden, Essex, UK), and the Macular Metrics Densitometer (Macular Metrics II, 
12 River St, Rehoboth, MA 02769, USA). The MPS 9000 procedure is described in 
section 7.3.1. It is also described in Van der Veen et al. (2009). A detailed description of 
the Densitometer is given in section 5.3.7. The instrument used first in the concordance 
arm of the study was randomly selected on a case-by-case basis in order to minimise the 
risk of introducing bias attributable to a learning effect or a fatigue effect from either 
instrument.  
                  
 
 
7.3.1 MPS 9000  
The MPS 9000 is a small, portable HFP instrument, capable of measuring MPOD at a 
single retinal locus (0.5
o 
retinal eccentricity). The Instrument uses a foveal target of 1
o
 
diameter (edge located at 0.5
o 
retinal eccentricity) with the reference location at 8
o
 
retinal eccentricity (parafoveal target of 1.75
o
) (Van der Veen et al. 2009).  
  
Testing was carried out according to the manufacturer‘s instructions. Prior to the first 
session, a short practice test was carried out to familiarise the participant with the 
technique. Once the subject successfully completed the practice run, the subject‘s 
sensitivity to flicker was determined by a built in pre-test routine, that enabled the 
appropriate initial luminance contrast of the two light sources to be established. This 
short (30 sec) pretest flicker sensitivity routine was used to ensure that participants were 
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in the middle of their flicker sensitivity range when performing the main task, as flicker 
sensitivity may vary between individuals.  
 
During the main test, the frequency of the blue (460nm) and green (540nm) light 
sources were automatically ramped down from 55Hz for a series of luminance ratios of 
the two light sources. Initially the observer viewed the target centrally and pressed a 
button when flicker was detected. This sequence of obtaining a flicker threshold for 
each blue-green ratio continued until a curve was obtained, where the minimum 
represents the equalisation of the blue and green luminance (Van der Veen et al. 2009). 
The procedure of obtaining the flicker detection for a series of blue-green ratios was 
repeated, after an additional short practice run, for peripheral viewing, with the subject 
fixating a red 1.75
o
 disc at a reference point of 8
o
 horizontal eccentricity. The central 
and peripheral minima were used to calculate a single MPOD reading. The formation of 
the central and peripheral curves was monitored by the examiner throughout the course 
of the examination to ensure reliability of the results.  
 
7.3.2 Densitometer
 
 The Densitometer
  
is a validated MPOD measurement instrument capable of 
determining a spatial profile of MP, by measurement of MPOD at various retinal 
eccentricities between 0.25
o
 and 3
o
 (Wooten et al. 1999).
  
For the purpose of this study, 
readings were taken centrally at 0.50º using a 1º disc (commonly used as it has been 
shown to have the highest repeatability of results (Snodderly et al. 2004) matching that 
used in the MPS 9000, and a reference location at 7° using a 2° target (Van der Veen et 
al. 2009).  
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Prior to using the Densitometer, all subjects were shown an explanatory video 
describing the method for recording null flicker matches. The subject‘s CFF was then 
measured, and the OFF determined using a defined test algorithm designed to minimise 
variance between readings, in a process that has become known as customised HFP 
(Stringham et al. 2008). The subject performed the test by turning a dial to adjust the 
ratio of blue to green light until, using a method of adjustment, a position of null, or 
minimum, flicker was defined. If a subject could not reach null flicker, the investigator 
increased the flicker frequency in increments of 1 Hz, until null flicker was perceived. 
Alternatively if a subject exhibited a wide variation in null flicker readings (>10% of 
mean radiance at null flicker), the flicker frequency was decreased in increments of 1 
Hz, until an acceptable null flicker range was achieved. An acceptable null flicker range 
was defined as one where the null flicker radiance values achieved by the subject were 
within 5% of the mean null flicker radiance at that test locus. Subjects were required to 
perform at least five null flicker matches for each target (foveal 0.5
o
 and parafoveal 7°). 
The Densitometer was calibrated daily prior to its use, in keeping with the 
manufacturer‘s instructions.   
 
7.3.3 Statistical analysis 
SPSS version 18 for windows was used for data analysis. Mean MPOD for the MPS 
9000 and the Densitometer were compared using paired samples t test.  Bland Altman 
analysis and plots were used to quantify the agreement between the two instruments. 
Inter-sessional repeatability is expressed as a coefficient of repeatability, which was 
calculated as the standard deviation of the mean difference between measurements, and 
multiplied by 1.96. A one way ANOVA was conducted to assess repeated MPOD 
measurements on both instruments to test for a learning or fatigue effect. Coefficients of 
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repeatability and 95% limits of agreement were calculated for (visit 1-visit 2), (visit 2-
visit 3), and (visit 1-visit 3) for each instrument.  
 
7.4 Results 
The data were analysed (1) to compare measurements taken at 0.5
 o
 on the two 
instruments, and (2) to assess inter-sessional repeatability of each instrument. Two 
subjects were excluded from the instrument concordance analysis, and one subject from 
the instrument inter-sessional repeatability analysis, on the basis that they were deemed 
unable to perform the MPS 9000 task satisfactorily. Data analysis is conducted and 
presented for the remaining 37 subjects in the concordance analysis [mean age 29 
(±11)], and 49 subjects [mean age 34 (±10)] in the inter-sessional repeatability analysis.  
 
7.4.1 Instrument Concordance   
A scatter plot comparing MPOD values at 0.5
o 
eccentricity obtained with each 
instrument, is shown in Figure 7.1 (r = 0.68, p < 0.001).                                
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Figure 7.1. Relationship between MPOD readings at 0.5
o
 retinal eccentricity obtained 
with each instrument, with the line y = x superimposed.  
 
A paired samples t-test comparing the mean MPOD, as measured on each instrument, 
yielded a statistically significant difference between instruments (t = -4.103, p < 0.001), 
demonstrating a bias of lower MPOD values obtained on the MPS 9000, reflected in an 
average difference in MPOD values of 0.1 log unit between the two instruments (Figure 
7.2). The 95% limits of agreement between instruments were ± 0.27. 
 
 
 
 
Figure 7.2. Bland-Altman plot for MPOD values at 0.5° retinal eccentricity, showing 
95% limits of agreement between the MPS 9000 and Densitometer 
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7.4.2 Test - Retest Repeatability  
A one way repeated measures ANOVA was conducted to assess repeat MPOD 
measurements for a learning or fatigue effect for each instrument. Mauchly‘s test of 
sphericity was not significant (P>0.05) for either instrument. There was no significant 
difference in repeat MPOD measurements for either the MPS 9000 or the Densitometer, 
indicating the absence of any learning or fatigue effect [MPS 9000 (F = 0.09, p = 0.92); 
Densitometer (F = 2.556, p = 0.09)].  
  
A Bland-Altman plot was constructed to assess agreement between repeat measures 
taken on the MPS 9000 (Figure 7.3). The coefficient of repeatability for the MPS 9000 
ranged from, 0.18 to 0.21 (see Table 7.1). 
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Figure 7.3. Bland Altman plot showing 95% limits of agreement for repeat measures at 
visit 2 and visit 3 for the MPS 9000.   
 
A Bland-Altman plot was also constructed to assess agreement between repeat measures 
taken on the Densitometer (Figure 7.4). The coefficient of repeatability for the 
Densitometer ranged from 0.11 to 0.12 (see Table 7.1).
 
 
 
Figure 7.4. Bland Altman plot showing 95% limits of agreement for repeat measures at 
visit 2 and visit 3 for the Densitometer.  
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Table 7.1. Inter - sessional MPOD (mean ± SD) and coefficient of repeatability for the 
MPS 9000 and Densitometer  
 
Instrument Mean (±SD) MPOD Coefficient of Repeatability  
 Visit 1 Visit 2 Visit 3 Visit 1 - 
Visit 2 
Visit 2 - 
Visit 3 
Visit 1 - 
Visit 3 
MPS 9000 0.31 
(±0.15) 
0.32 
(±0.16) 
0.32 
(±0.17) 
0.18 0.21 0.18 
Densitometer 0.40 
(±0.15) 
0.38 
(±0.16) 
0.40 
(±0.16) 
0.11 0.12 0.12 
 
7.5 Discussion 
The Densitometer has been validated in previous studies, (Wooten et al. 1999; 
Snodderly et al. 2004; Stringham et al. 2008) and the HFP technique for measuring 
MPOD has also been validated against the absorption spectrum of MP in vitro (Bone et 
al. 1992; Hammond et al. 2005). The MPS 9000 is a new commercial technology 
designed to measure MPOD which also employs the HFP technique. The use of HFP 
however does not imply that the results are automatically valid and accurate, and as of 
yet, these important test attributes have not been adequately evaluated for the MPS 9000 
instrument. Given the potential importance of MP measurement for clinical practice, the 
current study which assesses the accuracy and repeatability of this new commercial 
instrument in comparison to the current gold standard HFP instrument, the 
Densitometer, would seem both timely and necessary.  
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In the current study, the mean MPOD was 0.32 (±0.15) for the MPS 9000, and 0.42 
(±0.18) for the Densitometer. These values are consistent with previous studies (Ciulla 
et al. 2001; Snodderly et al. 2004; Loane et al. 2007; Nolan et al. 2008; Makridaki et al. 
2009; Bartlett et al. 2010). MPOD at 0.5° has been observed to range from 0.21(Ciulla 
et al. 2001), to 0.42 (Snodderly et al. 2004), with studies employing the MPS 9000, 
where mean MPOD ranged from 0.33 to 0.35, (Van der Veen et al. 2009; Makridaki et 
al. 2009; Bartlett et al. 2010) and studies employing the Densitometer, where mean 
MPOD was recorded at 0.41 and 0.40 (Nolan et al. 2008; Loane et al. 2007). 
 
A paired 
samples t-test showed the difference in mean MPOD between instruments to be 
significant, with a bias towards lower MPOD values being produced by the MPS 9000.  
 
Given the observed correlation between these HFP instruments (Figure 7.1), a 
difference between the two instruments would pose little difficulty for clinical practice, 
provided that the difference was systematic and predictable. In fact, a systematic 
difference of 0.1 might be expected between the instruments based on their respective 
suggested normative values, with MPOD classified as low once below 0.4 for the 
Densitometer, and once below 0.3 for the MPS 9000. The MPS 9000 does indeed 
consistently underestimate MPOD in comparison to the Densitometer (for ~85% of 
subjects here), and on average, the underestimation is indeed 0.10 (±0.14). This average 
difference of 0.10 is also replicated in the repeatability study (see Table 7.1), so it would 
appear that, despite both instruments using the HFP technique, there is a real, and 
consistent average discrepancy in MPOD values between instruments, and that the 0.1 
difference in expected normative values would therefore seem appropriate. 
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Closer inspection of the data however reveals some surprising and problematic issues. 
Figure 7.2 illustrates the difference and 95% limits of agreement between the two 
instruments, which at ±0.27 would seem unacceptable for clinical purpose. The central 
problem is not that there is a difference between the instruments, but that the difference 
does not appear to be systematic and predictable. The underestimation in MPOD 
between instruments is in the range 0.05 to 0.15 for approximately 36% of subjects 
only, and the difference between measurements (Densitometer – MPS 9000) ranges 
from 0.35 to -0.3, a 0.65 log unit range (it should be noted that all subjects were deemed 
to have understood and performed both measurements satisfactorily, so no cases can be 
dismissed as statistical outliers). This data demonstrates exquisitely that a correlation 
coefficient, as reported in Van der Veen et al, simply cannot be used in isolation to 
determine the validity and accuracy of an MPOD measurement instrument (Van der 
Veen et al. 2009). 
 
It should also be pointed out however that there are a number of exceptions to the trend 
for lower MPOD values on the MPS 9000 compared to the Densitometer. In five cases, 
the MPS 9000 demonstrated higher MPOD values, and in two of these cases the 
difference is substantial (0.26 and 0.30 respectively). Clinically these two cases could 
not be discarded as both subjects were deemed to have understood and performed the 
MPOD measurement to an acceptable standard on both instruments. But from a 
statistical viewpoint however, these may be regarded as outliers. Re-analysis of the data 
excluding these two cases does improve the observed correlation and agreement 
between instruments to more acceptable levels (r
2
 = 0.64, and the limits of agreement = 
0.20). There are a number of significant differences between the instruments and their 
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respective methodologies, which may explain both the observed lack of concordance 
and the disparity in respective inter-sessional repeatability.  
   
The difference in eccentricity of the peripheral target (7° for the Densitometer, and 8° 
for the MPS 9000) is minimal, and in any case, if significant, would tend to lead to an 
underestimation in the Densitometer, which is not the case. The MPS 9000 employs a 
1° stimulus for both the central and peripheral measurements, while the Densitometer 
employs a 2° stimulus for the peripheral measurement. Almost invariably, subjects 
reported significant difficulty completing the peripheral measurement using the MPS 
9000, whereas no such difficulty was reported for the Densitometer. It is likely that this 
difference in peripheral stimulus size is the source of the increase in comparative 
difficulty experienced by subjects using the MPS 9000, and may explain the required 
exclusion of three subjects unable to complete the peripheral measurement. In this 
instance, the manufacturer suggests the use of an age estimate method, which computes 
a value for MPOD based on the central measurement alone, with a peripheral estimate 
predicted on the basis of age. The validity of this age estimate method is however 
questionable, and would be expected to present a significant source of further variation, 
up to an approximate 0.4 log unit range (Makridaki et al. 2009).  
 
An additional potential source of variation lies in the fundamental difference in the 
respective methods for achieving the iso-luminance match. The Densitometer affords 
significant control to the subject, who adjusts the ratio of blue to green until a null 
flicker sensation is achieved. There is no significant time restriction. The subject is 
simply instructed to use a method of adjustment or bracketing method to define the null 
flicker zone. If the flicker rate is not optimal, it can be adjusted by the examiner to 
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facilitate the accurate determination of the point or zone of null flicker. The MPS 9000 
employs a substantially different technique, where a suprathreshold flicker rate is 
gradually reduced at a set rate of 6 Hz per second, and the subject responds by pressing 
a button to indicate the point at which flicker is detected. The rate of flicker decrease is 
a compromise between testing time and differences in subject reaction times (Van der 
Veen et al. 2009). Although, reaction times are known to vary little across age, 
(Porciatti et al. 1991), response times are significantly more complex, and include a 
decision criterion which may vary substantially across individuals, and is very much age 
dependent, particularly in the over 60 age group (where AMD is most prevalent) 
(Hommel et al. 2004). There is a speed-accuracy trade off exhibited in older adults, and 
the extent of such a trade off will critically depend on patient age, and interestingly, on 
task complexity (Madden & Allen, 1995). It is therefore entirely possible that subject 
threshold response criteria on the MPS 9000 may change during the course of an 
examination, in particular if insufficient pre-test practice is given to the subject so that 
the task becomes apparently easier during the test, and more probably, when switching 
to the peripheral target where task difficulty is increased (as is noted in the product 
literature, and evidenced by the inclusion of an age estimation method in the 
instrument). Such a change in response criterion between the central and peripheral 
targets could not be determined by evaluating the shape of the curve produced, and 
could result in under or over estimation of MP. 
   
Expanding on the issue of subject performance assessment during a test procedure, the 
MPS 9000 would additionally seem incapable of providing a useful measure of subject 
performance reliability. The MPS 9000 adopts a curve fitting technique, where 
measurements are repeated for a series of green-blue luminance ratios and a response 
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curve is formed which comprises the flicker detection points for each of the luminance 
ratios. The only performance check an examiner can use is to determine that a ‗typical‘ 
V shaped curve is produced. The product literature describes that ‗irregularities in the 
data‘ are typical, and that the shape of the curves can vary between individuals. This 
makes interpretation of the curve, and reliability of the result, therefore dependent on 
examiner skill and training, and subject to significant variation. The technique basically 
produces one minimum value which is used to determine MPOD by comparing the 
minimum centrally versus peripherally. The MPOD value determined by the 
Densitometer in comparison, represents the average of multiple (typically four to six 
measurements) endpoints determined by the subject. Variation in performance, or lack 
of understanding of the task, becomes immediately obvious by a large standard 
deviation in the radiance values produced. A low standard deviation for both central and 
peripheral measures is a requirement to ensure validity of the result. It is imperative that 
subject performance is assessed during this type of psychophysical task and the MPS 
9000 simply does not achieve this to an acceptable degree.  
 
The variation in the stimulus-background configuration between instruments is also 
significant, and certainly has potential to induce measurement discrepancies. For the 
Densitometer, the configuration is SW blue background, against which, an incremental 
blue target is viewed. For the MPS 9000, the blue target is viewed against a spectrally 
broadband white light surround. While it is likely that both configurations effectively 
suppress the contribution of rods and S-cones, the use of a white light surround could 
potentially create problems including a variation in retinal adaptation level between the 
target and surround (although it is stated that the luminance of the target area is ―close 
to‖ that of the surround (Van der Veen et al. 2009). It may also lead to increased 
215 
 
perception of imperfections at the target edge due to CA caused by the spectrally 
broadband background. These effects could potentially be further compounded by the 
relatively high power +5D focusing lens employed in the MPS 9000, particularly in the 
peripheral viewing condition where off axis lens effects may become problematic. Other 
HFP methods, such as those used by Beatty et al. (2000) and Bone & Sparrock (1971), 
which have employed a centre surround stimulus configuration, have been shown to 
produce a spectral curve that is best fit with a significant rod contribution (Hammond et 
al. 2005). It is simply unclear as of yet, whether the target-stimulus configuration, as 
employed in the MPS 9000, fulfills the basic principle of any technique for the 
measurement of MP, that the method ―should provide spectral absorption curves that 
match the extinction spectra of MP‖ (Hammond et al. 2005).  
 
Measurement repeatability is an additionally important feature of MP estimation using 
HFP. Precise and repeatable quantification of MPOD is essential to facilitate definitive 
management of patients in clinical practice. This is particularly important where dietary 
fortification or supplementation is advised in order to augment MP in individuals with 
low MPOD, or predicted to be at increased risk of AMD. Practitioners need to be able 
to reliably determine the change (if any) in MPOD as a result of the prescribed 
intervention. If instrument test-retest repeatability is not of a clinically acceptable 
standard, the instrument is simply unsuitable for robust clinical practice. The 
repeatability of the Densitometer and the MPS 9000 has been separately investigated 
previously (Snodderly et al. 2004; Gallagher et al. 2007; Van der Veen et al. 2009; 
Bartlett et al. 2010).
 
The Densitometer has been shown to demonstrate good test-retest 
and intraclass correlation, (Snodderly et al. 2004; Gallagher et al. 2007) and a 
coefficient of variation ranging from 17% to 22 %,( Snodderly et al. 2004; Gallagher et 
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al. 2007) all of which would indicate good test-retest repeatability. The MPS 9000 was 
similarly reported to demonstrate good correlation and coefficient of repeatability in a 
study by Van der Veen et al. (Van der Veen et al. 2009) but these results could not be 
replicated in a more recent study by Bartlett et al. which reported a coefficient of 
repeatability ranging from 0.28 to 0.33, and a coefficient of reproducibility of 0.25 to 
0.26 (Bartlett et al. 2010). This substantial discrepancy between results might be 
explained by a significant variation in the experimental protocol adopted in the two 
studies.  
 
In the Van der Veen study, only 11 subjects were included in the repeatability 
assessment, and the MPOD value used in analysis, represented the average of five 
repeated measurements conducted at each visit (Van der Veen et al. 2009). The Bartlett 
study recruited 40 subjects, employed two separate examiners, and used a single 
measurement of MPOD rather than the average value analysed by Van der Veen, 
(Bartlett et al. 2010).  Although, there was no learning or fatigue effect noted, it could 
be argued that these 40 subjects were substantially less ‗trained‘ than the 11 subjects 
who completed the MPOD examination a total of ten times. It could also be argued that 
the ‗averaged‘ data was substantially cleaner, and therefore more robust, than the raw 
single measurement used by Bartlett et al. The experimental protocol employed by 
Bartlett et al. is however, more representative of normal clinical practice, where 
multiple repeat measurements are typically unfeasible, and their results are perhaps, 
therefore, of more clinical importance. It has been suggested that the number of subjects 
in the Bartlett paper with significant variation in test – retest MPOD values, represents 
operator error (inappropriate acceptance of low quality V- shaped functions), rather than 
measurement noise (Murray et al. 2010). This may be the case, but if so, this reinforces 
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the observations herein, that MPOD values obtained using the MPS 9000, may well be 
significantly affected by examiner skill level and training, and furthermore, that the 
limited means to determine patient performance acceptability would seem unreliable at 
best.  
 
The coefficient of repeatability for the MPS 9000 in the current study ranged from 0.18 
to 0.21 respectively. Although these values represent significantly better repeatability 
than that determined by Bartlett et al. they do, nonetheless, still suggest a significant 
amount of expected variability between repeat measures of MPOD (Bartlett et al. 2010).  
 
For the purposes of comparability, the repeatability of the Densitometer was also 
assessed. The coefficient of repeatability for the Densitometer ranged from 0.11 to 0.12, 
which represents significantly better repeatability when compared to the MPS 9000. 
Indeed, the range of MPOD values across all three measures was less than 0.1 for 92%, 
and less than 0.05 for 44% of subjects using the Densitometer, compared to 54% and 
25% respectively, for those using the MPS 9000.  
 
The current study was designed to facilitate the assessment of the comparability and 
repeatability of MPOD measurements, as determined using the commercial MPS 9000 
in relation to the gold standard Densitometer. It is important to note that the 
experimental protocol here was designed to be of clinical relevance. Consistent with 
routine clinical practice, the tests in the current study were conducted as per 
manufacturer guidelines to determine a single measurement of MPOD. The MPS 9000 
underestimates MPOD in relation to the Densitometer and demonstrates poorer 
repeatability. Our analysis would suggest however, that the fundamental principles and 
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technique of the MPS 9000 seem generally robust, but that the increased variability 
observed here and elsewhere, (Bartlett et al. 2010) may largely be as a consequence of 
(a) the absence of a user friendly means to assess subject performance variability during 
the test procedure, (b) the increased difficulty associated with the peripheral task, and 
(c) the requirement of the user to make an instantaneous judgment as to the flicker 
detection endpoint. In the presence of such design features, we would recommend that 
best clinical practice using the MPS 9000 would require multiple measures of MPOD. 
Results should be discarded where large discrepancies such as those obtained by 
Bartlett et al. are found, and where results are more consistent, the average MPOD 
should be used to maximise the accuracy and validity of the MPOD value obtained.  
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CHAPTER EIGHT 
8.1 Discussion  
 The significance of healthy MP levels is becoming more important to eye care 
practitioners for a number of key reasons including; a general trend towards longer life 
spans and aging populations, the increasing prevalence of artificial SW light sources, 
the contemporary prevalence of smog and haze with consequential light scatter, and the 
explosion in the incidence of AMD. All of these factors heighten the importance of the 
preservation and augmentation of MP density, which may in turn lead to improved 
visual performance and health during one‘s lifetime, and possibly lower the risk of 
developing age-related eye diseases, such as AMD in the long-term. Importantly, MP is 
modifiable, and re-pigmentation of the macula can occur in as little as 6 months and 
usually plateaus in 2 years (www.macuscope.ie).  
 
8.2 Macular Pigment and its Role in Clinical Practice 
8.2.1 AMD 
A lot of focus has been placed on the protective role of MP and AMD. It is important to 
note that, although AMD is a late onset disorder, currently undetectable changes occur 
at the retina potentially decades before the condition presents. While signs and 
symptoms of AMD often present at circa 55 years of age, the condition in fact 
represents the end product of a lifetime of cumulative and chronic microscopic retinal 
changes. MP may have a key role to play in minimising the chronic effects of oxidation 
and consequential inflammatory response which lead ultimately to AMD development.   
 
220 
 
Researchers and clinicians have tended to focus primarily on the protective role of MP 
and AMD, as this eye disease is reaching epidemic proportions and is going to become 
a huge economic burden on society as people are living longer (See Figure 8.1).  
 
Figure 8.1 Life expectancy of men and women between 1950 and 2050 
(Department of Health, Ireland).  
 
Optometrists or clinicians need to target or identify patients ‗at risk‘ for AMD and look 
at prevention options. Whilst blue light, oxidative stress and low MP levels are thought 
to contribute to the pathogenesis of AMD, other risk factors, both modifiable and non-
modifiable, established and putative are thought to be involved in the aetiology of 
AMD. Non-modifiable risk factors include age, sex, and family history of AMD. 
Modifiable risk factors include smoking, a diet low in lutein and zeaxanthin, high 
cholesterol, BMI > 27, and raised BP. By being aware of the non-modifiable risk 
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factors, a person who may be ‗at risk‘ can become more proactive about the modifiable 
risk factors.  
 
 
 
Figure 8.2: Genetic and environmental influence on AMD development 
 
A person with a family history of AMD is already at a higher risk of developing AMD. 
Certain environmental stresses such as smoking, excess exposure to sunlight and low 
MPOD levels can increase this risk even further (See Figure 8.2). Early identification of 
those patients most suitable for certain interventions is essential. Appropriate advice, 
including the dietary modification and/or supplementation with MP carotenoids should 
be recommended to a person when their MPOD is low during life, rather than waiting 
for the first visible signs of AMD. 
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8.2.2 Visual performance and comfort 
The primary role of MP, from a Darwinian perspective, may rest on its role in visual 
performance. Augmented MP levels can affect visual performance and visual comfort 
throughout life. Most optometrists however remain blissfully unaware of this important 
function of MP. By increasing or maintaining MP levels, either through diet or 
supplementation, one can enhance a person‘s vision in terms of better acuity and 
reduced glare and/or reduced photophobia. Up until very recently however, optometrists 
were unable to measure MPOD in practice, so the ability to link MP levels with 
symptoms such as glare and photophobia wasn‘t possible (Stringham, 2003; Wenzel, 
2006; Stringham, 2007; 2008). Higher MP levels at a young age will not only lead to 
better visual performance during life, but to a healthier retina where the ―normal‖ and 
consequential signs of aging may be slowed or delayed. The age group that practitioners 
need to target is 20 years and upwards, as blue SW light damage is theoretically 
maximal at this age due to large pupils, clearer crystalline lens and optical media, and 
possible lifestyle choices such as smoking, excessive alcohol and diets which may be 
low in fruits and vegetables. 
 
Many patients present in practice with symptoms such as difficulty with night driving. 
Historically the recommended practice was to offer an anti-reflective coating for 
glasses, where used. The link between glare and visual discomfort and MP has been 
clearly established (Stringham, 2003; 07; 08). If MPOD is low, the patient should be 
offered advice on how to improve the situation either through diet and/or 
supplementation.  
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Photophobia is another symptom many people complain of, and often without any 
obvious supporting clinical indicators.  The threshold for photophobia tends to vary 
quite considerably and as we have seen there can be quite a dramatic variation in MP 
levels between individuals, which could partially explain why some people have 
problems with glare and others do not. Although the current study did not demonstrate a 
baseline correlation between MPOD and either glare or photostress recovery, this 
finding is largely inconsistent with studies employing SW dominated stimulus 
configurations, which are becoming more prevalent in modern society. Although the 
typical office or home environment (where the majority of us seem to spend most of our 
time) does not have many SW dominated light sources, the ever changing nature of 
internal and device lighting systems are extending our exposure to SW light, and may 
enhance the applicable relevance of MP for visual performance. Examples of this 
include the increased use of LED systems and xenon car headlights. The importance of 
healthy MP levels in the context of the growing prevalence of SW light is an issue 
which needs to be emphasised so that optometrists can give appropriate advice to their 
patients. 
 
It is therefore to be recommended that practitioners investigate MP levels where 
problems of glare or photophobia exist, and advise accordingly in an effort to minimise 
such troubling symptoms. 
 
Although MP has the potential to alter colour vision, our research, however, found no 
negative association between MP and colour vision. Supplementation, or dietary 
fortification designed to increase MPOD is unlikely, therefore, to adversely affect hue 
discrimination. 
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8.3 Dietary Intake of Macular Pigment Carotenoids 
Where possible a dietary approach to increasing MP should be considered first, as 
opposed to supplements, particularly those which may contain co-antioxidants, as some 
may be in excess of the RDA for certain vitamins and minerals. Patients need to be 
particularly mindful when also taking additional multivitamins. From a clinical point of 
view it appears that current FFQ‘s, analysed with the databases available, are not 
accurate enough to provide clinically useful feedback on actual intake of lutein and 
zeaxanthin. It is, therefore, simply more beneficial for eye care professionals to educate 
patients about the foods that are rich in lutein and zeaxanthin, and the number of 
portions one would need to take, in order to meet the recommended intake of 6 mg/day 
(See section 3.12.4; Table 3.1; appendix 8.1), and more importantly, to achieve a 
satisfactory increase in MPOD where necessary. From a practitioner‘s point of view, a 
leaflet outlining those foods high in lutein and zeaxanthin, and including information 
regarding the effect of bioavailability, storage, cooking of those foods, as well as the 
role of additional dietary fat intake on carotenoid uptake would be most useful. Such a 
leaflet could be used to educate patients, and could be given to such patients for home 
reference.  
 
8.3.1 Special precautions 
An important point to note in relation to green leafy vegetables and spinach in 
particular, is that many of these vegetables have a very high iron content, which is not a 
problem for most people but could pose a problem for someone with a condition such as 
haemochromotosis. This is a genetic condition which is quite common in Ireland 
resulting in deposition of excess iron in organs. People with this condition should avoid 
foods high in iron, so in this case a supplement would be more appropriate.  
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Additionally, it is important to note that a certain amount of dietary fat is needed to 
absorb these carotenoids. Some people may have a carotenoid-sufficient but fat-
depleted diet and this can impair carotenoid absorption. Medical conditions which lead 
to fat malabsorption such as pancreatic enzyme deficiency, surgical removal of part or 
all of the stomach, gall bladder disease or liver disease can also lead to problems with 
malabsorption. Certain foods and medications can also affect dietary absorption of 
lutein and zeaxanthin, such as dietary fibre,  margarines enriched with plant sterols such 
as ‗benecol‘ and cholesterol lowering medications.  HDL‘s are known to be primary 
carriers of lutein and zeaxanthin (Viroonudomphol, 2003), and hence an individual‘s 
lipoprotein profile may influence the transport and delivery of these carotenoids to the 
retina, with a consequential impact on MP. Therefore anyone on cholesterol lowering 
medication or have high cholesterol should have their MPOD routinely measured in 
clinical practice. Other conditions, such as cystic fibrosis, crohn‘s disease, and coeliac 
disease may cause problems with carotenoid absorption. Particular attention needs to be 
given to MPOD in such cases. 
 
8.4 Lutein, Zeaxanthin and meso-Zeaxanthin Supplementation 
A dietary approach may be impractical, unsuitable or unsuccessful for some people, so 
the use of carotenoid supplements should be considered. Patients who are at ‗high risk‘ 
for AMD, or people complaining of symptoms of glare and photophobia might consider 
adding lutein, zeaxanthin and meso-zeaxanthin to their diet in supplement form. To date 
there has been no known toxic effect with carotenoid supplementation. Macushield, it 
appears, is the only supplement on the market that contains all three carotenoids without 
added co-antioxidants. Other supplements generally contain co-antioxidants, some of 
which are well above the recommended  daily levels and can cause toxic effects if taken 
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to excess. High-dose zinc, for example, can cause gastric irritation or anemia (Johnson 
et al. 2007), vitamin A (as beta carotene) has been associated with an increased risk of 
lung cancer among smokers (Omenn, 1996). Supplements, therefore, should be 
prescribed on an individualised basis. Eye care practitioners should keep abreast of 
currently available supplements and their carotenoid and co-antioxidant content and 
advise accordingly (See Table 8.1 for list of available supplements). Given the enhanced 
antioxidant capacity of meso-Zeaxanthin, we would currently recommend the use of 
Macushield as the preferred supplement, and where necessary, in addition to, a routine 
multivitamin supplement. Sublingual sprays are now available (e.g New focus, Maxi 
focus). They claim to have a much greater benefit than tablets or capsules, as the 
carotenoids are immediately absorbed into the blood stream under the tongue. It can be 
difficult for some people with digestive problems to absorb capsules. These sprays 
would be especially important if a person has a condition such as crohns disease or 
cystic fibrosis. 
 
Table 8.1 Contains a list of some of the commercially available Visual Health 
Supplements  
Supplement Lutein mg Zeaxanthin 
     mg 
Meso- 
zeaxanthin 
Co- antioxidants 
Macushield 10 mg 2 mg 10 mg None 
Vitalux plus 
Omega 3 
2.5 mg 6.25 mg None Vitamins A,C, copper, 
Zinc & DHA,EPA 
I caps  4 mg L & Z 
Recommends 
2 tabs daily 
 None Vitamins A, C E, Zinc, 
copper, magnesium & 
selenium 
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Ocuvite lutein 6mg lutein None None Vitamins C, E, Zinc & 
Copper 
Ocuvite lutein 
complete 
10 mg 2 mg None Vitamins C, E, Zinc, EPA 
& DHA 
 
8.5 Measuring Macular Pigment Density in Practice 
New desktop MP measurement devices now make it possible to measure MPOD 
routinely in clinical practice. MP is modifiable through dietary changes and/or 
supplementation, so accurate, repeatable and non-invasive methods of measuring 
MPOD are becoming increasingly important.  
 
Ideally anyone over 20 yrs of age should have MP measured in practice. If not feasible 
in a busy clinic environment, then particular attention should be given to those with a 
family history of AMD, those complaining of symptoms of glare, night driving 
problems, individuals with high cholesterol and using statins, smokers, people exposed 
to excessive sunlight and anyone who might have a diet low in fruit and vegetables or a 
BMI > 30. 
 
Given the results of the current study, if using the MPS 9000 device, we would 
recommend that several MPOD measurements be taken to establish the baseline and 
subsequent MPOD levels. Because there is good inter-individual agreement of MPOD, 
with mean differences of only 5% for zeaxanthin and 11% for lutein between fellow 
eyes (Handleman, 1991), measuring MPOD on both eyes would be a good way of 
double checking instrument accuracy. Large discrepancies between the two eyes should 
be questioned. A suggested protocol would be to measure MPOD on both eyes and 
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repeat readings, discarding obvious outliers, and taking the average as the value for 
MPOD. Anyone with low MPOD values, particularly if they are in the ‗high risk‘ group 
for AMD, should consider modifying their diet and/or taking a supplement. 
 
8.6 Macular Pigment Protocol for Clinical Practice 
Increased awareness of the dual functional role of MP, coupled with coherent protocols 
when recommending MP carotenoid supplementation in clinical practice, may confer 
long-term visual health benefits, which may translate as improved visual performance 
and comfort during life, and also as a reduced risk of developing AMD in later years. 
Targeting people at a young age will not only reap beneficial visual effects during life 
but may also lead to a healthier lifestyle as MPOD is a biomarker for long-term nutrient 
status. If MPOD is routinely measured in practice, low MP levels can be addressed a lot 
earlier. Supplementation should not necessarily be the first port of call, but a holistic 
approach needs to be taken such as improve diet (include fruit and vegetables), reduce 
BMI, reduce cholesterol, if exposed to excessive sunlight exposure ensure the proper 
sunglass protection is worn. 
 
Anecdotally, current practice with regard to MP supplementation or dietary fortification 
appears highly unstructured, somewhat flippant, and most likely, therefore, not 
achieving maximal impact in terms of the reinforcement of the importance of the 
pigment for optimal and maintained visual health. A structured practice framework 
would seem logical to somewhat standardise the quality and appropriateness of MP 
related interventions. Such a structure might include: 
 
 A detailed case history can be used to determine the presence of symptoms that 
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might be attributable to MPOD deficiency, the presence of factors affecting 
absorption/ transport of lutein/zeaxanthin, the presence of any medical conditions 
such as crohns, cystic fibrosis, coeliac disease or any other malabsorption problems 
that might impact MPOD, and further, to identify patients at increased risk of 
AMD. 
 Repeat MPOD measurements should be incorporated into the normal eye 
examination routine for all patients, but in particular, for those ―risk‖, ―carotenoid 
compromised‖, or ―symptomatic‖ patients identified in the case history. 
  Where appropriate, dietary fortification or supplementation should be advised. It is 
important to note that there is no simple means to determine ―normal‖ MPOD 
levels. These may very much be individualised. Therefore, there should not be a 
specific and universal target optical density as such. The simplest, and probably 
most efficient protocol, should include the augmentation of MPOD where 
desirable, until a plateau level is reached which is most likely optimal for that 
individual. 
 Additional advice, regarding exposure to SW light, and additional risk factors for 
AMD, should be given to patients as appropriate. 
 Where dietary fortification and/or supplementation have been recommended, the 
patient should be provided with an information leaflet such as that outlined in 
section 8.3 above. Where supplementation is recommended, the patient should be 
informed of the unknown possibility of adverse effects and interactions with 
multivitamin supplements, in particular when co-antioxidants are included in the 
MP carotenoid formulation. 
 MPOD measurements should be re-assessed at routine, perhaps 6 monthly 
intervals. Such measurements will inform a review of the dietary or 
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supplementation requirements, and allow consideration for change of 
recommendation (e.g. change from diet to supplement based augmentation), or 
dose adjustment.  
 
8.7 Future Research 
At present, there are no definitively established, physiologically significant cut-off 
points for lutein, zeaxanthin or meso-zeaxanthin in serum or MPOD, above which 
protection or prevention against chronic diseases or enhancement  of vision is ensured. 
Reading & Weale (1974) suggested that an MPOD greater than 0.3 is superfluous to 
visual performance. Future studies should aim to determine optimal MPOD levels for 
maximal visual performance and for optimal visual health, and whether such levels are 
highly specific to the individual, or whether generalisations can be made about a 
population optimum level. 
 
Further work is also required to determine both the optimum dosage of the three 
constituent carotenoids, and any associated co-antioxidants, and the optimum duration 
of supplementation, which can be costly to the patient who may not ―see‖ a significant 
benefit for their expenditure. The question still remains as to whether supplementation 
needs to be continuous, or can be cycled using the assumption that once MPOD reaches 
a plateau, retinal turnover will be slow, and plateau levels will be sustained over a 
certain level of time. It may also be possible to simply reduce the dose, for example, 
taking a supplement every second day, once this plateau is reached. This question can 
certainly be easily answered on an individual basis through repeat MPOD measures 
over time in response to changes in supplementation protocol. 
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Additionally, there are newly emerging technologies available to practitioners for the 
measurement of MPOD. The Zeiss Visucam R200, for example, is a fundus camera 
with the additional capacity to measure MPOD using reflectance technology. The 
Wooten Clinical Densitometer is a new clinical version of the research gold standard. It 
would be highly desirable to initiate further research that will clarify if such instruments 
can accurately measure MPOD and changes in MPOD in response to supplementation. 
Furthermore, it would seem important to clarify whether measurements made using 
different techniques or devices, are in any way interchangeable. 
 
Finally, diabetes is another condition that is on the increase and it can affect the eyes. 
Diabetes is linked to oxidative stress and as MP is a powerful antioxidant, future studies 
could examine the relationship, if any; between MPOD and diabetes as a condition that 
causes macular damage. 
 
8.8 Conclusion 
There is now a growing body of evidence to support the value of high MPOD levels for 
both visual performance and visual health. Armed with such evidence, and the newly 
emerging MPOD measurement technology, optometrists, and primary eye care 
practitioners, are now keenly placed to drive a preventive health agenda that will have 
individual and societal relevance in an era where changing population demographics 
and lifestyle are causing a significant elevation in the burden of age-related disease. It 
has been shown here, and elsewhere, that MP can influence vision and visual health, 
and can reduce the burden of ocular disease. Technologies now exist to allow eye care 
practitioners to fully implement MP interventions in clinical practice, and to monitor 
their effects. Together with a structured protocol for MP assessment in clinical practice 
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as has been outlined here, it is now possible to define and decide the future of primary 
eye care practice that affords significantly increased focus and clinical assessment in 
relation to MP.     
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Appendix A 
 
 
Visual Health Supplement Formulations, Dosages, and Comparison with Recommended 
Intake Levels 
 
 
 
 
 
 
 
 
 
1:   No of tables needed to attain the values listed in the table  
2:  Equal to 700ug Vitamin A (retinol equivalents) McCance and Widdowson's 2004) 
3:  RDA for females only. RDA for males = 900ug/d 
4:  RDA for adult females. RDA for males = 9.5mg/d 
5:  DRI: Daily recommended intake. No RDA set in Irelan
No
5
 Vit. A 
%RDA 
2 
Vit.C %RDA Vit.E %DRI
4
 Zinc %RDA Cu %RDA Se %RDA L/Z 
  (IU) 2334 
1
 (mg) 60mg (IU) 10.05 (mg) 7 (mg) 1.1 (g) 40g (mg) 
1 28640 1227 452 271% 400 3980 69.6 994% 1.6 145% -   6 
4 28640 1227 452 271% 400 3980 69.6 994% 1.6 145% -   - 
1 1000 43 300 180% 100 995 40 571% 2 181% 55 137% 2 
2 -   120 200% 27 269 10 143%     40 100% 13 
1 5000 214 60 100% 45 448 15 214% 2 181% 20 50% 0.25 
2 20000 857 750 450% 200 1990 12.5 179% -   50 125% 10 
2 14320 614 226 377% 200 1990 34.8 497% 0.8 72% 4 10% - 
2 14320 614 226 377% 200 1990 34.8 497% 0.8 72% -   - 
Appendix B 
 
Estimated dietary requirement range 
 
(Current L and Z intake (mg/day)   x   (0.35g/ml )    to      ( Current L and Z intake (mg/day)   
x   (0.6g/ml) 2       
         Blood serum L and Z concentration (g/ml)                     Blood Serum L and Z 
concentration (g/ml) 
                             
 
1Based on optimal serum L/Z concentration (Granado et al., 2003) 
2Equation is based on dietary and blood serum L and Z concentrations in an Irish sample (Nolan et al., 
2007) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix C 
 
Food Source Lutein and 
Zeaxanthin 
Lutein Zeaxanthin 
Egg yolk 89 54 35 
Sweetcorn 86 60 25 
Kiwi 54 54 0 
Red grapes (seedless) 53 43 10 
Zucchini squash 52 47 5 
Pumpkin 49 0 0 
Spinach 47 47 0 
Orange pepper 45 8 37 
Yellow  squash 44 44 0 
Cucumber 42 38 4 
Pea 41 41 0 
Green pepper 39 36 3 
Red grape 37 33 4 
Butternut squash 37 37 0 
Orange juice 35 15 20 
Honeydew 35 17 18 
Celery (stalks, leaves) 34 32 2 
Green grapes 31 25 7 
Brussels sprouts 29 27 2 
Spring onions 29 27 3 
Green beans 25 22 3 
Orange 22 7 15 
Broccoli 22 22 0 
Apple (red delicious) 20 19 1 
Mango 18 2 16 
Green lettuce 15 15 0 
Tomato juice 13 11 2 
Peach 13 5 8 
Yellow pepper 12 12 0 
Nectarine 11 6 6 
Red pepper 7 7 0 
Tomato (fruit) 6 6 0 
Carrots 2 2 0 
Cantaloupe 1 1 0 
Dried apricots 1 1 0 
 
Lutein & Zeaxanthin = Macular Pigment (MP) 
 
Dietary Sources of Macular Carotenoids (mol %) 
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Appendix E
 
 
Appendix F 
Investigation of the Relationship between Dietary Antioxidants  
-and Eye Health Patient Information Sheet: 
 
Background 
There is increasing evidence that higher intakes of antioxidants could protect against oxidative and light damage in 
the eye.  Research has shown that a low dietary intake of two antioxidants in particular, Lutein and Zeaxanthin, is 
associated with an increased risk of a chronic eye disease, Age Related Macular Degeneration.  They are present in 
large quantities in the retina of the eye and are collectively referred to as ‘macular pigment’. Without macular 
pigment or a low lensity macular pigment your eye is more susceptible to damage. 
 
Invitation to Participate 
You are invited to participate in a research study designed to measure your macular pigment level and complete two 
dietary questionnaires. This will allow us to identify any relationship(s), which may exist between macular pigment 
and dietary intake of antioxidants. 
 
 Each volunteer will be asked to attend the Dublin Institute of Technology in Kevin St  for a once off visit of 
approximately one hour. 
 
The following will take place during your your visit: 
  
 You will be asked to sign an informed consent document which states that you are happy to participate in 
the study and that all aspects of the study have been explained to you by the study investigator. 
 You will be asked to complete a brief questionnaire to gather information about your diet and other 
demographic details. This questionnaire covers the following areas: contact details; lifestyle details; 
personal medical history; weight and height.. 
 A blood sample will be taken to measure macular pigment levels in your blood. 
 
 We will measure your macular pigment using a specialised vision testing technique.  
 
         
You will be asked to fill in two dietary questionnaire’s which are an important  
 measure of eye health. 
 Subject Payment 
This study is entirely voluntary. You will not be paid for your participation in this study.  If you decide to take part 
you are still free to withdraw at any time and without giving a reason.  This will not affect the standard of care you 
receive.   
 
Risks and/or Discomforts 
We foresee no risks to the subjects participating in this research.   
 
Benefits  
You will gain knowledge of your macular pigment level.  It has been suggested that a person’s macular pigment 
level is a good indicator of overall eye health.  You will also be informed of the quality of your diet.  
 
Difference of Research Study to Clinical Practice 
Your involvement in this study is for research purposes only.  This is not a medical examination for your benefit.  
 
Data Confidentially  
All the data collected in this study will be treated as strictly confidential and will be obtained and processed in 
keeping with the Data Protection Act 1988 and the amended Data Protection Act of 2003.   All data will be analysed 
collectively as a group and coded by data link to ensure subjects confidentiality. 
Compensation 
The study investigators are covered by an insurance, which protects you in case of problems caused by this study.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix G 
 
Comparison of 2 Heterochromatic Flicker Photometers and Evaluation of SightRisk Questionnaire as a 
Clinical Tool 
 
 
Subject Number:  __________ 
 
 
 
                                       Patient Information Sheet: 
Background 
Age Related Macular Degeneration (AMD) is a progressive disease of the retina in which the light-sensing cells 
in the central area of vision (the macula) stop working and eventually die. There is increasing evidence that 
higher concentrations of macular pigment in the eye protect against oxidative damage, which is the suspected cause 
of AMD. Research has show that this pigment is only available to the body via dietary intake. The macular pigment 
accumulates in the retina and acts as an anti oxidant. Low antioxidant levels, in particular Lutein and Zeaxanthin are 
associated with increased risk of developing AMD.  
Measuring the macular pigment density in the eye should eventually provide a more complete understanding of its 
functional role in the retina and the relationship between macular pigment levels and the development of AMD. A 
psychophysical method using heterochromatic flicker photometry (HFP) is one of the few non-invasive methods 
available to measure this pigment in the eye.  
 
Invitation to Participate 
You are invited to participate in a research study designed to measure your macular pigment level and complete a 
dietary questionnaire. This will allow us to identify any relationship(s), which may exist between macular pigment 
and dietary intake of antioxidants. 
Each volunteer will be asked to attend the Dublin Institute of Technology in Kevin St for a once off visit of 
approximately one hour.The following will take place during your visit: 
  
 You will be asked to sign an informed consent document which states that you are happy to participate in 
the study and that all aspects of the study have been explained to you by the study investigator. 
 You will be asked to complete a brief questionnaire. This covers the following areas: contact details; 
lifestyle details; personal medical history; weight and height. 
 We will measure your macular pigment using 2 instruments. 
a) The Macular Metrics Densitometer TM and 
b) The MPod (Tinsley Instruments)  
We will also measure your best-aided visual acuity (BVA) and correlate this value with macular pigment optical 
density (MPOD). 
Subject Payment 
This study is entirely voluntary. You will not be paid for your participation in this study.  If you decide to take part 
you are still free to withdraw at any time and without giving a reason.  This will not affect the standard of care you 
receive.   
 
Risks and/or Discomforts 
We foresee no risks to the subjects participating in this research.   
Benefits  
You will gain knowledge of your macular pigment level.  It has been suggested that a person’s macular pigment 
level is a good indicator of overall eye health.  You will also be informed of the quality of your diet.  
 
Difference of Research Study to Clinical Practice 
Your involvement in this study is for research purposes only.  This is not a medical examination for your benefit.  
 
Data Confidentially  
All the data collected in this study will be treated as strictly confidential and will be obtained and processed in 
keeping with the Data Protection Act 1988 and the amended Data Protection Act of 2003.   All data will be analysed 
collectively as a group and coded by data link to ensure subjects confidentiality. 
 
Compensation 
The study investigators are covered by an insurance, which protects you in case of problems caused by this study.   
 
Consent Form 
 
 
Date:           
 
 
1. I confirm I have read and understand the Information Leaflet regarding this study.  I further attest that the 
relevant information has been discussed fully in non-technical terms, and all my questions have been 
replied to with full satisfaction. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, without my 
medical care or legal rights being affected. 
 
3. I understand that my data concerning this study will be entered on a computer in order to be analysed 
together with the data obtained from other patients.  My identity will always be protected. 
 
4. I agree to take part in the above study and hereby give my consent to have any necessary measurements 
taken and my data analysed. 
 
 
              
      Name of Volunteer   Date    Signature of Volunteer 
 
 
           
Name of Witness    Date    Signature of Witness 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix H 
Subject number:     Subject Initials:________  Date:___________ 
                    
(DD/MM/YYYY) 
 
 
PHASE I 
 
COMPASS 
 
Collaborative Optical Macular Pigment 
Assessment Study 
 
 
 
 
 
 
 
 
 
 
CRF 
Case Report Form 
 
 
 
Investigator Parties: 
1. Macular Pigment Research Group  
Waterford Institute of Technology 
 
2. Optometry Department 
Dublin Institute of Technology 
 
3. Bausch & Lomb 
 
 
 
   
Appendix H 
 
 
 
Study procedures (Phase 1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DESCRIPTION EST. TIME MINS 
A.  Information leaflet discussion and informed consent 5 mins 
B.  Collection of blood for serum carotenoid analysis 5 mins 
C.  Demographic, medical history, lifestyle and vision case history questionnaires 20 mins 
D.  Visual acuity, high and low contrast visual acuity, and refraction 15 mins 
E.  Colour vision tests: colour anomoloscope; 100 hue test 20 mins 
F.  Glare tests (Optec + BAT) 10 mins 
G. Visual performance questionnaire 10 mins 
H.  Contrast sensitivity (Metropsis) 15 mins 
BREAK ~30 mins 
I.   Macular pigment optical density spatial profile measurement 35 mins 
J.  Dietary questionnaire 30 mins 
K.  Photostress recovery test  10 mins 
L.  Short wavelength perimetry 15 mins 
M. Fundus and iris photographs 5 mins 
 
 
A. Informed consent  
 
Was the patient given a copy of his/her consent?       yes        no 
 
If yes, 
Date of informed consent:      Obtained by:      
                                                (DD/MM/YYYY) 
                                    
 
Signature of person obtaining consent:      
 
 
 
 
 
 
 
 
B. Blood extraction record sheet 
 
Was a blood sample taken from the subject (2 x 5 mL yellow top vacuette)?  
           yes        no      
 
If yes, 
Time of blood extraction: _____________    
 
Time of subject’s last meal: _____________ 
 
Was this sample centrifuged, the serum extracted and stored in duplicate at -70
o
C?     
           yes          no 
    
If yes, 
Time of centrifugation: __________ 
 
Name of person obtaining blood: ____________ 
 
Signature of person obtaining blood: ____________ 
 
 
 
 
 
 
 
 
C. Demographic, medical history, lifestyle and vision case history questionnaires 
 
 
Forename:         Surname:      
    
 
Address:       
      
      
 
Contact No(s):           
 
Email:        
 
 
Date of birth:                 Age:     (years) 
 
                                          (DD/MM/YYYY)        
 
 
 
Please circle number corresponding to correct answer.  All questions must be answered unless 
otherwise specified. 
 
1. Sex  
 
 Male …………………………………. 1 
 
 Female ………………………………. 2  
 
 
If female, stage of Menopause (please circle):  
 
 Pre …………………………………. 1 
 
 During ……………………………...    2 
 
        Post ………………………………… 3  
                                                                                                      
 
2. Race   
    
         White ………………………………. 1     
Black ………………………………. 2   
Asian ……………………………….  3   
Spanish or Hispanic ..................... 4 
Mixed race………………………… 5  
 
3. Marital status 
Are you now: 
         Married (or cohabiting)…………… 1     
 Widowed ………………………….. 2   
Single ……………………………...  3   
Divorced or separated................. 4  
 
4. Education 
Briefly describe your educational background: 
____________________________________________________________________________________
______________________________________________________________________ 
 
5. Occupation 
Briefly describe your occupation: 
____________________________________________________________________________________
______________________________________________________________________                     
6. Smoking 
a) Which best describes your smoking habits (whether cigarette, cigar, pipe etc.)?  
 Never smoker (smoked < 100 cigs in lifetime)…………………………………... 1 
 Ex-smoker (smoked ≥ 100 cigs in lifetime and none in past year).……………. 2 
 Current smoker (smoked ≥ 100 cigs in lifetime and at least 1 cig in last year).. 3 
 
b) Have you smoked at least 100 cigarettes in your life?  yes       no         If no skip to question 6.1 
 
 
c) How long has it been since you last smoked? 
  
Less than 1 day    
 Less than 7 days 
 Less than 1 month 
 Less than 3 months 
 Less than 6 months 
 6 months to a year 
Greater than 1 year 
 
 
d) What is the average number of cigarettes you smoke (or smoked) on a daily basis?    
 
e) For how many years have you smoked (or did you smoke)?    
 
6.1 Are you commonly exposed to second-hand smoke at home or in the work place? yes        no         
 
7. Alcohol 
a) Regarding alcohol, which of the following statements best describes the way you drink? 
 I never drink………………………………………………..   1 
 I drink only on special occasions………………………...  2 
 I drink once or twice a month……………………………..  3 
 I drink once or twice a week………………………………  4 
 I drink every day……………………………………………  5 
 I drink twice a day or more………………………………..  6 
 
b) What is your average alcohol consumption on a weekly basis?   
 1 unit a week………………………………………………  1 
2-5 units a week…………………………………………..  2 
 6-10 units a week…………………………………………  3 
 > 10 units a week…………………………………………  4 
 
8. Medical History 
Have you any of the following medical conditions?  Yes No 
 Diabetes……………………………………….  1   2 
 High blood pressure…………………………. 1   2 
 High cholesterol……………………………… 1   2 
 Angina……………………………………….... 1   2 
 Stroke………………………………………….  1    2 
 
If yes for any of the above please give details in the space provided below (e.g. year it occurred, 
treatment, medication etc.) 
____________________________________________________________________________________
_____________________________________________ 
 
 
 
9.  History of Eye Disease 
      Yes No 
Have you ever been told by a doctor that you have Cataract?       1   2 
Have you had an operation for Cataract? 1   2 
Have you ever been told by a doctor that you have Macular Degeneration? 1   2 
Have you ever been told by a doctor that you have Glaucoma? 1   2 
Other?             1   2 
 If yes for any of the above please give details in the space provided below (e.g. year it was diagnosed, 
doctor etc.) 
    
    
   
 Yes      No  
Have you a family history of any of the above eye diseases?  1 2 
(e.g. age-related macular degeneration, glaucoma etc.)    
 
If a family member, what is their relation to you, and what eye disease do/did they have? 
_____________________________________________________________________________ 
 
10.  Exercise 
Do you perform any of the following physical activities?  Yes      No 
 Walking………………………………………..    1     2 
 Running……………………………………….   1     2 
 Cycling………………………………………..   1     2 
 Swimming…………………………………….   1     2 
 Gym-based work-outs..……………………..    1     2 
 Team sport……………………………………   1     2 
 Other………………………………………….   1     2  
  
If “Team sport” or “Other”, please describe in the space provided  
_____________________________________________________________________________ 
 
How many times a week do you carry out the above exercise?                     time(s)/week 
 
If you exercise, how long would each session usually last?                     minutes 
 
11.  Body Mass Index (BMI) 
Please record the subject’s weight and height in the spaces provided  
Weight…………………………………….                     Kg 
 
Height……………………………………..                      M 
  
BMI………………………………………..                       Kg/M
2
 
  
12.  Blood pressure  
Please record the subject’s blood pressure level in the space provided                   mmHg 
 
 
13.  Vision case history  
 
Approximately how long since your last eye examination?                      
  
 
Do you currently wear spectacles and/or contact lenses?  Yes      No 
 1        2 
If yes – for what? _________________________________________________ 
 
since when? ______________________________________________ 
 
any problems with? _______________________________________ 
 
 
 
Have you ever undergone any ocular treatment or surgery (including Laser eye surgery)?    
        Yes      No 
 1        2 
If yes – for what? _______________________________________________ 
 
when? _________________________________________________ 
 
any complications? _____________________________________ 
 
 
 
 
Were you required to wear an eye patch as a child?   Yes      No 
 1        2 
If yes, at what age?    
 
or how long?    
 
which eye?    
 
 
 
Do you have any current problems with your vision?   Yes      No 
       1        2 
If yes, please describe in the space provided  
 
  
_____________________________________________________________________________ 
 Do you use a computer?     Yes      No 
1    2 
 
If yes, 
Do you ever suffer eyestrain associated with using the visual display unit (VDU)?   Yes      No 
     1          2 
 
      
If yes, 
Is your VDU task difficult (e.g. lots of glare from windows, very small print, use of coloured 
print/backgrounds, lack of regular breaks from VDU etc)?              Yes      No 
1      2 
 
 
 
Do you ever suffer headaches?     Yes      No 
1         2 
 
If yes, please give details on the following: frequency, onset, location, duration, associated factors, 
relieving factors, medical history etc. 
_____________________________________________________________________________ 
 
Additional Information (please add any other details, if appropriate) 
 
____________________________________________________________________________________
______________________________________________________________________ 
 
  
D. High contrast visual acuity and refractive error 
 
1: High Contrast (HC) Visual Acuity (LogMAR) 
Please record the subject’s unaided VA and aided VA (own spectacles/contact lenses if appropriate) in 
the spaces provided: 
 
Current Rx Focimetry         
 
Unaided VA………………………………… R                                 L 
 
Habitual VA (own spx)…………………...  R              L 
 
 
 
2: Refractive Error 
Please record the subject’s refractive error for both eyes: 
 
R  ______________________  Best Corrected HC VA                                                          
L ______________________   Best Corrected HC VA                        
 
 
3:  Ocular Dominance 
Please record which eye is dominant: 
 
R                                       L        Equidominant            
 
 
4: Study Eye 
Please indicate which eye will be used for the current study (eye with best corrected HC VA) 
 
Note: The study eye is the eye with best corrected visual acuity.  If corrected visual acuity is the same in 
both eyes the dominant eye is thereafter used as the study eye. 
 
R                                      L 
 
 
  
 
 
 
 
 
 
E. Colour Vision  
 
 
FM 100 Hue Test results 
 
 
Colour Type  
 
Normal             Protan  Deutan  Tritan  Total Error Score 
 
    
 
 
Colour Discrimination Rank  
 
Low   Average       Superior 
 
 
 
Error score (with correction for minimum possible score) for each colour quadrant 
 
 
Quadrant 1 
 
 
Quadrant 2 
 
 
Quadrant 3 
 
 
Quadrant 4 
 
 
 
 
 
 
 
Note: Insert polar co-ordinate error chart. 
 
 
 
 
Oculus HMC Anomaloscope Results 
 
 
Moreland Mix 
 
 
Range     Mid-point       AQmin     AQmax 
 
 
 
 
 
 
Note: Insert Graph here 
 
 
 
  
 
F.   Glare / Photosensitivity 
 
 
Functional Acuity Contrast Test (FACT) 
 
Total Correct Patches 
 
 
Night Time No Glare  
 
 
Night With Glare 
 
 
Day Without Glare 
 
 
Day With Glare 
 
 
Attach Graph 
 
 
 
Brightness Acuity Test  
 
            Contrast Sensitivity 
 
Aided VA 
 
 
Low Glare VA (12 ft lamberts) 
 
 
Medium Glare VA (100 ft lamberts) 
 
 
High Glare VA (400 ft lamberts) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Optec 6500 Vision Tester 
 
 
G. Visual performance questionnaire 
 
All of the following questions assume you are using your best corrected vision (with glasses or contact lenses if 
necessary). 
 
Please circle the number which corresponds with the correct answer.  All questions must be answered. 
 
Colour Discrimination 
 
 
1: I have difficulty distinguishing between colours: 
 
         Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
 
2: I tend to confuse colours: 
 
     Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
 
3: The colour names that I use disagree with those that other people use: 
 
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
 
 
 
 
Quantitative Analysis 
 
In comparison to my friends/family, I would rate the quality of my colour vision as: 
 
 Significantly better than others ……………….. 5 
 Marginally better than others    ……………….. 4     
Equivalent to others                 ………………...  3   
         Marginally worse than others    ……………….. 2 
         Significantly worse than others ………………..        1 
 
 
How would you rate the overall quality of your colour vision, on a scale where zero equates to no colour 
perception and ten equates to best possible colour perception? 
     
 
Ten (best) …………………………….. 10  
Nine………………………………….… 9   
Eight ………………………………..… 8  
Seven…………………………………. 7     
Six…………………………………..… 6   
Five …………………………………...  5 
Four……………………………….….. 4  
Three……………………………….… 3   
Two ……………………………….…. 2 
One…………………………………… 1  
Zero (worst)………………………….. 0   
 
Glare Disability 
 
All of the following questions assume you are using your best corrected vision (with glasses or contact lenses if 
necessary). 
 
 
4: I have problems with lights around me causing glare when I’m trying to see something: 
  
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
 
5: I have trouble driving when there are headlights from oncoming cars in my field of view: 
 
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
 
6: My eyes are sensitive to bright sunny conditions: 
 
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
 
7: When driving at night in the rain, I have difficulty seeing the road because of headlights from oncoming 
cars: 
 
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
 
8: During the course of an eye examination I find the lights used to be excessively bright: 
 
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
 
 
9: My eyes become tired or sensitive when working under artificial light conditions: 
 
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
 
10: I need to adjust the brightness intensity of my computer screen to a low setting for comfortable use: 
 
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
 
Quantitative Analysis 
 
In comparison to my friends/family, I would rate my tolerance to glare as: 
 
 Significantly better than others ……………….. 5 
 Marginally better than others    ……………….. 4     
Equivalent to others                 ………………   3   
         Marginally worse than others    ………………           2 
         Significantly worse than others ………………..        1 
 
 
 
 
 
 
 
 
 
 
 
How would you rate the overall quality of your tolerance to glare, on a scale where zero equates to a 
complete inability to cope with glare and ten equates to absolutely no difficulty?  
    
Ten (best) …………………………….. 10  
Nine………………………………….… 9   
Eight ………………………………..… 8  
Seven…………………………………. 7     
Six…………………………………..… 6   
Five …………………………………...  5 
Four……………………………….….. 4  
Three……………………………….… 3   
Two ……………………………….…. 2 
One…………………………………… 1  
 Zero (worst)………………………….. 0  
 
 
 
Acuity / Spatial Vision 
 
All of the following questions assume you are using your best corrected vision (with glasses or contact lenses if 
necessary). 
 
11: I have problems reading small print (for example, labels on medicine bottles, phone books, glossy 
colour magazines, buy and sell magazine etc): 
 
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
12: I have trouble reading the menu in a dimly lit restaurant: 
 
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
13: I have difficulty recognising people from long distance: 
 
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
14: I find it difficult to recognise the bus number until the bus gets close: 
  
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
 
 15: I have difficulty reading teletext /small print (such as match scores/time elapsed) on TV: 
  
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
 
16: When driving, I struggle to read distant registration plates or signposts: 
  
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
 
 
17: I have difficulty performing fine handwork, such as threading a needle: 
  
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
 
18: I have problems carrying out activities that require a lot of visual concentration and attention: 
 
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
 
Quantitative Analysis 
 
In comparison to my friends/family, I would rate my ability to see fine detail as:  
 
 
 Significantly better than others ……………….. 5 
 Marginally better than others    ……………….. 4     
Equivalent to others                 ……………...…  3   
         Marginally worse than others    ……….…….….       2 
         Significantly worse than others …………….…..       1 
 
 
 
 
 
 
 
 
 
 
 
 
How would you rate the overall quality of your ability to see fine detail, on a scale where zero equates to a 
complete inability to perform fine tasks and ten equates to no difficulty with any type of visual task?  
 
Ten (best) …………………………….. 10  
Nine………………………………….… 9   
Eight ………………………………..… 8  
Seven…………………………………. 7     
Six…………………………………..… 6   
Five …………………………………...  5 
Four……………………………….….. 4  
Three……………………………….… 3   
Two ……………………………….…. 2 
One…………………………………… 1  
 Zero (worst)………………………….. 0  
 
 
 Light / Dark Adaptation 
 
All of the following questions assume you are using your best corrected vision (with glasses or contact lenses if 
necessary). 
 
 
19: I have problems adjusting to bright room lighting, after room lighting has been rather dim: 
 
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
20: It takes me a long time to adjust to darkness after being in bright light: 
  
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
 
21: It takes me a long time to adjust to bright sunshine after I have been inside a building for a lengthy 
period of time: 
 
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
  N/A............................................... 0 
 
 
  
22: I have trouble adjusting from bright to dim lighting, such as when going from daylight into a cinema: 
 
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
 
23: I have trouble driving at twilight / dusk:  
 
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
Quantitative Analysis 
 
In comparison to my friends/family, I would rate my capacity to cope with changes in illumination as: 
 Significantly better than others ……………….. 5 
 Marginally better than others    ……………….. 4     
Equivalent to others                 ……………...…  3   
         Marginally worse than others    …………..……        2 
         Significantly worse than others ………………..        1 
 
How would you rate the overall quality of your ability to continue to see effectively, despite changes in 
illumination, on a scale where zero equates to a complete inability to continue to function visually and ten 
equates to no difficulty continuing with any type of visual task?  
 
Ten (best) …………………………….. 10  
Nine………………………………….… 9   
Eight ………………………………..… 8  
Seven…………………………………. 7     
Six…………………………………..… 6   
Five …………………………………...  5 
Four……………………………….….. 4  
Three……………………………….… 3   
Two ……………………………….…. 2 
One…………………………………… 1  
         Zero (worst)…………………………..              0 
 
 
Daily Visual Tasks 
 
All of the following questions assume you are using your best corrected vision (with glasses or contact lenses if 
necessary). 
 
24: I have trouble finding a specific item on a crowded supermarket shelf: 
 
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
25: I have difficulty noticing when the car in front of me is speeding up or slowing down: 
 
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
26: I misjudge the position of steps / curbs when walking: 
 
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
27: I have problems locating something when it’s surrounded by a lot of other things (e.g. car keys on 
your desk): 
 
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
 
28: I have problems carrying out activities that require a lot of visual concentration and attention: 
 
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
 
 
29: I have trouble noticing things in my peripheral vision: 
 
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
 
 
30: I have difficulty driving on poorly lit back-roads: 
 
 Never………………………………. 5     
Rarely……………………………… 4   
Sometimes…………………………  3   
Often............................................. 2  
          Always.......................................... 1 
 N/A............................................... 0 
 
 
Quantitative Analysis 
 
In comparison to my friends/family, I would rate my visual performance for daily visual tasks as: 
 
 Significantly better than others ……………….. 5 
 Marginally better than others    ……………….. 4     
Equivalent to others                 ………….….…  3   
         Marginally worse than others    ………….….…        2 
         Significantly worse than others ………………..        1 
 
 
How would you rate your satisfaction with the overall quality of your vision in general, on a scale where 
zero equates to complete dissatisfaction and ten equates to complete satisfaction with every aspect of 
your vision?  
     
Ten (best) …………………………….. 10  
Nine………………………………….… 9   
Eight ………………………………..… 8  
Seven…………………………………. 7     
Six…………………………………..… 6   
Five …………………………………...  5 
Four……………………………….….. 4  
Three……………………………….… 3   
Two ……………………………….…. 2 
One…………………………………… 1  
         Zero (worst)…………………………..              0 
 
 
 
 
Scoring the VFNQ-30 
 
The purpose of the VFNQ-30 is to generate a composite score for each visual function area, which 
summarises the subject’s responses to the items addressing that visual function. To score an individual 
item, the following scale is used: 
 
Never = 5, Rarely = 4, Sometimes = 3, Often = 2, Always = 1 
 
If any questions are irrelevant to an individual, they are marked N/A and scored as “0”. 
 
(a)  The mean composite score for each functional section should be multiplied by 20, to give a numerical 
index of functional capacity scored out of 100 (where 100 = perfect visual function). 
 
(b)  The Quantitative (comparative) analysis section should be scored separately from the functional 
sections and be used to produce an additional index of performance using the same multiplier as above. 
 
(c)  The “Subject Satisfaction” question should be scored out of 100 also by multiplying the chosen 
number by 10 for each functional section. 
 
 
Subject Score 
 
Colour Discrimination 
 
(a) Functional Analysis          / 100      
 
(b) Quantitative/Comparative Analysis           / 100      
 
(c) Subject Satisfaction Score            / 100      
 
Glare Disability 
 
(a) Functional Analysis          / 100      
 
(b) Quantitative/Comparative Analysis           / 100  
 
(c) Subject Satisfaction Score             / 100      
 
Acuity / Spatial Vision 
 
(a) Functional Analysis          / 100      
 
(b) Quantitative/Comparative Analysis           / 100  
 
(c) Subject Satisfaction Score             / 100 
 
Light / Dark Adaptation 
 
(a) Functional Analysis          / 100      
 
(b) Quantitative/Comparative Analysis           / 100  
 
(c) Subject Satisfaction Score             / 100 
 
Daily Visual Tasks 
 
(a) Functional Analysis          / 100      
 
(b) Quantitative/Comparative Analysis           / 100  
 
(c) Subject Satisfaction Score             / 100 
 
 
H. Contrast Sensitivity Function 
 
 
Photopic CSF 
 
Attach Contrast Sensitivity versus Spatial Frequency (CSF) Plot Below 
 
 
Attach Data Sheet with minimum contrasts defined for all spatial frequencies 
 
 
 
 
 
 
 
 
 
Mesopic CSF 
 
Attach Contrast Sensitivity versus Spatial Frequency (CSF) Plot Below 
 
 
Attach Data Sheet with minimum contrasts defined for all spatial frequencies 
 
 
 
 
 
 
 
 
 
 
 
  
 
I. Macular Pigment Optical Density Spatial Profile 
 
Record the Critical Flicker Frequency (CFF) values and calculate the Optimal Flicker Frequency (OFF) 
values as per COMPASS densitometer SOP 
 
CFF obtained approaching from lower frequency (10 Hz) 
 
 
 
 
 
 
   
 
          Average:    
 
 
Use below calculation to calculate the OFF and report below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Location 
 
Calculation 
 
Predicted OFF 
 
0.25
0
 
 
 
CFF-8 
 
 
0.5
0
 
 
 
CFF-7 
 
 
1
0
 
 
 
CFF-7 
 
 
1.75
0
 
 
 
CFF-7 
 
 
3
0
 
 
 
CFF-9 
 
 
 
7
0
 
 
 
CFF-14 
 
 Predicted 
CFF  
 
Radiance 
 
 
 
   
 
  0.25 deg  
    
         
Predicted CFF            
Actual CFF        MPOD =   
             
   0.5 deg         
           
Predicted CFF           
Actual CFF        MPOD =   
             
   1 deg         
           
Predicted CFF           
Actual CFF        MPOD =   
             
   1.75 deg         
           
Predicted CFF           
Actual CFF        MPOD =   
             
   3 deg        
           
Predicted CFF           
Actual CFF        MPOD =   
            
   7 deg         
Predicted CFF            
Actual CFF            
         MPOD =   
             
 
 
Note: Please attach graph. 
 
 
J. Diet Questionnaire  
 
Note: Please attach complete dietary questionnaire. 
  
K. Photostress Recovery  
 
Pupil Size    Bleaching Exposure Time = 30 sec  
     Bleaching Exposure Distance = 15 cm 
 
           
      Foveal Sensitivity dB            Time (secs) 
 
Baseline (Pre-Bleaching)                            
 
 
1 (Post Bleaching)     
 
 
2     
 
 
3    
 
 
4    
  
 
5   
  
 
6     
 
 
7     
  
 
8     
 
 
9    
 
 
10     
 
 
 
 
Baseline dB    
 
 
Percentage sensitivity reduction post-bleaching  
   
 
Return to Baseline Sensitivity  
 
 
 
L. Short Wavelength Automated Perimetry 
 
Reliability Indices   Pass    Fail 
 
Attach reliable field plot printout below: 
 
 
Mean Central Sensitivity (db) 
 
Foveal threshold 
 
 
1 degree 
 
 
2 degree 
 
 
3 degree 
 
 
4 degree 
 
 
5 degree 
 
 
Overall 
      Note: Please insert Perimetry printout 
 
  
 
M. Fundus and iris photographs 
 
Fundus images taken from:  
 Right eye    Yes      No 
1 2 
 
 Left eye    Yes      No 
1          2 
     
 
Iris image taken from:  
 Right eye    Yes      No 
1   2 
 
 Left eye    Yes      No 
1          2 
     
 
Subject and Investigator agree that the subject’s iris colour is?       
 
 
Comments  
             
             
             
          
 
 
 
 
 
 
 
 
 
 
 
 
Signature of person obtaining images: _______________ 
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